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 Abstract 
Metastasis is the cause of death in 90% of cancer-related deaths in men. Melanoma and 
Non-Small-Cell Lung Cancer (NSCLC) are both tumour types with poor prognosis, 
lacking appropriate therapeutic possibilities, not least because of their high rate of 
metastasis. Thus understanding the process of metastasis might unravel therapeutic 
targets for developing further therapeutic strategies.  
The generation of a transgenic mouse model expressing B-Raf
V600E
 in melanocytes, a 
mutation that is found in about 60% of all melanoma, would result in an ideal tool to 
study melanoma progression and metastasis. In this work, a doxycycline-inducible 
system was constructed for expression of B-Raf
V600E
 and transgenic animals were 
generated, but the expression system has to be improved, since this strategy didn’t give 
rise to any viable, transgene carrying mice. 
Furthermore, since it was shown in the work of others that the metastatic behavior of 
tumour cell lines could be reversed by an embryonic microenvironment and the 
influence of a tumourigenic microenvironment on melanocytes lead to the acquisition of 
tumour cell-like characteristics, the question arose, whether B-Raf is as important in 
melanocyte development as it is in melanoma progression. In this work, the embryonal 
melanocyte development in B-Raf-deficient and wildtype mouse embryos was examined 
and there were no differences observed in the localization and number of neural crest 
stem cells as well as in the localization of the dopachrome-tautomerase positive 
melanoblasts in the embryos and in cultured neural tube explants. 
The expression of oncogenic C-Raf in lung epithelial cells has yielded a model for 
NSCLC giving rise to adenomas lacking spontaneous progression or metastasis. The co-
expression of c-Myc in the same cells accelerates the tumour development and gives rise 
to liver and lymphnode metastases. The expression of c-Myc alone in lung epithelial cells 
leads to late tumour development with incomplete penetrance. A mutation screen in this 
work resulted in the observation that a secondary mutation in KRas or LKB1 is 
necessary for tumour formation in the c-Myc single transgenic animals and suggested 
metastasis as an early event, since the corresponding metastases of the mutation-prone 
primary lung tumours were negative for the observed mutations. Furthermore, in this 
work it was shown that the expression of chicken c-Myc in a non-metastatic NSCLC cell 
line leads to metastatic clones, showing that c-Myc is sufficient to induce metastasis. 
Additionally a panel of metastasis markers was identified, that might serve as diagnostic 
markers in the future.  
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Zusammenfassung 
In 90% der Todesfälle aufgrund von Krebserkrankungen sind Metastasen für den Tod 
des Patienten verantwortlich. Sowohl Melanom, als auch nicht-kleinzelliges 
Lungenkarzinom (Non-Small Cell Lung Cancer, NSCLC) sind beides Tumortypen, die 
eine schlechte Prognose haben und für die sich wenige Therapiemöglichkeiten bieten, 
nicht zuletzt aufgrund ihrer häufigen Metastasierung. Somit würde ein besseres 
Verständnis des Metastasierungsprozesses neue therapeutische Angriffspunkte 
aufdecken und damit die Möglichkeit zur Entwicklung neuer Therapieansätze bieten. 
Die Entwicklung eines transgenen Mausmodells, in dem B-Raf
V600E
, eine Mutation die 
man in 60% der Melanompatienten findet, melanocyten-spezifisch exprimiert wird, 
würde ein geeignetes Werkzeug ergeben, um die Entstehung und die Metastasierung von 
Melanom zu untersuchen. Im Rahmen dieser Arbeit wurde ein Konstrukt zur 
Doxycyclin-abhängingen Expression von B-Raf
V600E
 erzeugt und mit diesem wurden 
transgene Tiere generiert. Da dieser Ansatz nicht zu lebensfähigen, das Transgen 
tragenden Linien führte, muss das Expressionssystem weiter verbessert werden.  
Da in der Arbeit von anderen gezeigt wurde, dass das metastasierende Verhalten von 
Tumor-Zelllinien durch eine embryonale Mikroumgebung aufgehoben werden konnte, 
und dass der Einfluss einer tumorähnlichen Mikroumgebung in Melanocyten zur 
Erlangung von Tumorzell-Charakteristika führte, kam die Frage auf, ob B-Raf  eine 
ähnlich wichtige Rolle in der Entwicklung von Melanocyten wie in der Entstehung von 
Melanomen spielt. Im Rahmen dieser Arbeit wurde die embryonale 
Melanocytenentwicklung in B-Raf-defizienten sowie in wildtypischen Mausembryonen 
untersucht. Es konnten keine Unterschiede in der Lokalisation und Anzahl von 
Stammzellen des Neuralrohres und in der Lokalisation von Dopachrome-tautomerase 
positiven Melanoblasten in den Embryonen und in kultivierten Explantaten des 
Neuralrohres festgestellt werden. 
Die Expression von oncogenem C-Raf in Lungenepithelzellen von Mäusen ist ein Modell 
für NSCLC und führt zur Ausbildung von Adenomen ohne spontane Weiterentwicklung 
oder Metastasen. Die Koexpression von C-Raf mit c-Myc in denselben Zellen 
beschleunigt die Entwicklung von Tumoren und führt zu Metastasen in Leber und 
Lymphknoten. Die Expression von c-Myc alleine in Lungenepithelzellen führt zu einer 
verspäteten Entwicklung von Tumoren mit nicht vollständiger Penetranz. Ein Screening 
für Mutation im Rahmen dieser Arbeit führte zu der Beobachtung, dass 
Sekundärmutationen in KRas oder LKB1 für die Tumorentwicklung in den c-Myc 
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transgenen Tieren notwendig sind und dass die Metastasierung ein frühes Ereignis zu 
seien scheint, da die zugehörigen Metastasen in Leber und Lymphknoten im Gegensatz 
zum Primärtumor in der Lunge keine Mutationen in diesen Genen trugen. Desweiteren 
wurde in dieser Arbeit gezeigt, dass die Expression von avianem c-Myc in einer nicht-
metastasierenden NSCLC Zelllinie zu metastasierenden Klonen führte, was zeigt, dass c-
Myc ausreichend ist um Metastasierung auszulösen. Zusätzlich wurde eine Reihe von 
Markern für Metastasen identifiziert, die in Zukunft als diagnostische Marker 
Verwendung finden könnten. 
 
   
Introduction 
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1 Introduction 
Right next to cardiovascular diseases, cancer is on the list of the most common causes of 
death in western countries. Lung cancer accounts for most of the cancer-related death in both 
men and women. The American Cancer Society estimates the rate of melanoma increasing 
2.5-4% per year. Both tumour types have a poor prognosis not least because of their high rate 
of metastasis, which is the cause of death in the vast majority of cancer patients. 
1.1 Melanoma 
Melanoma is a tumour that originates in the melanocytes, specialised pigment-producing 
cells, which are predominantly found in the skin and eyes. They originate from highly motile 
neural-crest progenitors that migrate to the skin during embryonal development and reside in 
the basal layer of the epidermis, where their homeostasis is regulated by the keratinocytes 
(Slominski et al., 2004). Although melanoma accounts for only 4% of all dermatologic 
cancers, it is the most dangerous form and is responsible for 80% of skin cancer related deaths 
(Miller and Mihm, 2006). The reason for this is a rather small, often undetected primary 
tumour with a high frequency of metastasis. Metastatic melanoma holds an extraordinary 
resistance to chemotherapy, radiotherapy and immunotherapy and patients have a median 
survival rate of 6 months and the 5-year survival rate is less than 5% (Cummins et al., 2006). 
The first step in melanoma development is the formation of a nevus upon disruption of the 
growth control of the melanocytes, often induced by a mutation in the mitogenic cascade. 
These nevi can stay dormant for decades and rarely progress to malignancy, probably because 
of oncogene-induced senescence (Braig and Schmitt, 2006). Upon an additional mutation of a 
tumour suppressor like p16
INK4a
 or PTEN, dysplastic nevi are formed, which carry 
abnormalities in genes responsible for cell growth, DNA repair and susceptibility to cell death 
(Thompson et al., 2005). The next stage in melanoma development is the radial-growth-phase, 
during which the cells acquire the ability to grow intraepidermally. Invasive characteristics of 
Introduction 
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the developing melanoma occur in the vertical-growth-phase, when the melanoma cells not 
only penetrate the basement membrane, but also grow intradermally as an expanding nodule. 
Once the tumour cells dissociate from the primary tumour, migrate through the surrounding 
stroma and invade blood and lymph vessels to form secondary lesions at distant sites, the 
disease has reached its metastatic stage (Haass et al., 2005). 
1.1.1 Molecular Biology of Melanoma 
Melanoma is a complex genetic disease and for improvement of its poor prognosis, it is 
necessary to understand the molecular biology of melanoma. As already described a mutation 
in the mitogenic cascade is often involved in nevi formation. In 15% of the patients this is a 
mutation in N-RAS and in about 60% it is an activating mutation of B-Raf. These mutations, 
which occur exclusively of each other cause a constitutive activation of the serine-threonine 
specific kinases in the ERK-MAPK cascade (Albino et al., 1989; Davies et al., 2002).  
The fact that B-Raf mutations occur in a similar frequency in nevi, primary tumours and 
metastatic cancer suggests that nevi must acquire additional mutations to free themselves of 
growth restraints and progress to malignancy (Pollock et al., 2003).  This second mutation is 
often found in familial melanoma in the CDKN2A locus, a single gene that encodes two 
tumour suppressor proteins, p16
INK4A
 and p19
ARF
 (Albino et al., 1989). p16
INK4A
 is a protein 
that blocks the cell cycle at the G1-S checkpoint by inhibiting cyclin-dependent kinases, while 
p19
ARF
 functions as a tumour suppressor by arresting the cell cycle or inducing cell death after 
DNA damage or upon oncogene-induced aberrant cell proliferation (Sharpless and Chin, 
2003). In contrast to familial melanoma, in non-familial cases with a frequency of 25-50% the 
predominant mutation is found in a different tumour suppressor, PTEN (Wu et al., 2003). 
PTEN encodes a phosphatase that attenuates signalling by a variety of growth factors that use 
phosphatidylinositol phosphate (PIP3) as an intracellular signal. In absence of PTEN, PIP3 
levels increase and by this activate the protein kinase AKT, which phosphorylates and by this 
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inactivates proteins that suppress the cell cycle or stimulate apoptosis (Wu et al., 2003). In 
murine models for melanoma the inactivation of one, either the CDKN2A or the PTEN locus 
is not sufficient to induce melanoma, only the combination of both or of one with mutations 
in other genes leads to the development of melanoma (You et al., 2002).  
Since the failure of differentiation is necessary for dysplasia, many nevi regress through 
differentiation (Clark et al., 1984). During normal melanocyte development differentiation 
requires exit from the cell cycle and the expression of melanogenic enzymes, like 
dopachrome-tautomerase (DCT) or Tyrosinase, which are involved in the melanin synthesis. 
The microphthalmia-associated transcription factor (Mitf), the according gene of which has 
been shown to be amplified in 10-20% of malignant melanoma metastases (Garraway et al., 
2005), is involved in both processes during melanocyte development (Hodgkinson et al., 
1993). During development Mitf appears to contribute to melanocyte survival by upregulating 
the expression of the Bcl-2 gene, which is a key antiapoptotic factor (McGill et al., 2002). 
Additionally, Mitf induces cell cycle arrest by induction of INK4A expression during 
melanocyte differentiation (Loercher et al., 2005). Mitf is present in nearly all melanomas, 
although it causes differentiation and cell cycle arrest in normal melanocytes. 
1.1.2 Melanocyte Development 
For an in-depth understanding of the disease melanoma, a broad knowledge in the 
physiological melanocyte biology might improve the insights into melanoma progression. 
Melanocytes are pigmented cells that derive from the neural crest, which is a unique 
population of cells that emigrate from the dorsal neural tube during early embryonal 
development. During development these neural crest cells migrate extensively along defined 
pathways to specific sites in the embryo, where they differentiate and form bone, cartilage and 
adipose tissue, endocrine cells, several types of neurones and glia, as well as melanocytes 
(Thomas and Erickson, 2008). The specification of the cells depends on their axial level, 
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neural crest cells from the trunk give rise to neurons and glia of the sensory, autonomic and 
enteric nervous system, to chromaffin cells of the adrenal gland and to pigment cells (Harris 
and Erickson, 2007). These cells are divided into two populations, the neurogenic and the 
 
Figure 1-1 Migratory pathways of trunk neural crest cells (Thomas and Erickson, 2008). 
Neural crest cells migrate along the ventral and the dorsolateral migratory pathways after 
emerging the premigratory neural crest. Premigratory neural crest cells are positive for Sox10, 
while emerging the neural tube, they start to express Mitf and once they reached the migration 
staging area they are positive for the melanoblast markers TRP1 and DCT. When the 
melanoblasts invade the ectoderm they fully differentiate to mature melanocytes and express 
the melanogenic enzyme Tyrosinase. 
melanogenic population, and have distinct migratory properties (Henion and Weston, 1997). 
While neurogenic neural crest cells migrate ventrally along the neural tube, the melanoblasts 
migrate dorsolaterally between the somites and ectoderm and later invade the ectoderm, 
where they differentiate to mature melanocytes (Thomas and Erickson, 2008) (Figure 1-1). 
1.2 Non Small Cell Lung Cancer (NSCLC) 
Lung cancer is categorized into two main types, depending on the size and appearance of the 
malignant cells, the non-small cell lung cancer (NSCLC), which comprises 80% of all lung 
cancers, and the small cell lung cancer (SCLC), which comprises 20% of all lung cancers. 
Introduction 
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SCLC is a tumour of neural crest origin, while NSCLC is thought to originate in the lung 
epithelial cells and is divided in several histological subtypes, like adenocarcinoma, 
bronchioalveolar, squamous cell carcinoma and large cell lung cancer (Sharma et al., 2007). 
Adenocarcinoma is the most common subtype of NSCLC, accounting for 25-35% of lung 
cancers. Although there are advances in early detection and standard treatment, NSCLC is in 
about 75% of the patients detected at an advanced stage of the disease, which usually is in line 
with a poor prognosis (Borczuk and Powell, 2007). SCLC and NSCLC show major 
differences in histopathologic characteristics that can correlate with the distinct patterns of 
genetic lesions found in both tumour classes (Zochbauer-Muller et al., 2002). Although other 
markers have prognostic significance, none are more significant than the clinicopathological 
stage (Mountain, 1997). Therefore the identification of novel markers is an urgent need. 
In NSCLC tumour onset and progression proceed via morphologically distinct lesions, 
hyperplasia, metaplasia, dysplasia, carcinoma in situ and fully invasive tumours (Meuwissen 
and Berns, 2005). A fundamental step in the progression of a dormant, local tumour to a 
malignant stage cancer is the attraction of blood supply and the growth of new vessels from 
pre-existing ones, the process of angiogenesis (Horn and Sandler, 2009). 
1.2.1 Molecular Biology of NSCLC 
Many genetic and epigenetic aberrations have been identified in human lung cancer. 
Significant progress has been made in identifying genetic lesions in lung cancer by 
sequencing-based mutation screenings (Futreal et al., 2004) and characterizing copy-number 
alterations (Weir et al., 2007). The most frequent genetic aberrations in NSCLC are shown in 
Table 1-1. These genetic aberrations do not only occur on the chromosomal level as large 
deletions resulting in the loss of heterozygosity (LOH) or as amplifications of genes like Myc-
family genes. Genetic changes also occur through nucleotide exchange mutations like 
alterations in the DNA sequence of the KRas gene and epigenetic changes in the promoter 
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methylation, i.e. of the CDH1 promoter, which drives the expression of E-cadherin, a cell 
adhesion molecule expressed in epithelial tissue (Angst et al., 2001). 
Gene Aberration Frequency 
Myc  Amplifications  5%-20%  
KRas  Mutations  15%-20%  
EGFR  Mutations  20%  
INK4a  LOH  70%  
p16 INK4a  Mutations  20%-50%  
p14 ARF  Mutations 20%  
TP53  LOH  60%  
TP53  Mutations  50%  
RB  LOH  30%  
RB  Mutations  15%-30%  
FHIT  Mutations  40%  
DMBT1  Mutations  40%-50%  
LOH in various regions 3p 
4p 
4q 
8p  
10%-100%  
INK4a  Promoter hm  8%-40%  
RARß  Promoter hm  40%  
CDH1 Promoter hm  55%  
TIMP-3  Promoter hm  25%  
Table 1-1 Major genetic aberrations in NSCLC. LOH: loss of heterozygosity. Modified from 
(Meuwissen and Berns, 2005) 
One of the early events in NSCLC is a mutation in one of the Ras-genes resulting in persistent 
signaling. Ras-mutations are not found in SCLC and the presence of KRas mutations marks a 
poor prognosis in early- as well as late-stage NSCLC (Meuwissen and Berns, 2005). Another 
alteration that is frequently found in NSCLC is an amplification and by this overexpression of 
genes of the Myc-gene-family. While in SCLC L-, N- and c-Myc are often amplified, in 
NSCLC it is exclusively c-Myc (Angst et al., 2001).  
1.2.2 Lung development 
During embryonal development, the cells present in the lung bud of the ventral foregut 
endoderm form the epithelial lining of the conducting airways and the distal sak-like 
structures, which form the gas-exchange surface. The postnatal maturation of the lung 
involves the formation of septa in the terminal sacs leading to the expansion of the gas-
exchange surface (Cardoso and Lu, 2006). In the adult lung different types of epithelial cells 
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line the trachea, bronchi, bronchioli (Clara cells and bronchio-alveolar stem cells (BASCs)) 
and alveoli (Type I and Type II pneumocytes). The alveolar Type II pneumocytes secrete 
surfactant proteins (SP), like SP-C, and are the precursors of the Type I pneumocytes, which 
form the thin diffusion barrier, important for gas exchanges in the alveoli (Cardoso and Lu, 
2006). SP-C is not only expressed in the Type II cells of the murine lung, but also by a rare 
cell population located at the bronchio-alveolar duct-junction, which also express the Clara-
cell antigen CC10, a marker for Clara cells, which line the bronchi and bronchioles 
(Giangreco et al., 2002). These cells have been shown to be capable of self-renewal and 
differentiation in vitro and are called bronchio-alveolar stem cells (BASCs) (Kim et al., 
2005). More recent lineage tracing experiments raise the question about the role of BASCs in 
regeneration of the distal lung (Rawlins et al., 2009). 
1.2.3 The Neuroendocrine Cell Population in the lung 
Pulmonary neuroendocrine cells (PNECs) are part of the diffuse endocrine system (DES) 
distributed throughout the body (Linnoila, 2006). Other parts of the DES include cell 
populations in the hypothalamus and adenohypophysis, pineal gland, paraganglia, cell 
populations in the thymus, pancreatic islets, thyroid C cells, parathyroid glands, endocrine 
cells of the breast, gastrointestinal and genitourinary tracts, melanocytes and Merkel cells of 
the skin (Baylin, 1990). The PNEC system is located in the bronchial epithelium and consists 
of solitary PNECs and neuroepithelial bodies (NEBs). In 1972, Lauweryns and Peuskens 
introduced the term neuroepithelial body. By definition, NEBs are corpuscular, organoid 
structures composed of PNECs, which are heavily innervated and reach from the basement 
membrane to the airway lumen (Lauweryns and Peuskens, 1972). Perl et al., 2002 showed 
that there is an early spatial restriction of progenitor cells forming the proximal conducting 
airways, compared with the peripheral lung during development. PNECs were shown to be 
derived from a  different group of precursors than those forming the peripheral subset of 
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respiratory epithelial cells (Perl et al., 2002b). PNECs are thought to regulate branching 
morphogenesis  and cellular growth and maturation in fetal and newborn lung development 
(King et al., 1995). NEBs emerge as foci of growth by secreting neuropeptides and growth 
factors in a paracrine fashion. Although PNECs are only a minor component of normal lung 
epithelium, one third of human lung cancers display features of neuroendocrine 
differentiation. Clinicopathologically, the most important NE carcinoma is the SCLC, which 
accounts for 15-20% of all lung cancers; others include NSCLC with neuroendocrine features 
(NSCLC-NE), carcinoid and Large Cell NE Carcinoma (LCNEC) (Travis et al., 2004). 
Approximately 10-15% of all NSCLCs may show differentiation towards the NE phenotype 
by immunohistochemical characterization (Linnoila et al., 1988). 
1.3 Metastasis 
Metastasis causes 90% of death from solid tumours and the risk of metastatic recurrence can 
sometimes be predicted from certain features of the primary tumour (Nguyen and Massague, 
2007). Metastasis is a complex, multistep process, for which the tumour cells have to fulfil 
certain tumourigenic prerequisites, like unlimited proliferation, evasion of cell-intrinsic and 
environmental constraints, attraction of blood supply and the capacity to detach and move 
away from the primary tumour (Nguyen and Massague, 2007). When aggressive tumour cells 
become invasive and start to enter the bloodstream, dissemination starts. Intravasation is 
promoted by processes like epithelio-mesenchymal transition (EMT), and the fact, that 
pathologically leaky vasculature is common for many tumours. Once the tumour cells have 
survived the stresses of the bloodstream due to acquired features like evasion from anoikis, 
they have to enter the parenchyma of a target organ either by vascular-remodelling events or 
as a result of mechanical disruption of capillaries by expanding tumour emboli.  On entry the 
tumour cells have to survive a different microenvironment and can then either immediately or 
after a prolonged, micrometastatic dormancy grow to full metastatic lesions (Nguyen and 
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Massague, 2007). These functions are acquired during tumour initiation and local 
development, but must remain active during malignant progression. The metastatic 
dissemination has stereotypical patterns of organ tropism that reflects the heterogeneity of the 
tumour cells and depends on the cancer type (Weiss, 2000). 
1.4 The mitogenic cascade 
In a variety of human tumours one can find a deregulation of the mitogenic cascade on 
different levels. Going through the list of hallmarks of cancer defined by Hanahan and 
Weinberg in 2000 (Hanahan and Weinberg, 2000), the Ras/Raf-signaling can contribute to 
any individual of these  criteria (Table 1-2). The growth factor receptor that triggers the 
consecutive signalling pathway, the EGF-receptor (EGFR), was found to be mutated in 
various epithelial tumours (Gschwind et al., 2004), i.e. in 20% of NSCLC a mutation in the 
EGFR can be observed (Meuwissen and Berns, 2005). Furthermore, the Ras proteins, the 
transceiver of the receptor signals, are also popular targets for mutations in approximately 
30% of human cancers (Karreth and Tuveson, 2009), as for example in 15-20% of NSCLC 
activating KRas–mutations are found (Meuwissen and Berns, 2005). Other important targets 
for mutations in the mitogenic cascade are the Raf-kinases, which are the central players of 
the mitogenic cascade, i.e. B-Raf is mutated in 66% of the melanoma patients (Schreck and 
Rapp, 2006). 
Hallmarks of a cancer cell Corresponding effect of the Ras/Raf-signalling pathway 
Immortalisation Telomerase induction 
Growth-factor-independent growth Cell-cycle activation 
Insensitivity to growth-inhibitory signals Inactivation of tumour suppressors 
Ability to invade and metastasise Stimulation of motility and extracellular matrix remodelling 
Ability to secure nutrients by stimulating 
angiogenesis 
Stimulation of the production of pro-angiogenetic factors 
Avoidance of apoptosis BAD inactivation; caspase inhibition 
Resistance to therapeutical measures Induction of radiation resistance; induction of the multidrug-
resistance protein MDR1 
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Table 1-2 The Ras/Raf-signaling impacts on all hallmarks of cancer defined by Hanahan and 
Weinberg (modified from (Kolch et al., 2002)). 
1.4.1 Raf-isoforms 
In multicellular organisms the Raf-family consists of three members, A-, B- and C-Raf, which 
are serine/threonine specific kinases and have all the same structural organization. All Raf-
family proteins have three highly conserved regions, two in the N-terminus (CR1 and CR2) 
and the third (CR3), which contains the kinase activity, in the C-terminal part of the protein 
(Figure 1-2). All three isoforms can be activated via phosphorylation of the activation 
segment (Chong et al., 2001), but while there are further phosphorylations of serine and 
threonine residues in the kinase domain necessary for full activation of A- and C-Raf, B-Raf 
is fully activated by this single phosphorylation event. Not least for this reason B-Raf has a 
higher basal kinase activity than the other two isoforms (Wan et al., 2004). There are three 
different functional Raf-genes, which are located on different chromosomes, encoding the 
three isoforms. While C-Raf is expressed ubiquitously, the expression pattern for A- and B-
Raf is more restricted. Urogenital organs show elevated expression levels of A-Raf and B-Raf 
is expressed on high levels in neuronal tissue and testis (Luckett et al., 2000; Storm et al., 
1990). The generation of transgenic and knock-out mice has shown the crucial role of all three 
isoforms in embryonal development. While A-Raf deficient mice survive until birth, but die 
7-21 days later due to neurological and gastrointestinal defects (Pritchard et al., 1996), the b-
raf
-/-
 and c-raf
-/-
 embryos die in utero 10.5 to 12.5 days postcoitum due to growth retardation, 
vascular and neuronal defects and massive liver apoptosis, respectively (Wojnowski et al., 
1998; Wojnowski et al., 1997). Although there is clearly a functional overlap in the three Raf-
isoforms in the activation of the mitogenic cascade, the differences in structure and tissue 
distribution suggest additional specific roles of the different isoforms (Hagemann and Rapp, 
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1999).
 
Figure 1-2 Structure of the Raf-family proteins (modified from (Wellbrock et al., 2004)). 
Proteins of the Raf-family share three highly conserved domains. The CR1 domain (yellow) 
contains the two regions required for Ras-binding and membrane recruitment, the Ras-binding 
domain and the cysteine rich domain. Displayed in orange is the CR2 domain and in red the 
CR3 domain, which is the catalytic region containing the activation segment (highlighted in 
purple). 
1.5 Ras/Raf-signalling 
Raf proteins are part of a highly conserved signalling module, the mitogenic cascade, which 
transduces signals from the cell surface to the nucleus (Figure 1-3). The upstream regulators 
of the Raf-proteins are members of the Ras-family of small G-proteins (Robbins et al., 1994). 
Ras is activated by extracellular ligands such as growth factors, cytokines or hormones 
binding to their receptor leading to the exchange of GDP with GTP, which converts Ras into 
its active conformation (McCormick, 1993). Activated Ras directly interacts with high 
affinity with Raf and recruits it to the cytoplasm membrane, where Raf activation via 
phosphorylation takes place (Avruch et al., 1994). Activated Raf phosphorylates and by this 
activates the kinases MEK1 and MEK2 on two serine residues in their activation segment. 
These kinases phosphorylate and activate the mitogen-activated protein kinases (MAPK) 
ERK1 and ERK2 (extracellular signalling related kinase) on threonine and tyrosine residues 
within their activation segment. ERK1/2 have both cytosolic (kinases and cytoskeletal 
proteins) and nuclear (transcription factors) substrates (Flory et al., 1996; Marshall, 1999). 
The activation of this cascade leads to transcriptional activation of proteins possessing cell 
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cycle stimulating, pro-survival and anti-apoptotic properties (Rapp et al., 2003). In addition to 
the Raf-kinases, Ras also regulates other proteins, for example the 
 
Figure 1-3 Raf signaling pathway regulating cell growth, differentiation, proliferation and 
survival (modified from (Rapp et al., 2003)). The induction of the mitogenic cascade via 
growth factor binding to a receptor leads to the transcriptional onset of a variety of genes 
including the induction of autocrine loops of the growth factors themselves. 
phosphatidylinositol-3 (PI3) kinases, which activates the serine/threonine-specific protein 
kinase Akt (PKK) via phosphorylation leading to phosphorylation and inactivation of the 
proapoptotic protein Bad (Downward, 1998).  Raf-kinases not only phosphorylate and by this 
activate MEK1/2, but also interact with the antiapoptotic protein Bcl-2 and by this block the 
mitochondrial apoptotic pathway. Furthermore they phosphorylate and thereby inactivate the 
proapoptotic Bcl-2 family protein BAD (Troppmair and Rapp, 2003). 
1.6 Myc-family proteins 
c-Myc has been one of the first oncogenes identified and has subsequently been linked with a 
wide spectrum of human cancers, i.e. it is amplified in 5-20% of NSCLC (Meuwissen and 
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Berns, 2005). The family of Myc genes consists of three members, c-Myc, N-Myc and L-Myc, 
which all have been implicated in the genesis of specific human tumours (Patel et al., 2004). 
In vivo Myc proteins are not occurring as monomers, but are always bound to a partner 
molecule, most commonly Max, through a C-terminal domain (Blackwood et al., 1992) 
(Figure 1-4). To regulate the transcription of the target genes, this complex binds directly to a 
 
Figure 1-4 Structure of Myc-family proteins (modified from (Adhikary and Eilers, 2005)). 
The C-terminus of Myc contains a basic-region/helix-loop-helix/leucine zipper (BR/HLH/LZ) 
domain, where Max is binding (Max binding domain (BD), red). In the N-terminal part of the 
protein are three highly conserved regions located, which are called Myc-boxes I-III (yellow). 
specific DNA sequence, which is a subset of the general E-box sequence (Blackwell et al., 
1990) or is recruited by other DNA binding factors to the corresponding binding sites (Mao et 
al., 2003). The study of in vivo binding sites of Myc-proteins has yielded in as many as 
~25,000 sites in the human genome, which by far exceeds the number of Myc molecules that 
are present in one cell, leading to the suspicion that a relatively brief binding of Myc leads to 
longer-lasting changes in the chromatin organization (Adhikary and Eilers, 2005). The N-
terminal part of Myc proteins contains three highly conserved elements, the Myc-boxes I, II 
and III (Figure 1-4). While Myc-box I is implicated in the turnover of the protein (Bahram et 
al., 2000), Myc-box III is required for full transactivation and transrepression of the target 
genes (Herbst et al., 2005). Myc-box II is not required for DNA or Max binding, but is known 
to be necessary for all known biological functions of Myc (Stone et al., 1987). It has been 
shown in the last decades that the elevated expression of Myc contributes in many different 
ways to tumour development, i.e. by driving unrestricted cell proliferation and inhibiting 
differentiation (Rapp et al., 1985), by its ability to drive cell growth (Johnston et al., 1999) 
and angiogenesis (Baudino et al., 2002), by reducing cell adhesion (Arnold and Watt, 2001), 
and by promoting metastasis (Rapp et al., 2009) and genomic instability (Felsher and Bishop, 
1999).  But although Myc is overexpressed in many human and rodent tumours, it is not 
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sufficient to convert human and rodent cells into tumour cells alone. Tumours that arise from 
Myc transgenic mice are clonal and have a long latency, which implies that additional 
mutations are required for tumour formation (Rapp et al., 2009). Cooperation of Myc with 
oncogenes that function i.e. in the Ras/Raf-pathway results in cellular transformation and 
tumourigenesis (Rapp et al., 2009). Downstream kinases of the Ras/Raf-pathway 
phosphorylate and thereby stabilize Myc. Furthermore, Ras inhibits the glycogen synthase 
kinase-3 (GSK3), which targets Myc for ubiquitylation (Sears et al., 2000). Additionally 
several Myc target genes are co-regulated by members of the FoxO protein family. 
Unphosphorylated these transcription factors bind to and by this repress many Myc target 
genes until they are phosphorylated and activated by the Akt kinase, which is a downstream 
kinase of the Ras/Raf-signalling (Bouchard et al., 2004). Another reason for the incapability 
of Myc alone to transform cells is its ability to induce apoptosis (Askew et al., 1993; Evan et 
al., 1992) by two distinct mechanisms. It induces the expression of p19
Arf
 leading to the 
stabilization of the tumour-suppressor protein p53 (Eischen et al., 1999) and it represses the 
anti-apoptotic proteins Bcl-2 and Bcl-XL (Eischen et al., 2001). The effects of Myc are dose-
dependent. Low levels of Myc promote ectopic proliferation of somatic cells and oncogenesis, 
while its overexpression leads to apoptosis (Murphy et al., 2008). 
1.6.1 Cooperation of Raf with other oncogenes 
Myc and Raf are oncogenes that go well together, not only because they complement each 
other in their limitations in the ability of fully transforming a cell by cancelling out each 
other‟s deleterious oncogene effects, but also because coexpressing cells fulfil both key 
elements of carcinogenesis, tumour initiation and promotion, via induction of genomic 
instability by Myc (Prochownik and Li, 2007) and assurance of survival and genomic stability 
by Raf (Rapp, 2007). To result in proliferation and survival of progenitor cells, Raf and Myc 
oncogenic effects have to be in equilibrium. While the predominance of Myc induces 
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genomic instability in early progenitor cells and a differentiation block, leading to 
dedifferentiation and apoptosis, the prevalence of Raf results in differentiation, G1-arrest and 
survival in late progenitor cells and differentiated cells leading to oncogene-induced 
senescence. Additionally, the predominance of Raf promotes an overall genomic stability 
(Rapp, 2007). Furthermore, several publications of the group of Rapp showed the ability of 
Raf and Myc in combination to induce cellular plasticity (Principato et al., 1988; Rapp et al., 
2009).  
Another example for the cooperation of Raf with another oncogene is the cooperation of Raf 
and Mitf in melanoma. The protein-levels of Mitf must be carefully controlled, because 
critically high levels of Mitf result in cell cycle arrest and differentiation and reduce 
melanoma cell tumourigenicity, while low levels lead to cell cycle arrest and apoptosis. Only 
at intermediate levels proliferation is favoured. A constitutive active signalling of the 
mitogenic cascade, i.e. as a result of B-Raf
V600E
, in this context not only provides essential 
survival functions and contributes to proliferation, but also keeps the Mitf protein doses on an 
intermediate level by targeting Mitf for degradation after its phosphorylation by ERK (Gray-
Schopfer et al., 2007). 
1.7 Experimental design and aim of the project 
1.7.1 Melanoma 
Constitutive active B-Raf was shown to play an important role in melanoma development as it 
seems to lead to the first step in melanoma development, the nevi formation.  But B-Raf is not 
sufficient to induce full malignancy, as already described, additional mutational events are 
necessary for malignant progression.  Mouse models for human disease offer the opportunity 
that the effects of oncogenes can be studied and their roles in the stages of the disease and 
disease progression can be identified. Thus a mouse model expressing the oncogenic B-
Raf
V600E
, which accounts for most of the oncogenic B-Raf mutations with just one amino acid 
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substitution leading to a constitutive kinase activity (Pollock and Meltzer, 2002), in 
melanocytes would be a powerful tool to gain more insights in melanoma progression and the 
secondary events that are necessary for full malignancy and to develop new therapeutic 
approaches. Since the constitutive expression of oncogenic C-Raf (Rapp et al, unpublished 
data) and for B-Raf even the tissue-specific expression under the control of the Tyrosinase-
promoter was embryonal lethal (Marais et al, unpublished data), in this work a tetracycline-
regulatable vector for the B-Raf
V600E
 expression was designed (Figure 1-5). In this 
tetracycline-regulatable system, several repeats of the TetO DNA sequence are fused to a 
minimal CMV promoter forming a compound tetracycline-responsive promoter (Gossen and 
Bujard, 1992). The tetracycline-controlled transcriptional activator (tTA) protein binds in the 
absence of Dox to the TetO DNA sequence, which results in the expression of the adjacent 
gene. Binding of Dox to the tTA protein leads to a conformational change of the protein 
causing the protein to detach from the TetO DNA sequence leading to silencing of the 
 
Figure 1-5 Tetracycline-inducible gene expression system. A tissue-specific promoter drives 
the expression of the reverse tetracycline-controlled transcriptional activator (rtTA). In the 
presence of the tetracycline-analogue doxycycline (Dox) the rtTA can bind to and by this 
activate the expression activity of the tetracycline-inducible promoter element (Tet-O). 
corresponding gene expression (Furth et al., 1994).  The usefulness of this system is limited, 
because to turn off the system the administration of Dox during a long period of time would 
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be necessary. Four mutations in the tTA sequence reverse the behavior of the protein in 
interacting with the TetO DNA sequence in response to presence or absence of Dox. This 
mutant reverse tTA (rtTA) protein stays soluble in the absence of Dox and binds to the TetO 
DNA sequence in the presence of Dox inducing its promoter activity (Gossen et al., 1995). In 
this work a vector for tetracycline-inducible expression of B-Raf
V600E
 was designed to 
generate transgenic mice that can be combined with animals expressing the rtTA tissue-
specific, in the case of a melanoma model for example under the control of the DCT- or the 
Tyrosinase-promoter. 
Multipotent tumour cells and many embryonic progenitor cells share common characteristics 
of cell fate plasticity and invasiveness. Furthermore, growing evidence suggests that cancer 
might arise from aberrant activation of normally carefully controlled developmental 
pathways. Understanding of the processes during embryonal development as they relate to 
tumour development and progression might lead to new therapeutic approaches for cancer. 
Exciting studies have recently shown that signals derived from the embryonic 
microenvironment can influence multipotent tumour cells to behave like their embryonal 
progenitors (Kulesa et al., 2006). To gain more insights into the role of B-Raf in melanocyte 
development, in this work the previously established B-Raf knock-out mouse was used 
(Wojnowski et al., 1997). For the generation of this mouse, a neo-cassette was introduced into 
the exon3 of B-Raf, which is common for all splice isoforms and contains the Ras-binding 
domain. While in heterozygous animals no phenotype was observed, homozygous animals die 
in utero between day E10.5 and E12.5 during embryonal development probably due to 
vascular and placental defects (Wojnowski et al., 1997). In this work the melanocyte 
development in E9.5 B-Raf
-/-
-embryos was examined to get an idea about the role of B-Raf 
during melanocyte development. 
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1.7.2 Non-small-cell lung cancer 
During the past three decades, many genes have been identified for which gain or loss of 
function results in autonomous proliferative activity, resistance to cell death, angiogenesis and 
altered cell adhesion and motility. These processes are involved in the initiation and the local 
progression of the primary tumour and are prerequisites for metastasis. However, the genetic 
determinants of metastases, that mediate tumour cell invasion, intravasation, survival in 
circulation, scattering to distant tissues, extravasation and colonization of vital organs, are just 
in the beginning of being unraveled. To gain more information about the process of 
metastasis, in this work a previously established mouse model for metastasis in NSCLC was 
used for mutation and gene expression analyses (Rapp et al., 2009). In this model single 
transgenic SpC-C-Raf-BxB mice, which express oncogenic C-Raf-BxB just containing the C-
terminal part of the protein including the kinase domain, but lacking the N-terminal regulatory 
parts in the alveolar type II cells under control of the SpC-promoter, were combined with 
single transgenic SpC-c-Myc animals overexpressing c-Myc in the type II pneumocytes under 
the control of the same promoter. The SpC-C-Raf-BxB single transgenic animals develop 
premalignant adenoma lacking spontaneous progression, but show complete tumour 
penetrance at an age of two weeks (Kerkhoff et al., 2000). In contrast, in SpC-c-Myc single 
transgenic mice pleomorphic clusters could be observed, but these were often diminished or 
completely absent in long term survivors. Only in a fraction of late SpC-c-Myc animals 
rapidly expanding tumour foci containing columnar cells could be detected. Cells in these 
tumour foci carried mutations in KRas or LKB1, indicating that secondary genetic events were 
required to rescue premalignant c-Myc foci. Combining these two transgenes in compound 
SpC-C-Raf-BxB/SpC-c-Myc animals resulted in accelerated tumour development and a 
phenotypic switch of the in the SpC-C-Raf-BxB mice observed cuboidal to columnar shape 
tumour cells. Furthermore, multiple macroscopic liver- and lymphnode- metastases were 
observed in the compound SpC-C-Raf-BxB/SpC-c-Myc animals as early as ten months of age 
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and in late SpC-c-Myc single transgenic mice. Although the incidence of metastasis was 
higher and the development was earlier in the SpC-C-Raf-BxB/SpC-c-Myc compound 
animals, macroscopic metastases could also be observed in the SpC-c-Myc single transgenic 
animals (Rapp et al., 2009). 
Furthermore, since a mouse model for a disease not always completely phenocopies the full 
human disease, in this work a cell culture model was established by the introduction of 
chicken c-Myc into a non-metastatic human NSCLC cell line and this cell line was analyzed 
in comparison to the data obtained from the mouse model. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Instruments 
Hardware Manufacturer 
Berthold Luminator BioRad 
Blotting Chamber BioRad 
Cell Culture Hud Heraeus Instruments 
Cell Culture Incubator Heraeus Instruments 
Cryo microtome Leica 
Developing machine Agfa 
Electrophoresis power supply BioRad 
Electrophoresis unit for Agarose Gels BioRad 
Electrophoresis unit for SDS Gels BioRad 
Fluorescence Microscope Keyence, Leica 
Glass plates for SDS Gels BioRad 
Heat Block Liebisch, Type 2099-DA 
Homogenizer Ultra-Turrax 
Incubator Heraeus Instruments 
Megacentrifuge Beckman 
Minicentrifuge Eppendorf 
Microtome Leitz, Wetzlar 
Neubauer Chamber Hartenstein 
Paraffin Embedding Machine Leica 
pH meter Microprocessor, WTW 
Roto-Gene 2000 Corbett Research 
Shaker New Brunswick Scientific 
Sonicator Sono Plus HD70 
Spectrophotometer Ultraspec 3000, Pharmacia Bio. 
Thermocycler Eppendorf 
Ultracentrifuge Beckmann 
Vortex Scientific Industries 
Waterbath Amersham-Buchler 
2.1.2 General Material 
Material Purchased from 
1.2/2ml reaction tubes Eppendorf 
15/50ml tubes Sarstedt 
100/40/20 µm cell strainer BD Falcon 
Beckmann Quickseal Tubes Beckmann 
Cell culture flasks Sarstedt 
Cell culture plates Sarstedt 
Cryotubes Sarstedt 
Earmarks Harlan 
Glass coverslips Leica 
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Material Purchased from 
Glass slides Leica 
Hybond-N Membrane Amersham 
Pasteur Pipette Hartenstein 
Petridish Roth 
Scalpel Hartenstein 
SuperFrost Slides Menzel-Gläser 
Whatman-paper Hartenstein 
X-Ray films Agfa 
All used materials not listed was ordered with Noras or Hartenstein. 
2.1.3 Chemicals 
Reagent Purchased from 
1kb DNA ladder Fermentas 
100bp DNA ladder Fermentas 
Acetone Hartenstein 
Acrylamide(30%)/Bisacrylamide(0.8%) Roth 
Agarose, ultra pure Invitrogen 
Ammoniumpersulfate (APS) Sigma 
Ampicillin Sigma 
Bacto-Agar Roth 
Bacto-Tryptone Roth 
-Mercaptoethanol Roth 
BCP Molecular Research Center Inc. 
BCIP-T Fermentas 
Blocking reagent Roche 
Bovine serum albumin (BSA) Sigma 
Bromphenol blue Sigma 
CHAPS Sigma 
Chloroform Roth 
Citric acid Roth 
CsCl Sigma 
DAPI Sigma 
DEPC Roth 
Diaminobenzidine (DAB) Sigma 
Dimethylforamide Roth 
Dimethylsulfoxide (DMSO) Sigma 
Doxycycline Sigma 
dNTPs Fermentas 
ECL-solutions Amersham 
EDTA Sigma 
Endothelin-3 Sigma 
Entellan Merck 
Eosin Merck 
Ethanol Roth 
Ethidiumbromide Invitrogen 
Fetal Calf Serum (FCS) Invitrogen 
Fibronectin Sigma 
Ficoll Hartenstein 
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Reagent Purchased from 
Formaldehyde Roth 
Formamide Roth 
Glacical acetic acid Roth 
Glucose Sigma 
Glycerol Sigma 
HCl Roth 
Hematoxilin Merck 
Heparin Roth 
HEPES Roth 
Hydrogenperoxide (30%) Hartenstein 
Isopropanol Merck 
Kalimacetate Sigma 
Ketanest Pfizer 
Levamisol Sigma 
LiCl Sigma 
Lipofectamine Invitrogen 
Low-melting agarose Biozyme 
Luciferin Promega 
Methanol Hartenstein 
MgCl2 Sigma 
Mowiol Calbiochem 
Na2EDTA Sigma 
NaCl Roth 
NaOH Sigma 
NBT Fermentas 
n-butanol Roth 
Paraformaldehyde (PFA) Sigma 
Paraffin wax Merck 
Phenol Roth 
Phosphate-buffered saline (PBS) Roth 
Prestained protein ladder Fermentas 
Polybrene Sigma 
Polyvinil Pyrolidine (PVP-40) Roth 
Ponceau S Sigma 
riboseATP Fermentas 
Rompum Bayer 
Sea Plaque Agarose Biozym 
Serum (rabbit, goat, donkey) Chemicon 
Sodiumchloride Roth 
Sodiumdodecylsulfat (SDS) Roth 
TEMED Roth 
Tissue TEK (OCT) Chemicon 
Tris Roth 
triSodium dihyrdrate Roth 
Triton X-100 Sigma 
Trizol reagent Invitrogen 
Tween-20 Roth 
Whatman 3MM Paper Schleicher & Schüll 
X-ray film Amersham 
Yeast-extract Invitrogen 
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Reagent Purchased from 
Yeast tRNA Invitrogen 
All used chemicals not listed were ordered with Roth, Sigma, Invitrogen or Fermentas. 
2.1.4 Antibodies 
Primary Antibody Cat. or Clone number Purchased from 
Anti- -actin (rabbit) I-19 Santa Cruz 
Anti-B-Raf (rabbit) C-19 Santa Cruz 
Anti-chicken Myc (rabbit)  Klaus Bister 
Anti-Cytokeration7 M7018 Dako 
Anti-Digoxigenin-AP 11093274910 Roche 
Anti-Gata4 (goat) C-20 Santa Cruz 
Anti-Gata6 (rabbit) H-92 Santa Cruz 
Anti-p75 (mouse)  Abcam 
Anti-pERK1/2 (rabbit) 4094 Cell signalling 
Anti-Sox10  Michael Wegener 
Anti-VEGF (rabbit) sc-507 Santa Cruz 
 
Secondary Antibody Purchased from 
Anti-rabbit IgG conjugated Peroxidase Amersham 
Anti-mouse-biotinylated (rabbit) Dako 
Streptavidin-Alexa555 Molecular Probes 
Anti-rabbit-Cy5 (donkey) Jackson Immuno Research 
Anti-rabbit-Alexa488 (goat) Molecular Probes 
Anti-goat-Alexa647 (donkey) Molecular Probes 
Anti-rabbit-Cy3 (donkey) Jackson Immuno Research 
2.1.5 Enzymes 
Enzyme Purchased from 
Agarase Biozym 
Calf Intestine Alkaline Phosphatase Fermentas 
DNaseI Fermentas 
Proteinase K Roth 
Restrictionendonucleases Fermentas 
RNaseA Fermentas 
T4 Ligase Fermentas 
Taq Polymerase Genecraft 
2.1.6 Kits 
Kit Purchased from 
BCA-Kit Thermo Scientific Pierce 
DIG RNA labeling kit Roche 
DyNAMO HS SYBR Green qPCR Kit New England Biolabs 
ECL Western blotting detection reagents Amersham 
First strand synthesis Kit Fermentas 
Luciferase assay kit Promega 
QIAGEN DNeasy tissue kit  Qiagen 
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Kit Purchased from 
QIAGEN GelExtraction Kit Qiagen 
QIAGEN PCR Purification Kit Qiagen 
QIAGEN Plasmid Maxi Kit Qiagen 
QIAGEN Plasmid Midi Kit Qiagen 
QIAGEN Plasmid Mini Kit Qiagen 
QIAGEN RNeasy Kit Qiagen 
2.1.7 Plasmids 
Plasmid-Name Source 
J5 Prof. Dr. U.R.Rapp 
pcDNA3 Invitrogen 
pBi5-B-Raf
V600E
 PD Dr. R.Götz 
B-Raf-EGFP Dr. C. Xiang 
pBi5-B-Raf
V600E
-EGFP this work 
pLKO.1-puro-shGATA4-24 Sigma Mission® shRNA Bacterial Glycerol stocks 
pLKO.1-puro-shGATA4-25 Sigma Mission® shRNA Bacterial Glycerol stocks 
pLKO.1-puro-shGATA4-26 Sigma Mission® shRNA Bacterial Glycerol stocks 
pLKO.1-puro-shGATA4-27 Sigma Mission® shRNA Bacterial Glycerol stocks 
pLKO.1-puro-shGATA4-28 Sigma Mission® shRNA Bacterial Glycerol stocks 
2.1.8 Oligonucleotides 
For Genotyping 
Mouse-line Sequence ANN. 
TEMP. 
 
B-Raf-KO            
 
mB3-1 (WT/KO) 
5‟-GCCTATGAAGAGTACACCAGCAAGCTAGATGCCC-
3‟ 
mBdel (WT) 
5‟-TAGGTTTCTGTGGTGACTTGGGGTTGTTCCGTGA-3‟ 
NeoL (KO)  
5'-AGTGCCAGCGGGGCTGCTAAA -3‟ 
 
60°C 
SpC-c-Myc SpC_S1 
5‟GAGGAGAGGAGAGCATAGCACC-3‟ 
SpC-cMyc 
5‟AAGGACTTGGCTGGCAGACAGG-3‟ 
60°C 
SpC-C-Raf-BxB as 5‟-GCTGGTGTTCATGCACTGCAG-3‟ 
s   5‟-AAAGACTCAATGCATGCCACG-3‟ 
60°C 
SpC-rtTA as 5‟-TCCTGGCTGTAGAGTCCCTG-3‟ 
s   5‟-CTCCAGGAACCCACTCTCTG-3‟ 
60°C 
Tet-O-B-
RafV600E-
EGFP 
B-Raf*_end_for 
5‟-TCAGAACCCTCCTTGAATCG-3‟ 
B-Raf*_EGFP_rev 
5‟-GCTGAACTTGTGGCCGTTTA-3‟ 
 
56°C 
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For Cloning 
Name Sequence ANN. 
TEMP. 
DCT-RT-for 
DCT-RT-rev 
5‟-GTGCTGAACAAGGAATGCTG-3‟ 
5‟-CAAGCTGTCGCACACAATCT-3‟ 
54°C 
Mitf-RT-for 
Mitf-RT-rev 
5‟-TGAGTGCCCAGGTATGAACA-3‟ 
5‟-AAGTTGGAGCCCATCTTCCT-3‟ 
54°C 
Sox10-RT-for 
Sox10-RT-rev 
5‟CTGCTGCTATTCAGGCTCACT-3‟ 
5‟-AGGGCCCCATGTAAGAAAAG-3‟ 
55°C 
Tyrosinase- 
NotI-for 
Tyrosinase-
XbaI-rev 
5‟-GCCCAAAGCGGCCGCGCACCATCTGGACCTCAGTT-3‟ 
 
5‟-CGTTGGGTCTAGAGCTTCATGGGCAAAATCAAT-3‟ 
54°C 
For Expression analysis 
Primers used for expression analysis. All primers were designed using the program AIO 
(Karreman, 2002). 
Gene Sequence PRODUCT 
SIZE 
ANN. 
TEMP. 
s 5‟-ACGCAGTCAATAAGTGATACCA-3‟ 
as 5‟-GGATGTTTCCTGGTCAGCCT-3‟ 
177 56°C 
-actin s1  5‟-GTCGTACCACAGGCATTGTGATGG-3‟ 
as1 5‟-GCAATGCCTGGGTACATGGTGG-3‟ 
500 56°C 
AFP s 5‟-TGCAGAAACACATCGAGGAGAG-3‟ 
as 5‟- GCTTCACCAGGTTAAGAGAAGCT-3‟ 
474 56°C 
APQ5 s 5‟- AATCCGGCCATTACTCTGGC-3‟ 
as 5‟-TCAGCTCGATGGTCTTCTTC-3‟ 
583 56°C 
ASCI s 5‟-TCGCCCACCATCTCCCCCAA-3‟ 
as 5‟-GATGCAGGATCTGCTGCCAT-3‟ 
205 56°C 
Axud1 s 5‟-ACCAGGTGGTCAGGCACCCC-3‟ 
as 5‟-GCCATGCCCAGGGTACAGCC-3‟ 
195 56°C 
B-Raf Braf ex1s 5‟-GACCCGGCCATTCCTGAAG-3‟ 
Braf ex4as 5‟-CTGTCTCGAACTGTAACACCAC 
AT-3‟ 
 54°C 
CCL19 s 5‟-TTCCCAGCCCCAACTCTGGG-3‟ 
as 5‟-CCACCCAGGGCTGGTCTGGA-3‟ 
196 56°C 
CCR7 s 5‟-GCCAGAGAGGGCTAGCTGGA-3‟ 
as 5‟-CACCGTGGTATTCTCGCCGA-3‟ 
196 56°C 
CD44 s 5‟-TATCCGGAGCACCTTGGCCA-3‟ 
as 5‟-CCAGTGCCAGGAGAGATGCC-3‟ 
 56°C 
CDCA7L s 5‟-ACTCTGCTTCTGATGCCGAG-3‟ 
as 5‟-AGAAGGCCCGTCGTGGTGTT-3‟ 
201 56°C 
CLECSF8 s 5‟-CAGTGGGTGGACAAGACGCC-3‟ 
as 5‟-GATCACTTCGAGGGCTTCCAA-3‟ 
203 56°C 
DBPHT2 s 5‟-TGCCAGACCTGGGGGCATGA-3‟ 
as 5‟-CCTTTCCGGACCTGCTCTGT-3‟ 
200 56°C 
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Gene Sequence PRODUCT 
SIZE 
ANN. 
TEMP. 
DCT Ex7 5‟-AACAACCCTTCCACAGATGC-3‟ 
Ex8 5‟-TTGAAGAAAAGCCAGCAACC-3‟ 
249 56°C 
Enol s 5‟-CTCCCAGTGGGTGCTGAGAG-3‟ 
as 5‟-GTGTAGCCAGCCTTGTCGAT-3‟ 
200 56°C 
ERAF s 5‟-GGCGGGCTCAGCACCATTAG-3‟ 
as 5‟-TCCCCATGCACGAGCTTCTT-3‟ 
204 56°C 
ERFI s 5‟-TATGAAGTCCTGCTGGGGCA-3‟ 
as 5‟-GGGGCAAGCTTGACCTTGGA-3‟ 
194 56°C 
FoxD3 s 5‟-CCAGCGATATGTCCGGCCAG-3‟ 
as 5‟-GGCTTGCGGTTGAGACTGGC-3‟ 
200 56°C 
Fzd10 s 5‟-AAGTGCCAGCCGGTGGAGAT-3‟ 
as 5‟-ACCTGCTCGGTGCACATGGG-3‟ 
200 56°C 
Gadd45a s 5‟-CTCCTGCTCTTGGAGACCGA-3‟ 
as 5‟-TCATTCAGATGCCATCACCG-3‟ 
212 56°C 
Gadd45b s 5‟-ACGAGTCGGCCAAGTTGATG-3‟ 
as 5‟-CGCACGATGTTGATGTCGTT-3‟ 
151 56°C 
Gadd45g s 5‟-GTGCTGAGCTCTGGCTGTCA-3‟ 
as 5‟-AGCAACTCATGCAGCGCTTT-3‟ 
175 56°C 
GATA4 s 5‟-CTACATGGCCGACGTGGGAG-3‟ 
as 5‟-CTCGCCTCCAGAGTGGGGTG-3‟ 
132 56°C 
GATA6 s 5‟-TCCATGGGGTGCCTCGACCA-3‟ 
as 5‟-CCCTGAGGTGGTCGCTTGTG-3‟ 
200 56°C 
HBBB1 s 5‟-AAGGGCACCTTTGCCAGCCT-3‟ 
as 5‟-CTTGTGAGCCAGGGCAGCAG-3‟ 
189 56°C 
Ifi202b s 5‟-AGGCTGGTTGATGGAGAGTT-3‟ 
as 5‟-TCAGAAACCACTCATCTGCA-3‟ 
196 56°C 
Jagged s 5‟-CGGGATGGAAACAGCTCAC-3‟ 
as 5‟-CACCAAGCAACAGACCCAAG-3‟ 
135 56°C 
Klf4 s 5‟-CTCATGCCACCGGGTTCCTG-3‟ 
as 5‟-CCACAGCCGTCCCAGTCACA-3‟ 
110 56°C 
Lats s 5‟-CAGCAAATGAGAGCCACCCC-3‟ 
as 5‟- CTCCTACTGCCCGTCTGCTT-3‟ 
200 56°C 
Malat1 s 5‟-ACTTGAGAGGCCCTGGGCTT-3‟ 
as 5‟-CATGGTGGCGATGTGGCAGA-3‟ 
195 56°C 
Mucin2 s 5‟-CGACTAACAACTTCGCCTCCG-3‟ 
as 5‟-CGCGGGAGTAGACTTTGGTG-3‟ 
246 56°C 
Myc (MM) s 5‟-TCTCTCCTTCCTCGGACTCG-3‟ 
as 5‟-GAGATGAGCCCGACTCCGAC-3‟ 
198 56°C 
Myc (GG) s 5‟-CGGCCTCTACCTGCACGACC-3‟ 
as 5‟-GACCAGCGGACTGTGGTGGG-3‟ 
298 56°C 
Mitf Mitf-RT-for 5‟-TGAGTGCCCAGGTATGAACA-3‟ 
Mitf-RT-rev 5‟-AAGTTGGAGCCCATCTTCCT-3‟ 
822 56°C 
NeuroD1  s 5‟-CCCACGCAGAAGGCAAGGTG-3‟ 
as 5‟-GTCTGCCTCGTGTTCCTCGT-3‟ 
196 56°C 
Notch1 s 5‟-TCAATGCCGTGGATGACCTA-3‟ 
as 5‟-CCTTGTTGGCTCCGTTCTTC-3‟ 
102 56°C 
Notch2 s 5‟-TGGCGCCTTCCACTGTGAGT-3‟ 
as 5‟-CACACGGGTTGCTCTGGCAT-3‟ 
200 56° 
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Gene Sequence PRODUCT 
SIZE 
ANN. 
TEMP. 
Notch3 s 5‟-CACTCCCTGCCGGAATGGTG-3‟ 
as 5‟-TCTCACAGCGTATGCCCGTA-3‟ 
204 56°C 
Notch4 s 5‟-TTCCCAAAAGGAGCCTCTGC-3‟ 
as 5‟-TCTACACAACACCCGGCACA-3‟ 
88 56°C 
ODC s 5‟-GGTTCCAGAGGCCAAACATCT-3‟ 
as 5‟-GCTCTCCTGGGCACAAGACA-3‟ 
140 56°C 
p53 s 5‟-GCACATGACGGAGGTTGTGA-3‟ 
as 5‟-ATGATGGTGAGGATGGGCCT-3‟ 
264 56°C 
p63 s 5‟-CCTCCAACACCGACTACCCA-3‟ 
as 5‟-TCACCTTGATCTGGATGGGG-3‟ 
150 56°C 
p73 s 5‟-CGCGTGGAAGGCAATAATCT-3‟ 
as 5‟-GTTCATGCCCCCTACACAGC-3‟ 
156 56°C 
PBK s 5‟-AGCCAGCCCGTCACTTTCAC-3‟ 
as 5‟-GCTGACCCCAGTCCCAAAGC-3‟ 
197 56°C 
PGP9.5 s 5‟ ATTCCTGTGGCACAATCGGA-3‟ 
as 5‟-GACATTGGCCTTCCTGTGCC -3„ 
195 56°C 
RSAD2 s 5‟-CTAGCCCTGCCCTCTGTGAG-3‟ 
as 5‟-CCTGCACCACCTCCTCAGCT-3‟ 
198 56°C 
SHMT1 s 5‟-GAAGGACCAGGGGCTCCACG-3‟ 
as 5‟-TCTGAGCTGGTAGAGGCCGC-3‟ 
198 56°C 
SNCA s 5‟-GGAGGGAGTTGTGGCTGCTG-3‟ 
as 5‟-GCGACTGCTGTCACACCAGT-3‟ 
198 56°C 
SNCG s 5‟-ACATCGTGGTCACCACCGGG-3‟ 
as 5‟-GCAGGGCATTCAGTGTGCCA-3‟ 
419 56°C 
Sox2 s 5‟-TCAAGAGGCCCATGAACGCC-3‟ 
as 5‟-GGGTGCTCCTTCATGTGCAG-3‟ 
196 56°C 
Sox9 s 5‟- TGAAGAAGGAGAGCGAGGAAGATAA-3‟                               
as 5‟- GGTGGCAAGTATTGGTCAAACTCA-3‟ 
721 56°C 
Sox10 Sox10-RT-for  
5‟-CTGCTGCTATTCAGGCTCACT-3‟ 
Sox10-RT-rev 
5‟-AGGGCCCCATGTAAGAAAAG-3‟ 
693 56°C 
SYB s 5‟-TGCAGGCCGGAGCATCACAA-3‟ 
as 5‟-GGCAGGGCTGGGAGAAGTCT-3‟ 
196 56°C 
SYK s 5‟-TCAGCGGGTGGAATAATCTC-3‟ 
as 5‟-TGTGCACAAAATTGCTCTCC-3‟ 
625 56°C 
tert s 5‟-GCACTGGCTGATGAGTGTGT-3‟ 
as 5‟-CTCGGCCCTCTTTTCTCTG-3‟ 
322 56°C 
Tiam2 s 5‟-TGTGTGCCCGCGCTGTATGA-3‟ 
as 5‟-CGTATGCCAGGCTGTCAGGG-3‟ 
202 56°C 
TMP4 s 5‟-GAGGAGGAACTGGACCGGGC-3‟ 
as 5‟-ACTTGCGGTCGGCTTCGTCA-3‟ 
199 56°C 
Tyrosinase Ex1 5‟-GGGATTGGAGAGATGCAGAA-3‟ 
Ex2 5‟-TCAGGTGTTCCATCGCATAA-3‟ 
175 58°C 
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2.1.9 Media and Additives 
Media and Additives for bacterial culture 
LB (Luria-Bertani)-Medium g for 1 liter H2O 
Bacto-tryptone 10g 
NaCl 10g 
Yeast extract 5g 
 
After the substances were dissolved, the pH was adjusted to 7.5 using NaOH. 
For production of plates, 15 g/l bacto-agar was added. All media were autoclaved for 20 min 
at 120°C. Antibiotics for the production of selective plates were added after cooling of the 
autoclaved liquids to about 45°C. The plates were stored at 4°C. 
Additive Stock-solution Final concentration 
Ampicillin 100 mg/ml in H2O 100 g/ml 
Kanamycin 20 mg/ml in H2O 20 g/ml 
Media and Additives for Eukaryotic cell culture 
Medium Source 
D-MEM Invitrogen 
 
Additive Source Final concentration 
Doxycycline Sigma 100nM 
Fetal Calf Serum (FCS) Invitrogen 10x stock 
Penicillin/Streptomycin Invitrogen 10x stock 
Trypsin-EDTA Invitrogen  
2.1.10 Bacterial strains, Cell lines, Mouse lines 
Cell lines 
Cell lines Source 
3041 Mouse lung adenocarcinoma cell line (MSZ) 
A-549 Human lung adenocarcinoma cell line (MSZ) 
B16 Murine melanoma cell line (Dermatology, University of 
Würzburg) 
NIH3T3-tTA Murine fibroblast cell line (MSZ) 
Phoenix ampho MSZ 
Mouse strains 
Mouse lines Source 
B-Raf-KO MSZ 
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Mouse lines Source 
C57Bl6 All were obtained from Harlan Winkelmann GmbH 
NMRI All were obtained from Harlan Winkelmann GmbH 
FvB/N All were obtained from Harlan Winkelmann GmbH 
Rag1
-/-
 All were obtained from Harlan Winkelmann GmbH 
SpC-c-Myc Gift from Roland Halter 
SpC-C-Raf-BxB MSZ 
Bacterial strains 
Bacterial strain Source 
E.coli DH5  MSZ 
E.coli XL1-Blue Stratagene 
2.1.11 Solutions and buffers 
General Solutions 
Solution Ingredients  
Blotting buffer 25mM Tris 
192mM Glycine 
10% Methanol 
 
6x DNA loading dye Glycerol 
0.5mM Na2EDTA 
20% SDS 
bromphenol blue 
water 
1.2ml 
1.2ml 
300 l 
 
up to 10ml 
Injectionbuffer 5mM Tris-HCl (pH7.4) 
0.1mM EDTA 
in water 
ProteinaseK buffer 10mM Tris-HCl (pH8.0) 
1mM EDTA 
1% Tween 
 
Running buffer (for SDS-
PAGE) 
25mM Tris 
250mM Glycine 
0.1 % SDS 
 
5x SDS loading buffer 50mM Tris-HCl (pH 6.8) 
10% Glycerol 
5% -mercaptoethanol 
2% SDS 
0.05% bromophenolblue 
 
Stripping buffer 1M Tris-HCl (pH6.7) 
20% SDS 
dH2O 
-mercaptoethanol 
3.125ml 
5ml 
42ml 
0.35ml 
50x TAE buffer Tris-base 
Glacial acetic acid 
0.5M NA2EDTA (pH8.0) 
H2O 
242g 
57.1ml 
100ml 
up to 1000ml 
Tail lysis buffer 50mM EDTA 
50mM Tris-HCl (pH8.0) 
in water 
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Solution Ingredients  
0.5% SDS 
10x TBS 500mM Tris-HCl (pH7.4) 
1.5M NaCl 
 
in water 
TBST 1x TBS 
000.05% Tween-20 
 
TE 10mM Tris-Hcl (pH7.5) 
1mM EDTA 
in water 
Buffers for CsCl-Plasmid Preparation 
Solution Ingredients  
SolutionI 50mM Glucose 
25mM Tris-HCl (pH8.0) 
10mM EDTA 
in water 
SolutionII 0.2M NaOH 
1% SDS 
in water 
SolutionIII 5M Kaliumacetate 
glacial acetic acid 
 
 
115ml 
ad to 1l water 
Water saturated n-butanol 5M NaCl 
n-butanol 
Mix, wait until the 
phases separate and 
the lower NaCl 
phase becomes 
salt-saturated 
Buffers for in-situ hybridisation 
Solution Ingredients  
BCIP-stock 50mg/ml BCIP in 100% 
dimethylformamide 
Blocking Solution 2% Blocking Reagent 
20% heat inactivated FCS 
 
in TBST 
Denhard‟s Solution (100x) 2%BSA 
2% Polyvinil Pyrolidine (PVP-40) 
2% Ficoll 
In water-DEPC  
Hybridisation buffer 100% deionized Formamide 
20x SSC 
20mg/ml yeast tRNA 
10mg/ml Heparin 
0.5M EDTA (pH8.0) 
10% Tween-20 
10% Chaps 
50x Denhard‟s solution 
water-DEPC  
1M citric acid 
50ml 
25ml 
1.25ml 
1ml 
1ml 
1ml 
1ml 
1ml 
ad to 100ml 
to pH5 
NBT-stock 75mg/ml NBT in 70% 
dimethylformamide 
NTMT 1M Tris-HCl (pH9.5) 
1M MgCl2 
1M NaCl 
20ml 
10ml 
20ml 
Materials and Methods 
 
 40 
Solution Ingredients  
10% Tween-20 
water 
1M HCl 
1M Levamisol (add before use) 
10ml 
ad to 200ml 
to pH 9.5 
1ml 
Proteinase K-buffer 50mM Tris 
5mM EDTA 
 
in PBS 
RNaseA buffer NaCl 
1M Tris-HCl (pH7.5) 
0.5M EDTA 
water 
29.23g 
10ml 
2ml 
ad to 1l 
SSC (20x) NaCl 
triSodiumdihydrate 
water-DEPC 
1M citric acid 
17.65g 
8.82g 
to 100ml 
to pH 5 
TAE-buffer 0.1M triethanolamin (pH8.0) 
add slowly while stirring 
acetic anhydride 
50ml 
135 l 
 
2.2 Molecular Biology Methods 
2.2.1 Bacterial Manipulation 
Transformation of competent bacteria 
For transformation of plasmid-DNA into E.coli, the XL1-Blue Competent Cells (Stratagene) 
were used as described in the according manual. After transformation the bacteria were plated 
on LB-agar plates containing a selective antibiotic. After incubation at 37°C overnight, a 
single colony can be picked and expanded in LB medium containing the selection antibiotic 
and used for DNA preparation. 
Purification of Plasmid-DNA 
To amplify plasmid DNA, a colony of E.coli that were transformed with the according 
plasmid before, was grown in 50 ml of LB medium overnight. From the pellet of this culture, 
the plasmid-DNA was isolated using the QIAGEN Plasmid Kits as described in the according 
manual. 
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CsCl Plasmid Preparation 
For CsCl plasmid preparation 500ml of plasmid containing bacterial overnight culture were 
pelleted at 5000rpm at 4°C for 10min and the supernatant was discarded. The bacterial pellet 
was resuspended in 20ml of solution I and after 10min of incubation at room temperature 
40ml of solution II were added. The mixture was incubated on ice for 10min before 30ml of 
ice-cold solution III were added, followed by 10min incubation on ice. The lysed bacteria 
were then pelleted again via centrifugation for 10min at 9000rpm at 4°C. The DNA-
containing supernatant was filtered and the DNA was precipitated by addition of 0.6 volumes 
of isopropanol and 10min incubation at room temperature. After 10min centrifugation at 
9000rpm at 4°C the supernatant was discarded, the pellet was air-dried and resuspended in 
30ml of TE-buffer. 
Exactly 33.4g of CsCl were added to 30ml of the DNA-solution, mixed until the CsCl was 
completely dissolved and 0.5ml of Ethidiumbromide were added. The solution was then 
transferred to Beckmann Quickseal Tubes and the tubes were closed with the apposite 
equipment. The exactly balanced tubes were centrifuged overnight at 45000rpm in an 
ultracentrifuge. The DNA-band, which was visualized by UV-light, was removed using an 
injection-needle and a syringe. To remove the ethidiumbromide, the DNA-solution was then 
added an equal volume of water-saturated n-butanol and the organic and the aqueous phase 
were mixed by vortexing. After the organic and the aqueous phase had separated, the upper 
organic phased was removed using a Pasteur pipette. This extraction was repeated until the 
pink colour had disappeared from the organic as well as from the aqueous phase. 
To precipitate the DNA from the CsCl-DNA-solution, three volumes of water and 8 volumes 
of ethanol were added and the precipitation was performed overnight at 4°C. To collect the 
precipitate, the mixture was centrifuged for 30min at 4200rpm at 4°C. The pellet was washed 
with 70% ethanol, air-dried and dissolved in 500 l TE-buffer. 
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2.2.2 Analysis of DNA-molecules 
Agarose-Gelelectrophoresis of DNA-molecules 
Double stranded DNA fragments with a length between 150 bp and 10 kbp can be separated 
according to their length on an agarose gel. For this purpose a suspension of agarose (0.8-2%) 
in 1xTAE-buffer was cooked until the agarose was completely dissolved. After cooling to 
about 50°C, 0.5 g/ml Ethidiumbromide was added before the solution was poured into the gel 
apparatus. When the gel was solidified, the DNA mixed with loading dye was applied on the 
gel and electrophoresis was performed in 1xTAE buffer at 120V for 30min. The DNA bands 
then could be visualized under UV-light. 
Preparation of DNA-Fragments from an agarose gel 
The DNA-fragments separated by agarose-gelelectrophoresis visualized by UV-light can be 
excised with a sterile scalpel from the gel. Afterwards this DNA was isolated from the gel 
using the QIAGEN Gel Extraction kit according to the included manual. 
Preparation of DNA-Fragments from an agarose gel for microinjection 
For the preparation of DNA-Fragments from an agarose gel for microinjection was performed 
using an agarose-digesting enzyme, agarase, from Biozym according the included manual. 
Isolation of DNA from tissue 
For isolation of DNA from murine tissue, the QIAGEN DNeasy tissue kit was used according 
to the included manual. 
2.2.3 Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction (PCR) is used for amplification of specific regions of a 
DNA-target. Usually PCR was performed in an 30 l reaction mix containing 3 l of 10x Taq-
Polymerase buffer, 1 l of 2mM dNTP-mix, 0.5 l of 20pM forward and reverse Primer and 
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0.3 l Taq-Polymerase, filled up with water. The PCR reaction typically consists of 20-40 
repeated temperature changes called cycles. After an initialization step for 10min at 95°C 
follows a cycling of the denaturation step (usually for 30sec at 95°C), the annealing step (the 
temperature depends on the primers that are used) and the elongation step (30sec-1min at 
72°C). Finally before cooling down the reaction mix, there is an additional elongation step at 
72°C for 10min. All PCR reactions were performed as described above as long as there are no 
other conditions mentioned. 
2.2.4 Mutation-Analysis 
Isolation of DNA from paraffin-sections 
For the isolation of DNA from tissue sections, after an H&E staining the sections were not 
mounted but air-dried. 25 l of ProteinaseK-buffer (containing 20mg/ml ProteinaseK) were 
propounded into a 1.5ml reaction tube. 10 l of ProteinaseK-buffer were directly pipetted on 
the region to be isolated from the section and the tissue was scraped from the glass slide using 
a sterile scalpel, transferred to the prepared reaction tube and incubated overnight at 37°C. 
After inactivating the ProteinaseK by incubating the samples at 92°C for 30min, the samples 
were centrifuged at 12000rpm and the DNA was isolated from the supernatant. For this 
purpose ProteinaseK-buffer was added to a final volume of 450 l and 250 l 6M NaCl were 
pipetted to the samples and they were incubated for 5min at room temperature. After 10-
15min of centrifugation at 12000rpm, the supernatant was transferred to a fresh reaction tube 
and 600 l of Isopropanol were added. After incubating the samples for 5min at room 
temperature, they were centrifuged at 12000rpm for 10-15min and the pellet was first washed 
with 600 l 70% Ethanol and later with 100% Ethanol. Finally, the pellet was dried and 
dissolved in sterile Millipore water. 
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PCR for KRas Exon1 and LKB1 Exon6 
To have enough material for sequencing KRas Exon1 and LKB1 Exon6 to detect mutations, 
before PCR was performed as described above to amplify the DNA isolated from paraffin-
sections. First a PCR was performed with primers that bind adjacent to the Exon of interest 
and afterwards an additional PCR was done using primers that lead to the amplification of the 
complete Exon of interest. All primers used for the mutation-analysis are listed in Table 2-1. 
Primer Sequence PCR-conditions 
KRas_S_OUT 
KRas_AS_OUT 
5‟-GGCTGAGGCGGCAGCGCTGTG-3‟ 
5‟-GCTGAGGTCTCAATGAACGGAAT 
CC-3‟ 
50°C annealing temperature 
40 cycles 
KRas_S 
KRas_AS 
5‟-GGCTGAGACGGCAGGGGAA-3‟ 
5‟-CTTGCTAACTCCTGAGCCTG-3‟ 
50°C annealing temperature 
40 cycles 
LKB_6OUTS 
LKB_6OUTAS 
5‟- GGGGTCACACTGTAAGTGTC-3‟ 
5‟- TGGGGGGAAGCAATCTCAGA-3‟ 
50°C annealing temperature 
40 cycles 
LKB_6S 
LKB_6AS 
5‟- ACCCTGTAGCAGATGGGGGG-3‟ 
5‟- CCTCCCATCCTGGCGGACAA-3‟ 
50°C annealing temperature 
40 cycles 
Table 2-1 PCR-conditions for Mutationanalysis. 
Sequencing of KRas Exon1 and LKB1 Exon6 
Before sequencing the PCR-products were purified via gelextraction as described above with 
the Gelextraction-Kit of QIAGEN. The DNA was eluted with 30 l of water and for 
sequencing, 4 l of the DNA was mixed with 1 l of the primer KRas_S, KRas_AS, LKB_6S 
and LKB_6AS, respectively, and with 25 l of Millipore water and the samples were sent for 
sequencing to StarSEQ for sequencing. The resulting sequences were compared with the 
published sequences of KRas and LKB1 with carefully searching for doublepeaks in the 
sequences indicating a heterozygous mutation. 
2.2.5 Enzymatic Manipulation of DNA 
Restriction Digestion of DNA using Restrictionendonucleases 
Restrictionendonucleases bind doublestranded DNA specifically and cut in or next to their 
target sequence containing 4-8 basepairs. Depending on the enzymes used, the digestion of 
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the DNA results in blunt or sticky ends. For analytical digestion 1-3 g DNA were incubated 
with 1-3 units of the restrictionendonuclease for 2hrs at the enzyme-specific temperature in a 
final volume of 20 l containing the according buffer. For a preparative approach 10 g of 
plasmid were digested using up to 20 units of enzyme in a final volume of 50 l. The 
composition of the according buffers and the reaction conditions are described in the 
catalogue of the enzyme supplier. 
Dephosphorylation of digested plasmid-DNA 
To prevent religation of linearized plasmid-DNA, the DNA was treated with Calf Intestine 
Alkaline Phosphatase (CIAP) before ligation, which is removing the 5‟-phosphate-groups 
from the DNA-ends. This reaction was performed in the reaction mix of the 
restrictionendonuclase-digestion reaction. For this purpose 1/10 of the final volume 10x 
CIAP-buffer and 1 l CIAP was added and the reaction was incubated for 30min at 37°C. 
Finally the reaction was stopped by heating to 85°C for 15min. The dephosphorylated DNA 
was then purified from an agarose gel. 
Purification of PCR-products 
To remove the nucleotides and the Taq-Polymerase-buffer from the PCR-product, the PCR 
reaction was purified using the QIAGEN PCR Purification kit according to the included 
manual. 
Phosphorylation of PCR-products 
To increase the effectivity of the ligation reaction into a CIAP-treated vector, the PCR-
fragments were phosphorylated on the 5‟-ends using the T4-Polynucleotide-Kinase. For this 
purpose, 15.5 l of the PCR-product were incubated with 2 l of 10xbuffer, 1 l T4-
Polynucleotide-Kinase and 1.5 l Ribose-ATP for 30min at 37°C. To inactivate the enzyme, 
1 l of 0.5M EDTA was added and the EDTA was extracted by the same volume of 
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chloroform. To assure, that there is no chloroform left in the mix, the DNA was finally 
purified from an agarose gel. 
Ligation of DNA-fragments 
DNA-Ligases catalyze the formation of a phosphodiesterbinding between neighbouring 5‟-
phosphate- and 3‟-hydroxylgroups of double stranded DNA-molecules. For this reaction, the 
concentration of the insert was about three times higher related to the vector-concentration. 
To a final volume of 15 l, 1.5 l 10xligation buffer and 1-2 units of T4-Ligase were added. 
The reaction was performed for 2hrs at 22°C or overnight at 14°C. 
2.2.6 Isolation of RNA 
RNA-Isolation from cells and tissue 
For isolation of RNA from cells, after removal of the medium 1ml of Trizol-reagent was 
directly added on the cells. In case of shock-frozen organs, the tissue was mechanically 
homogenized at 4°C using a homogenizer in 1ml of Trizol-reagent. The procedure of RNA-
isolation was performed as described in the protocol provided by the manufacturer.  
For isolation of RNA from rare samples, i.e. the neural tube explants, the QIAGEN RNeasy-
kit was used. The RNA-isolation was performed as described in the manual included in the 
kit. 
The RNA was dissolved and eluted, respectively, using RNase-free water and was stored at -
80°C. 
Quantification and determination of Quality of RNA 
The concentration of the isolated RNA was determined by measuring the absorbance at 
260nm (A260) using a spectrophotometer. An absorbance of 1 unit at 260nm equals 44 g of 
RNA per ml. The ration between the absorbance values at 260 and 280nm, which should be 
between 1.7 and 2.1, gives an estimate or RNA purity. 
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2.2.7 RT-PCR 
cDNA -synthesis 
Total RNA obtained from eukaryotic cells or tissue, was treated with RNase-free DNaseI to 
remove DNA contamination from the RNA-sample. For this purpose 1 g RNA was filled up 
to a volume of 9 l with RNase-free water and 1 l DNaseI-buffer was added to the reaction 
mix. After pipetting 1 l of DNaseI to the sample, the mix was incubated for 30min at 37°C. 
The reaction was stopped by the addition of 1 l 25mM EDTA and heating to 65°C for 10min. 
The first strand synthesis was performed, using the sample directly from the DNaseI-
treatment with the Fermentas first strand synthesis kit and random hexamer primers as 
described in the according manual. 
The cDNA was used as a template for RT-PCR and qPCR, respectively. 
Real-Time-PCR 
Depending on the cDNA-quality, 0.5-2 l of cDNA obtained from cDNA-synthesis described 
above was used as template for real-time PCR analysis. 10 l of the Finnzymes SYBR Green 
master-mix, the template cDNA, 0.5 M of the primers specific for the gene of interest or for 
the housekeeping gene, respectively, and 0.4 l of the dye ROX as an internal control were 
used in a 20 l reaction. To calculate the relative amount of the transcript of the gene of 
interest, the amplification efficiency was raised to the power of the threshold cycle (Ct-value). 
This gives the number of cycles necessary for the product to be detectable. The resulting 
value was normalised to the level of the housekeeping gene for all samples in the same 
experiment. Assays were performed in triplicates following the manufacturer‟s instructions in 
a Rotor-Gene 2000 detection system. 
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2.2.8 Microarray 
Microarray experiments and analysis were performed by Ellen Leich at the Institute for 
Pathology at University of Würzburg using Affimetrix Gene Chip products. 
2.3 Biochemistry Methods 
2.3.1 Measurement of Protein concentration 
For the measurement of protein concentration in the BCA-Kit from Thermo Scientific Pierce 
was used according to the included manual. BSA was used as a standard control. 
2.3.2 SDS-PAGE 
Proteins can easily be separated by size by electrophoresis in a polyacrylamide gel under 
denaturing conditions. 5x SDS-loading buffer was used to denature 20-50 g of protein 
sample and the diluted samples were then heated at 95°C for 5min. The denatured protein 
samples were then separated in a gel composed of two layers, the separating gel and the 
stacking gel with a lower concentration of acrylamide to insure that the proteins 
simultaneously enter the separating gel. The composition of the gel is indicated in Table 2-2.  
 Separating Gel Stacking Gel 
3M Tris-HCl, pH 8.8 2.5 ml  
1M Tris-HCl, pH 6.8  1.3 ml 
Acrylamide/bisacrylamide 29:1 (30%) 2.7-6.5 ml 1.1 ml 
10% SDS 200 l 100 l 
ddH2O 14.4-10.6 ml 7.6 ml 
10% APS 200 l 100 l 
TEMED 20 l 10 l 
Table 2-2 Components of a separating and a stacking gel. 
After preparation and solidifying of the gel at room temperature, the gel was put into a 
running chamber and this chamber was filled with running buffer. The denatured samples 
were then loaded into the wells of the stacking gel as well as a protein ladder for mass 
determination and 45mA were applied until the running front of loading dye was on the 
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bottom of the gel. The due to the SDS negatively loaded proteins are running from the anode 
to the kathode. 
2.3.3 Immunoblotting 
After SDS-Gelelectrophoresis the proteins were transferred by electroblotting from the gel to 
a nitrocellulose-membrane. SDS-gels were blotted at 400mA in blotting buffer for 1hr. After 
the transfer, the membrane was incubated with blocking buffer containing 5% slim milk in 
PBS for 1hr at room temperature or over night at 4°C. To detect the protein of interest, after 
blocking, the membrane was incubated with the primary antibody diluted in PBS (1:50-
1:10000, depending on the antibody) for 2hrs at room temperature or overnight at 4°C. Before 
applying the secondary antibody, the membrane was washed at least three times for 10min 
with PBS-0.3%Tween. The appropriate peroxidase-conjugated secondary antibody was 
diluted in PBS (1:100-1:10000, depending on the antibody) and incubated with the membrane 
for 45 min at room temperature. An additional washing step was performed before the 
membrane was incubated for 1min at room temperature with a 1:1 mixture of the ECL-
solutions I and II. The incubation of the peroxidase bound to the secondary antibody with the 
ECL-solutions leads to the emission of light photons, which can be detected on an X-Ray 
film. 
2.3.4 Immunoblot-stripping 
To reprobe the same nitrocellulose membrane with the bound proteins with another antibody, 
it is possible to remove the primary and secondary antibodies using stripping buffer and 
incubating the membrane for 30min at 50°C. After stripping and washing, the membrane can 
be blocked and reprobed as described above. 
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2.3.5 Luciferase-Reportergene-assay 
For the Luciferase-Reportergene-assay, samples were prepared in lysis buffer containing 
0.25M Tris, pH7.6, 1% Triton-X100. Tissue samples were homogenized in the lysis-buffer at 
4°C, cell culture samples were lysed directly on a 6-well dish. After centrifugation at 
11000rpm for 10min at 4°C, the luciferase of the supernatant was measured in a luciferase 
assay using a Berthold luminometer and the luciferin substrate. Finally the protein 
concentrations were measured as described above and luciferase activity was normalized to 
the protein concentration. 
2.4 Eukaryotic Cell Culture Techniques 
All handling of cell cultures was performed using a clean bench. To the media used for the 
cell lines as described, 10% fetal calf serum was added and 1% Penicillin/Streptomycin was 
used to avoid contamination. To passage the adherent cell lines, the cells were washed with 
PBS, treated with Trypsin-EDTA for 3-5min and the splitted as required. The cultures were 
kept in an incubator at 37°C in a humidified atmosphere with 5% CO2. 
2.4.1 Freezing cell lines 
By addition of an anti-freezing compound like DMSO, eukaryotic cell lines can be stored in 
liquid nitrogen for several years. For this purpose, the trypsinized cells were spun down in a 
centrifuge (1000rpm, 5min, room temperature), the pellet was washed with PBS, counted 
using a Neubauer chamber and diluted in ice-cold medium containing 20% FCS and 10% 
DMSO to obtain at least 1-2x10
6
 cells per ml. 1ml of this cell suspension was then transferred 
into a cryotube and stored at –80°C for at least 24hrs. For prolonged storage the cryotubes 
were then transferred to liquid nitrogen.  
For reculturing of the frozen cells, the cell suspension was defrosted at 37°C and immediately 
put into prewarmed medium. To remove the toxic DMSO, the cells were spun down 
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(1000rpm, 5min, 37°C) and the pellet was resuspended in warm medium and cultured at 37°C 
as described before. 
2.4.2 Transient Transfection of cells using Lipofectamine 
For transient transfection of adherent cells with plasmid-DNA, the cells were seeded the day 
before transfection to reach about 70% confluency at the time of transfection in medium 
without Penicillin/Streptomycin. The transfection was performed according to the 
recommendations in the manual. The day after transfection the medium was changed to 
normal culture medium. Antibiotics for selection of the transfected cells were added 48hrs 
after transfection. Expression of a transfected vector was tested 48hrs after transfection. 
2.4.3 Viral infection of cell lines 
For virus production the amphotrophic retrovirus producer cell line Phoenix was transfected 
with the viral plasmid using Lipofectamine as described above. 24hrs after transfection the 
medium of the virus producing cell line was changed to a minimal amount to have a high 
virus concentration in the supernatant. Cells for infection were seeded to be about 50% 
confluent on the day of infection. 48hrs after transfection, the virus containing supernatant of 
the virus-producing cells was collected and centrifuged at 500rpm at 4°C to pellet cell debries 
and was used immediately. Before pipetting the virus-containing supernatant onto the cells to 
be infected, it was mixed 1:1 with fresh medium and 8 g/ml of Polybrene was added. 
2.4.4 Soft-agar-assay 
The soft-agar-assay was performed using cells 24hrs after virus-infection or cells transfected 
with a plasmid containing a selectable marker selected for at least 5days. First, the bottom 
agar was prepared using an autoclaved stock of 5% Sea Plaque Agarose, which was 
microwaved and mixed with D-MEM-medium to a final concentration of 0.5% Agarose. For 
the bottom agar 5ml of 0.5% Agarose was used per 60mm dish. When the bottom agar was 
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solid, for the topagar the 5% stock was diluted to 0.6% Agarose with medium and stored in a 
waterbath at 40°C. Dilutions of the cells were prepared in 1ml of medium (10
3
 to 10
6
 cells per 
60mm dish) and then mixed 1:1 with the 0.6% Agarose and poored on top of the bottom agar. 
After solidifying the soft-agar-assay was incubated in a wet chamber at 37°C for 21-28days. 
For quantification the colonies were counted and categorized by size. If necessary for the 
experiment, colonies were picked using a Pasteur pipette and were subsequently grown under 
adherent cell culture conditions. 
2.4.5 Cultures of Neural Tube Explants (Jontes et al.) 
Fibronectin-coating of cell-culture dish 
For coating of the cell-culture dish with the extracellular adhesion molecule fibronectin, the 
dish was incubated with 2.5% fibronectin in PBS for one hour at room temperature. Finally 
the dish was washed with sterile millipore water and stored at 4°C until use. 
Preparation and culturing of Neural Tube Explants 
For culturing of neural tubes, embryos in the age of E9.5 were isolated from the pregnant 
female and were transferred into cold PBS. Using a stereolupe, the neural tube was separated 
from the rest of the embryo and transferred to fibronectin-coated dish containing prewarmed 
D-MEM-Medium. The head of the embryo was kept at –20°C for genotyping. The neural tube 
explants were cultured in D-MEM medium containing 5nM Endothelin-3. The medium was 
changed every other day. 
2.4.6 Analysis of cultured cells via Immunocytochemistry 
Immunocytochemistry 
For immunocytochemical staining of cultured cells, the cells were grown on sterile coverslips, 
washed three times with PBS and fixed for 15min at room temperature using 4%PFA-PBS. 
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After fixation the cells were washed three times for 5min with PBS and blocked with 
blocking solution containing the blocking reagent indicated in Table 2-3 and 0.3% TritonX-
100 for 1hr at room temperature. The primary antibody was diluted as indicated in Table 2-3 
in blocking solution and incubated at 4°C overnight on the cells. Before incubation with the 
secondary antibody diluted in blocking solution as indicated in Table 2-3 for 2hrs at room 
temperature, the cells were washed three times for 5min with PBS. The cells were washed 
again three times for 5min with PBS and if the secondary antibody was biotinylated, the cells 
were then incubated with streptavidin-Alexa555 diluted 1:200 in 0.2% TritonX-100 for 1hr. 
Otherwise or after this step, after washing three times for 5min, the cells were counterstained 
with DAPI diluted 1:200 in PBS at 37°C for 15min. After washing with Millipore water, the 
cells were mounted with mowiol and stored at 4°C until fluorescence microscopy. 
staining blocking 
reagent 
dilution primary 
antibody 
secondary antibody dilution secondary 
antibody 
p75/Sox10 1% BSA Sox10 1:50 
p75 1:250 
rabbit- -mouse-biot. 
Goat- -rabbit-
Alexa488 
1:200 
1:200 
chicken 
Myc 
4% donkey 
serum 
1:10000 donky- -rabbit-Cy5 1:200 
GATA4 4% donkey 
serum 
1:100 donky- -goat-
Alexa647 
1:200 
GATA6 4% donkey 
serum 
1:50 donky- -rabbit-Cy3 1:200 
VEGF 4% donkey 
serum 
1:500 donky- -rabbit-Cy3 1:200 
Table 2-3 Antibody conditions for Immunocytochemistry. 
Quantification of p75/Sox10 positive cells 
For quantification of the percentage of neural crest stem cells in the neural tube explants, after 
staining the cultured cells for p75 and Sox10, explants of two wildtype and two B-Raf-
deficient embryos were quantified. Using a fluorescent microscope all cells were counted 
according to being positive for the counterstaining DAPI and all double-positive cells were 
counted. 
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2.5 Histological Methods 
2.5.1 Preparation of tissue-sections 
Paraffin-embedded tissue sections 
The fresh tissue was washed with PBS and fixed in 4% PFA in PBS at 4°C overnight. After 
washing with PBS, the tissue was deposited in 70% ethanol and stored at 4°C until the 
embedding procedure. Paraffinization step involves 40min in 50% ethanol, 40min in 70% 
ethanol, 40min in 80% ethanol, 40min in 90% ethanol, 40min in 95% ethanol, 3x 40min in 
100% ethanol, 2x 30min in chloroform:ethanol (1:1), 30min in chloroform. All procedures 
were performed at RT. Afterwards the tissue was transferred into melted paraffin and 
incubated for 1h at 65°C and then in fresh paraffin 2hrs or overnight at 65°C. Finally the 
tissue was casted into paraffin blocks. These blocks were then sectioned into 6-10µm 
microsections and used for the further histological analysis after drying for at least one night.    
Cryosections 
The fresh tissue was washed with PBS and fixed in 4% PFA in PBS at 4°C overnight. After 
washing with PBS, the tissue was transferred into 30% sucrose in PBS and incubated at 4°C 
until the tissue was fallen to the bottom of the tube. Before embedding on dry ice with OCT, 
the tissue was washed with PBS. The blocks were sectioned into 6-10 m microsections and 
used for further histological analysis. The blocks and the sections were stored at –80°C until 
use. 
2.5.2 H&E-staining 
For histological analysis of paraffin sections, the tissue was stained with H&E. As indicated 
in first the paraffin has to be removed from the sections, then the tissue is stained with H&E, 
dehydrated and mounted with Entellan. 
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reagent  incubation time 
Xylol 2x 10min 
100% Ethanol 3x 5min 
70% Ethanol 10min 
Millipore water 5min 
Hematoxilyn 30sec 
tap water 5min 
Millipore water 5min 
Eosin 20sec 
Millipore water 5min 
70% Ethanol 10min 
100% Ethanol 3x 5min 
Xylol 2x 10min 
Table 2-4 H&E staining of paraffin sections. 
2.5.3 Immunohistochemistry for Cytokeratin7 
After deparaffinization instead of H&E-staining, the paraffin sections can be stained 
immunohistochemically using a specific antibody. For this purpose, an antigen-retrival step 
was performed using 10mM Citrate buffer, pH6.0 and cooking the tissue in the microwave for 
15min. After cooling down at room temperature, the sections were washed with tap water and 
then three times for 5min with PBS. Before incubation with the primary antibody, the sections 
were blocked for 1hr at room temperature with 1%BSA, 0.1% TritonX-100 in PBS. The 
primary antibody was diluted 1:200 in blocking solution and was applied on the tissue 
overnight at 4°C. Afterwards the sections were washed three times for 5min with PBS. The 
secondary antibody (Goat-anti-mouse-biotinylated) was diluted 1:200 in blocking solution 
and the sections were incubated for 90min at room temperature. Before applying the A+B 
reagent that was prepared 30min before 1:1 for 30min at room temperature, the tissue was 
washed three times for 5min with PBS. Afterwards the sections were washed again three 
times for 5min with PBS and incubated with DAB (1ml DAB + 0.8ml 30%H2O2) until the 
brown colour appeared. The reaction was stopped with tap water for 5min and afterwards the 
tissue was counterstained shortly with hematoxylin, washed with tap water, dehydrated and 
mounted with Entellan.  
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2.5.4 In-situ Hybridization 
Cloning of Sox10, Mitf, DCT and Tyrosinase cDNA into pcDNA3 
cDNAs of different neural crest and melanocyte development markers were cloned in order to 
synthesize riboprobes for in-situ hybridization. The cDNA obtained from RNA from the 
murine B16 melanoma cell line using the Fermentas first strand synthesis kit and the random 
hexamer primers was used as a template for RT-PCR using primers specific for the different 
markers. The resulting fragments were digested with restrictionendonucleases, to create sticky 
ends and were cloned into the pcDNA3-vector (Invitrogen) for in-vitro transcription for probe 
generation (Table 2-5). In the case of Tyrosinase, the primers were designed with overhangs 
to introduce a NotI and a XbaI restriction site into the DNA-sequence. 
Gene Primer PCR-Fragment-
Size 
Enzymes used 
for cloning 
Fragment 
Size 
 DCT DCT-RT-for 
DCT-RT-rev 
765 bp KpnI 
XbaI 
506 bp 
Tyrosinase Tyrosinase-NotI-for 
Tyrosinase-XbaI-rev 
858 bp NotI 
XbaI 
290 bp 
Mitf Mitf-RT-for 
Mitf-RT-rev 
822 bp KpnI 
BamHI 
626 bp 
Sox10 Sox10-RT-for 
Sox10-RT-rev 
693 bp EcoRV 693 bp 
Table 2-5 Cloning of plasmids for in-vitro transcription. 
In-situ hybridisation-riboprobe synthesis 
Probe Enzyme RNA-Polymerase 
DCT-Sense HindIII Sp6-Polymerase 
DCT-Antisense XbaI T7-Polymerase 
Tyrosinase-Sense XbaI T7-Polymerase 
Tyrosinase-Antisense BamHI Sp6-Polymerase 
Mitf-Sense HindIII Sp6-Polymerase 
Mitf-Antisense NotI T7-Polymerase 
Sox10-Sense NotI T7-Polymerase 
Sox10-Antisense BamHI Sp6-Polymerase 
Table 2-6  Linearization of Plasmid-DNA for DIG-labelling via in-vitro transcription. 
The cDNA-containing plasmids were linearized as described in Table 2-6. The linearized 
plasmid were then gel-isolated and used as templates for antisense and sense Digoxigenin 
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(Addya et al.) -labeled riboprobe synthesis. The in-vitro transcription was perforemed as 
described for the DIG RNA labeling kit (Roche) using 1 g of linearized plasmid DNA. 
The riboprobes were then purified through a precipitation step by addition of 2.5 l 4M LiCl 
and 75 l 100% Ethanol and incubation for at least 2 hours at –20°C. The riboprobes were 
pelleted via centrifugation at 4°C, the pellet was washed with 70% Ethanol and resuspended 
in 75 l DEPC-treated water. To control the length and integrety of the probes, 
gelelectrophoresis was performed before using the riboprobes for in-situ hybridisation. 
In-situ Hybridisation 
After thawing the sections for at least 30 min at room temperature and drying them for 2 
hours at 40°C, the tissue was fixed for 5 min using  4% PFA in PBS (pH7.5). To permabilize 
the cells, the sections were treated with 0.3% Triton X-100 in PBS for 15 min and with 
0.2 g/ml Proteinase K in Proteinase K buffer for 5 min at room temperature and fixed again 
for 5 min at room temperature. For acetylation, the tissue was incubated for 10 min at room 
temperature in TEA-buffer. Between all treatments, the sections were washed with PBS. 
The tissue was then prehybridized in hybridisation buffer for 1 hour at room temperature. 
Before adding the riboprobes to the hybridisation buffer, they were denatured by incubation at 
80°C for 5 min. For hybridisation 500ng/ml riboprobe was added to the prewarmed 
hybridisation buffer. The sections were incubated with the riboprobe containing hybridisation 
buffer overnight at 63°C. Prehybridisation and hybridisation were performed in a box 
saturated with 5x SSC and 50% foramide and the slides were covered by a rectangular piece 
of parafilm to avoid evapuration. After hybridisation, the sections were washed with 
prewarmed 2x SSC, 50% formamide for 1 hour at 63°C and then equilibrated in prewarmed 
RNaseA-buffer for 20 min at 37°C. To reduce the background, the single-strand RNA was 
removed by RNaseI-treatment (20 g/ml RnaseI-buffer) for 30 min at 37°C. 
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Before blocking the tissue for 1 hour at room temperature with blocking solution, the sections 
were washed for 30 min in TBST. To detect the DIG-labeled riboprobes, the tissue was then 
incubated with alkaline-phosphatase-coupled anti-digoxigenin antibody diluted 1:2000 in 
blocking solution overnight at 4°C. To avoid evaporation, this was performed in a box 
saturated with water and the slides were covered with rectangular pieces of parafilm. 
Excess antibody was removed by washing the tissue several times in TBST and the sections 
were then equilibrated in NTMT. Color development was performed overnight at 4°C using 
4.5 l NBT and 3.5 l BCIP per ml NTMT buffer in a box saturated with NTMT buffer and 
covered with rectangular pieces of parafilm. When the color had the desired intensity, the 
staining was sections were washed with PBS and then fixed with 4% PFA in PBS (pH7.5) for 
15 min at room temperature. After washing with PBS the sections were mounted with 
mowiol. 
2.6 In-vivo experiments 
All animal experiments were performed according the German law for animal protection. 
Animals were sacrificed via cervical dislocation unless described differently. 
2.6.1 Generation of transgenic mice 
For microinjection the pBi5-B-Raf
V600E
-EGFP plasmid-DNA was prepared by CsCl plasmid 
preparation as described before. To remove the vector-backbone 50 g of DNA were digested 
using the restrictionendonucleases XbaI and PvuI and the resulting 5.4kb fragment was 
isolated from a low-melting agarose gel using the agarose digesting enzyme agarase as 
described by the manufacturer. The DNA was dissolved in injection buffer for microinjection. 
Finally, purified DNA-fragment was injected into the pronucleus of fertilized mouse eggs by 
Hildegard Troll and the resulting mice were genotyped by PCR as described in the next 
paragraph. 
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2.6.2 Genotyping of transgenic mice 
For gaining DNA for genotyping the mouse tails were cut in the age of 3-4 weeks and the 
mice were marked by earmarks. The tails were lysed by the addition of 190 l of tail lysis 
buffer and 12 l of 0.4mg/ml ProteinaseK and incubation overnight at 54°C. The resulting 
lysate was then centrifuged at 10000rpm for 5min and the supernatant was diluted 1:10 with 
water and was used as a template for a PCR-reaction as described above with primers for 
genotyping listed in the material part. 
2.6.3 Transplantation-experiments 
For subcutaneous injection of A549 and A549 J5-1 cells, the cells were washed two times 
with sterile PBS after trypsinisation and were counted. 10
6
 cells were subcutaneously injected 
in 100 l of sterile PBS into Rag1
-/-
-mice. The tumour size was measured weekly and the 
animals were sacrificed when the first tumours in the different groups were close to 2cm of 
diameter. Under anaesthetic the animals were perfused using 4% PFA-PBS and the primary 
tumours, the lungs, the livers and the lymph nodes were collected for histology. 
2.6.4 Neural Tube Explants 
Fibronectin-coating of cell culture dish 
For culturing the neural tube explants, the cell culture dish was before coated with the cell 
adhesion molecule fibronectin. For this purpose, 8 g fibronectin were diluted in 300ml of 
sterile PBS per well of a 24-well-plate. The solution was pipetted onto the dish and incubated 
for 1hr at room temperature. After this the fibronectin-solution was removed and the dish was 
washed three times with sterile Millipore water and was then used immediately or stored at 
4°C. 
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Preparation of the neural tube 
Time-matched pregnant mice were sacrificed via cervical dislocation, the skin was opened 
and with a different, sterile surgery set, the uterus was prepared and opened and the embryos 
were transferred to sterile PBS. Using a stereolupe, the neural tube of the embryos was 
prepared and transferred to the fibronectin-coated dish already containing D-MEM-medium 
including Endothelin-3. The head of the embryos were stored at -20°C for genotyping. 
Culturing Neural Tube Explants 
The neural tubes were cultured on fibronectin-coated dish in D-MEM-medium containing 
5nM Endothelin-3 at 37°C for 2-5 days. The medium was changed every other day. 
2.7 Statistical Analysis 
Statistical analyses of data sets were performed using the Graphpad Prism version 4.0 
software. For all tests, statistical significance was considered to be at P<0.005. 
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3 Results 
3.1 Generation of a transgenic mouse model for melanocyte-specific and inducible 
expression of B-RafV600E 
The goal of this part of the thesis was to establish a mouse model that expresses the human 
oncogenic B-Raf
V600E
 in melanocytes. For this purpose the tetracycline-inducible system was 
chosen. The promoter used in this system contains a tetracycline-responsible element (TetO), 
which can be bound by the reverse tetracycline-controlled transcription activator protein 
(rtTA) in the presence of doxycycline to induce the transcription of the gene of interest (Zhu 
et al., 2002). This mouse can then be combined with a strain that expresses the rtTA under the 
control of a tissue-specific promoter, in this case in the melanocytes for example driven by the 
DCT- or the Tyrosinase-promoter. The resulting bitransgenic mice would express the 
oncogenic B-Raf
V600E
 tissue-specific in the presence of doxycycline. The tissue-specific and 
inducible expression of B-Raf
V600E
 is crucial to obtain viable offspring, since it is known that 
the constitutive expression of C-Raf as well as the tissue-specific, but constitutive expression 
of B-Raf
V600E
 under control of the Tyrosinase promoter is embryonal lethal (unpublished data 
Rapp et al., Marais et al.). 
3.1.1 Construction of pBi5-B-RafV600E-EGFP 
To generate transgenic mice conditionally expressing the constitutive active B-Raf
V600E
, a 
plasmid was used that encodes the B-Raf
V600E
-sequence and the reporter gene Luciferase, 
controlled by a bidirectional CMV promoter unit, that contains a tetracycline-responsible 
element (TetO) (Figure 3-1). To be able to distinguish the exogenous B-Raf
V600E
 from the 
endogenous wild type B-Raf, an EGFP-tag was introduced into the pBi5-B-Raf
V600E
 that was 
previously generated by PD Dr. R.Götz. For this purpose, a plasmid that was generated by Dr. 
C.Xiang was used that contained the wild type B-Raf tagged with EGFP. Both plasmids were 
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cut using the restriction endonucleases Mph1103I and SalI and the EGFP-tagged C-terminal 
part of B-Raf was combined with the N-terminal V600E-mutation containing part in the pBi5 
vector. The DNA was linearized and purified for pronucleus injection, which was performed 
by Hildegard Troll. 
  
Figure 3-1 Design of a vector for tetracycline-regulated transgene expression. The plasmid 
contains a bidirectional tetracycline-regulatory CMV promoter element controlling in one 
direction the oncogenic version of human B-Raf tagged with EGFP and in the other direction 
the reporter gene Luciferase. 
3.1.2 In vitro analysis of B-RafV600E-EGFP expression and functionality 
To test the resulting pBi5-B-Raf
V600E
-EGFP construct, the fibroblast cell line NIH3T3, stably 
expressing the tetracycline-controlled transcriptional activator (tTA), was transfected with the 
plasmid using Lipofectamine reagent. Western blot analysis showed, that the protein level of 
B-Raf was elevated in the cells 48hrs post transfection (“On”-status) and that the expression 
could be turned off by the addition of Doxycycline (“Off”-status) to the cell culture medium 
(Figure 3-2 A). More quantitative analysis was possible due to the additional reporter gene 
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Luciferase for the promoter activity. The Luciferase was expressed in the absence of 
 
Figure 3-2 Conditional Expression of B-Raf
V600E
 in NIH3T3-tTA cells. A Western Blot 
analysis shows the expression of the B-Raf-protein in dependency on the tetracycline-
controlled transactivator protein tTA and Doxycycline (1000 g/ml) 48 hrs post transfection. 
B-Raf was detected using a C-terminal B-Raf antibody. B Analysis of the cells with a 
luciferase assay shows elevated luciferase levels only in the “On”-status of the tetracycline-
inducible CMV-promoter. 
Doxycycline, while after treating the cells with Doxycycline the Luciferase activity per mg of 
protein was about 160 times lower than detected in the “On”-status (Figure 3-2 B).  
 
Figure 3-3 Expression of EGFP-tagged B-Raf
V600E
 in NIH3T3-tTA cells. A Western Blot 
analysis shows elevated pERK levels using a phospho-specific ERK antibody in the “On”-
status. B The transgenic B-Raf
V600E
 can be detected via fluorescence microscopy. 
To examine whether the EGFP-tagged B-Raf
V600E
 protein was functional, a Western Blot for 
pERK was performed. As shown in Figure 3-3 A in the absence of Doxycycline the pERK-
levels in NIH3T3-tTA cells that were starved for 24 hrs (reducing the FCS amount from 10% 
to 0.5%) were higher compared to Doxycycline-treated cells, indicating that the kinase 
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activity of the exogenous B-Raf
V600E
-EGFP is functional. To show, that the EGFP-tag can be 
detected by fluorescent microscopy, the cells were fixed and analyzed using a fluorescent 
microscope. As shown in Figure 3-3 B, the green fluorescent cells could only be detected in 
the absence of Doxycycline. These data show, that the regulation of the B-Raf
V600E
-EGFP and 
the luciferase-expression using Dox is working and that the resulting protein is functional in 
respect to the kinase activity and the EGFP-tag. 
3.1.3 Generation and Characterization of transgenic B-RafV600E-EGFP founder lines 
To generate transgenic mice, pBi5-B-Raf
V600E
-EGFP was cut with the 
restrictionendonucleases XbaI and PvuI to remove the vector backbone. The resulting 5445 
bp fragment containing the bidirectional inducible promoter and the B-Raf
V600E
-EGFP as well 
 
Figure 3-4 Luciferase-assay from lung lysates of induced tet-o-B-Raf
V600E
-EGFP/SpC-rtTA 
bitransgenic animals. No difference was observed in the luciferase activity in samples from 
induced animals from both founder lines when compared to samples from not-induced or 
wildtype animals. 
as the luciferase was isolated by gelextraction from an agarose gel and was injected in the 
pronucleus of fertilized mouse oozytes and the resulting mice were genotyped by PCR. From 
the six positively (2832, 2772, 2831, 2833, 3593, 3595) genotyped animals, only two (3593, 
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3595) were transmitting the transgene to their offspring. These founder animals were crossed 
with the well established SP-C-rtTA inducer mice that express the rtTA in lung alveolar type 
II epithelial cells (Perl et al., 2002a) to generate bitransgenic (SP-C-rtTA/TetO-B-Raf
V600E
-
EGFP) animals. Analysis of luciferase activity in lung tissue extracts of Dox-induced 
bitransgenic mice, that were induced for one week with Dox-food and additional daily 
injections, showed no increased luciferase levels in both founder lines (Figure 3-4), 
suggesting no expression of the transgene. 
3.2 The Role of B-Raf in Melanocyte Development 
This part of the thesis addresses the role of B-Raf in murine melanocytes to gain insights into 
its physiological role in healthy melanocytes versus melanoma cells. Since B-Raf-deficient 
embryos die during embryonal development, the role of B-Raf in the early embryonal 
melanocyte development was determined. As mentioned already in the introduction an 
important step during tumour development from a benign tumour to malignant metastatic 
cancer might be tumour cell reprogramming by which the tumour cells gain features that are 
comparable with properties of precursor cells during developmental processes.  
3.2.1 Expression of Melanocyte Development markers in the Neural Tube at day E11.5 
To address whether the precursors of the melanocytes, the neural crest stem cells and the 
melanoblasts, are present in the absence of B-Raf, RT-PCR was performed using RNA 
isolated from neural tubes prepared from E11.5 wildtype and B-Raf
-/-
 embryos. As described 
in the introduction, during the early melanocyte development, the precursors are located in the 
neural crest and are positive for the neural crest marker Sox10. When the cells exit the neural 
tube and start to migrate, the expression of the transcription factor Mitf, which is said to be 
the master regulator in melanocyte development, is unregulated. Melanoblasts migrate 
dorsolaterally and express first the melanogenic enzyme dopachrome-tautomerase (DCT) and 
later also Tyrosinase (Le Douarin, 2003).  As shown in Figure 3-5 the neural crest marker 
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Sox10 is expressed in the neural tube of wildtype as well as of B-Raf-deficient embryos. The 
same is true for one of its target genes Mitf. Furthermore even the melanogenic enzyme 
 
Figure 3-5 RT-PCR from RNA of the neural tubes of E11.5 embryos shows the expression of 
the neural crest stem cell marker Sox10 as well as the melanocyte development markers Mitf 
and DCT in the presence and absence of B-Raf respectively. 
DCT, which is a melanoblast marker and involved in the melanin synthesis is expressed in the 
presence as well as in the absence of B-Raf in the neural tube of E11.5 embryos Figure 3-5. 
These data suggest that B-Raf is not necessary for the expression of these genes involved in 
melanocyte development.  
3.2.2 Neural Crest Stem Cells in Neural Tube Explants 
To gain more quantitative insights into the neural crest stem cell population in wildtype 
versus B-Raf
-/-
 embryos, the neural tubes from E9.5 wildtype and B-Raf
-/-
 embryos were 
isolated and cultured for five days in D-MEM-medium containing Endothelin-3 on 
fibronectin-coated cover slips. At early stages a high percentage of all neural crest stem cells 
in these neural tube explant cultures are early neural crest stem cells and express the neural 
crest stem cell markers p75 and Sox10 (Kleber et al., 2005). As shown in Figure 3-6 A, most 
of the cells in the migratory front of the neural tube explants are positive for both markers in 
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the presence as well as in the absence of B-Raf. When the double positive cells were counted 
in the complete explants, there was no significant difference between the number of cells 
expressing both markers in the B-Raf-deficient neural tube explants compared to the wildtype 
cultures (Figure 3-6 B). These data suggest that B-Raf is not necessary for the early neural 
crest development. 
  
Figure 3-6 Neural crest stem cell markers in neural tube explants cultured for 5 days in the 
presence of Endothelin-3 in the presence and absence of B-Raf respectively. A 
Immunocytochemistry for the neural crest stem cell markers p75 and Sox10 shows that there 
are double positive cells in the migratory front of the neural tube explant cultures in the 
presence as well as in the absence of B-Raf. B The Quantification of the p75/Sox10 double 
positive cells in two cultures of WT and KO embryos, respectively, shows, that there is no 
reduction of the neural crest stem cells in the absence of B-Raf. 
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3.2.3 Neural Crest Development in vivo in B-Raf-deficient embryos 
Since it was published earlier that B-Raf plays an important role in migration of cortical 
neurons in the developing brain (Camarero et al., 2006), an in-situ hybridization was 
 
Figure 3-7 in-situ hybridization on horizontal sections of E11.5 embryos shows no difference 
in localization of cells expressing the neural crest stem cell marker Sox10 as well as of cells 
expression the melanoblast markers Mitf and DCT in B-Raf-deficient embryos compared to 
wildtype animals. 
performed to see the localization of the melanoblast precursors in the wildtype and B-Raf
-/- 
embryos. As shown in Figure 3-7, there are Sox10-positive cells present in the migratory 
stream from the neural crest stem cell population to the dorsal root ganglia in the wildtype as 
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well as in the B-Raf-deficient embryos. Furthermore the in-situ hybridization showed the 
Mitf-expressing cells in the migration staging area and in the dorsolateral migratory pathway 
of the neural crest derived cell population in the presence and absence of B-Raf. The 
melanoblast localization was detected using probes for the melanogenic enzyme DCT. As 
indicated in Figure 3-7 the melanoblast are located independently of B-Raf-expression in the 
dorsolateral part of the embryos next to the epidermis. 
3.3 Myc-induced metastasis in NSCLC   
In this part of the thesis, a transgenic mouse model for metastasis in NSCLC was used to 
determine the differences in the gene expression profiles of non-metastatic lung tumours 
compared to liver metastases of primary lung tumours. As described in the introduction, 
transgenic mice expressing oncogenic C-Raf under the control of the SpC-promoter in the 
alveolar type II pneumocytes develop premalignant adenoma with high penetrance, but 
lacking spontaneous progression. In contrast the expression of c-Myc targeted to lung alveolar 
type II cells leads to late tumour development with a relatively low penetrance. When these 
two transgenes are combined in compound animals, a phenotypic switch of the tumour cells 
from a cuboidal to a columnar shape was observed. Furthermore, in 24% of the bitransgenic 
animals metastases were found in liver or lymphnodes (Rapp et al., 2009). 
3.3.1 Mutation analysis of primary tumours and metastasis of SpC-c-Myc and SpC-C-
Raf-BxB/SpC-c-Myc animals 
Since the tumour development in the SpC-c-Myc animals was delayed and the number of 
tumour foci was lower when compared to the compound mice, a screen for secondary 
mutations in Exon1 of the oncogene KRas and in Exon6 of the tumour suppressor LKB1, 
which is mutated in 34% of human NSCLC (Shah et al., 2008), was performed (partly by 
Valentina Serafin). As shown in Table 3-1 in all tumours of single transgenic SpC-c-Myc 
animals, a secondary mutation was found and mutations in KRas Exon1 and LKB1 Exon6 
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were mutually exclusive with one exception. In the bitransgenic compound animals on the 
other hand, only in a small fraction of animals a mutation in KRas Exon1 was identified, 
while they were all negative for mutations in LKB1 Exon6. These results suggest an inhibition 
of the tumour suppressor gene LKB1 by the mitogenic cascade in lung alveolar type II cells. 
Genotype ID-number KRas Exon1 LKB1 Exon6 
 
S
p
C
-c
-M
y
c 
2 [G12->D]  
6389 [G12->D] [G279->S] 
8445 - [P275->S] 
8530 [G12->D] - 
8898 - [P275->S] 
9119 [G12->D] - 
10466 - [P275->S] 
11163 [G12->C] - 
12084 [G12->D] - 
12926 [G12->D] - 
 
S
p
C
-C
-R
a
f-
B
x
B
/S
p
C
-c
-
M
y
c 
468 [G12->D] - 
10219 - - 
10416 - - 
10617 - - 
10621 - - 
11136 - - 
11501 - - 
11528 - - 
11556 - - 
11560 [G12->D] - 
Table 3-1 Mutation analysis of primary tumours. The long latency tumours of the SpC-c-Myc 
mice carry frequently mutations in the oncogene KRas or in the tumour suppressor gene 
LKB1. 
The discovery of the high frequency of mutations in KRas Exon1 in the primary tumours of 
the SpC-c-Myc single transgenic animals suggested that it might be possible to use these 
mutations as markers for lineage tracing in the metastases. In Table 3-2 it is shown that the 
metastases of the single transgenic SpC-c-Myc animals were negative for the KRas mutation 
detected in the primary lung tumour with only one exception. In the mouse number 16740, 
which had multiple organ metastases, the KRas mutation in the primary lung tumour was 
similar to the mutation found in the liver metastasis. These results suggest that metastasis is 
an early event. 
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  lung liver 
Genotype ID-number KRas Exon1 KRas Exon1 
 
S
p
C
-c
-M
y
c 
1 - n.m. 
44 - n.m. 
46 - n.m. 
1895 [G12->D] - 
8445 - - 
8530 - n.m. 
11163 [G12->C] n.m. 
14226 - - 
16740 [G12->C] [G12->C] 
22620 [G12->D] - 
30424 - - 
30413 - - 
 
S
p
C
-C
-R
a
f-
B
x
B
/S
p
C
-c
-
M
y
c 
322 - n.m. 
10219 - - 
10617 - n.m. 
10621 - - 
11176 - n.m. 
11501 - n.m. 
11518 - - 
14203 [G12->C] n.m. 
16479 - - 
17623 - n.m. 
Table 3-2 Mutation analysis of primary tumours and the corresponding metastases. The 
metastases of the primary tumours in the SpC-c-Myc transgenic animals do not carry the same 
KRas Exon1 mutations as the primary tumours (n.m.: no metastases). 
3.3.2 Gene expression analysis of primary tumours of SpC-c-Myc and of compound 
animals 
To investigate the differences in the gene expression profile of the SpC-C-Raf-BxB/SpC-c-
Myc lungs compared to the SpC-C-Raf-BxB and wild type lungs, qPCR was performed for a 
panel of candidate genes (Table 3-3), that are known to be involved in processes like: organ 
development, Wnt-signalling, regulation of transcription, cell-adhesion or cell-cell-signaling, 
vasculogenesis, neuronal tissue or Type-II-pneumocytes, stem cell maintenance, the cell cycle 
and in tumourigenesis, that are necessary for cell-cycle progression and that are involved in 
cytokine-signaling. Furthermore, this list contains candidate proteins and genes expressed in 
hematopoietic cells picked from microarray data and the transgenes c-Myc and C-Raf-BxB. 
Surprisingly, the only gene that was found to be highly significantly upregulated in the SpC-
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C-Raf-BxB/SpC-c-Myc compound compared to the single transgenic SpC-C-Raf-BxB and 
wildtype animals, respectively, was the Synuclein SNCA , which is expressed normally in 
the brain and is involved in Alzheimer and Parkinson‟s disease and dementia (Bisaglia et al., 
2009). 
Gene wt CRaf-
BxB 
Cpd CRaf-
BxB/wt 
p-value Cpd/CRaf
-BxB 
p-value 
57578
1 0,000556 0,000492 0,00062 0,884363 0,85554 1,261603 0,672598 
AFP
2 0,0012966 0,000649 0,00083882 0,50028169 0,1133043 1,2931772 0,3621580 
AQP5
10 0,0916433 0,170599 0,18930793 1,86155041 0,3030432 1,1096693 0,8877917 
ASCI
6 0,1849785 0,079031 0,12063433 0,42724555 0,3248567 1,5264133 0,3984433 
AXUD1
2,3 0,00896 0,007458 0,006047 0,832355 0,713729 0,810866 0,415423 
CCL19
6 2,279920 1,678303 3,85955363 0,7361237 0,245285 2,2996761 0,3236408 
CCR7
6 0,0099881 0,003929 0,00606607 0,39338607 0,3415127 1,5438542 0,194230 
CD44
5 0,3832155 0,381220 0,44394464 0,99479378 0,4947715 1,1645353 0,3665909 
CDCA7L
4 0,011819 0,012814 0,011878 1,084237 0,894375 0,926946 0,892581 
CLECSF8
5,6 0,001205 0,001336 0,001142 
 
1,108763 0,834706 0,854758 0,709895 
C-RAF
16 0,1474777 13,63718 16,5425 92,4694917 0,0001 1,2130438 0,0131 
DBPHT2
2 6,87E-05 2,65E-06 3,02E-06 0,038629 0,3816 1,13783 0,789521 
ENOL
9 0,000991 0,000588 0,001262 0,59257 0,141969 2,148539 0,078509 
ERAF
7 0,002035 0,001201 0,00057 0,590368 0,405218 0,474445 0,196053 
ERFI
8 10,30684 8,84907 12,5388 0,858562 0,819747 1,416962 0,179143 
FOXD3
2 8,2213734 1,849395 1,13315397 0,22494959 0,0804918 0,6127162 0,2914543 
FZD10
2,3 0,0035117 0,003329 0,00380563 0,94787817 0,1640242 1,1432983 0,4274523 
HBBBH1
7 0,588658 0,082675 0,142033 0,140447 0,15272 1,717962 0,365726 
IFI202B
7 0,023095 0,008267 0,0135190 0,3579665 0,0328788 1,6352768 0,154656 
JAGGED
2 0,1010275 0,076452 0,06243959 0,7567462 0,3286535 0,8167145 0,3576276 
KLF4
11 0,1410194 0,116246 0,0698515 0,82432319 0,14085 0,6008961 0,0380691 
LATS
12 0,386345 0,604052 0,265197 1,563504 0,196018 0,439031 0,085538 
MALAT1
13 2,5765939 2,291542 2,45155872 0,8893685 0,3272480 1,0698295 0,3956217 
MYC
16 0,0105068 0,012967 0,03177759 1,23413090 0,5143 2,4506908 0,0251 
NEURODI
9 0,4172601 0,557438 1,45343679 1,33594875 0,4288621 2,6073509 0,3112298 
NOTCH1
2 0,0537009 0,058160 0,04705475 1,08303617 0,358757 0,8090564 0,2870955 
NOTCH2
2 0,0393950 0,046429 0,04709058 1,17855955 0,2673994 1,0142428 0,4847522 
NOTCH3
2 0,0229184 0,028635 0,02340299 1,24942743 0,2361030 0,8172892 0,2608844 
NOTCH4
2 9,4745859 0,247757 0,36855509 0,02614966 0,1866442 1,4875655 0,2487878 
ODC
2 0,209083 0,277562 0,190878 1,32752 0,598424 0,687696 0,511083 
PBK
14 0,002272 0,002323 0,003345 1,022465 0,944062 1,43993 0,261408 
RSAD2
15 0,738283 0,435451 0,728339 0,589816 0,191024 1,672607 0,077373 
SHTM1
1 0,01396 0,020894 0,013205 1,496665 0,307386 0,632002 0,256547 
SNCA
9 0,002285 0,00669 0,14804 2,927831 0,361006 22,12732 0,009796 
SNCG
9 0,9851209 0,215649 0,41625916 0,21890617 0,0472698 1,9302621 0,4667407 
SYB
9 1,2336177 0,010366 0,01573141 0,00840291 0,1869330 1,5175998 0,1659027 
SYK
2 0,651939 0,086118 0,06986264 0,13209524 0,3847539 0,8112431 0,5781639 
TIAM2
2,13 0,0104784 0,006825 0,00579676 0,65129778 0,2526831 0,8493979 0,3797876 
TMP4
12,13 0,426306 0,391205 0,354294 0,917664 0,626968 0,905647 0,721871 
Table 3-3 Candidate Genes. wt: wildtype, Cpd: compound SpC-C-Raf-BxB/SpC-c-Myc. 
1
hypothetical protein, 
2
organ development, 
3
regulated by Wnt-signalling, 
4
regulation of 
transcription, 
5
cell-adhesion, 
6
cell-cell-signalling, 
7
hematopoetic cells, 
8
vasculogenesis, 
9
expressed in neuronal tissue, 
10
Type-II-pneumocytes, 
11
stem cell maintenance, 
12
regulation of 
the cell cycle, 
13
involved in tumourigenesis, 
14
cell-cycle progression, 
15
cytokine-signalling, 
16
transgenes. 
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Figure 3-8 qPCR analysis of total lung RNA of wildtype, SpC-C-Raf-BxB and SpC-C-Raf-
BxB/SpC-c-Myc bitransgenic animals (>10 months). A The relative mRNA-levels of C-Raf-
BXB are increased highly significant in the SpC-C-Raf-BxB and in the compound animals 
when compared to the wildtype mice (n=3 for all genotypes). B The relative mRNA-levels of 
c-Myc are significantly higher in the bitransgenic animals compared to the wildtype and the 
SpC-C-Raf-BxB mice, respectively (n=3 for wildtype and SpC-C-Raf-BxB, n=2 for 
compound). C qPCR analysis for the neuroendocrine gene Synuclein  shows a highly 
significant increase of mRNA levels in the compound mice versus the wildtype and the single 
transgenic SpC-C-Raf-BxB animals, respectively (n=3 for SpC-C-Raf-BxB, n=2 for wildtype 
and compound). 
 (Figure 3-8 C). The expression of the transgene C-Raf-BxB was as expected highly 
significantly different in the SpC-C-Raf-BxB and SpC-C-Raf-BxB/SpC-c-Myc compound 
mice when compared to the wildtype animals (Figure 3-8 A). Furthermore the expression of 
the c-Myc transgene in the compound mice lead to a significant increase in the C-Raf mRNA 
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levels when compared to the single transgenic SpC-C-Raf-BxB animals.  The relative mRNA 
levels of c-Myc were also highly significantly higher in the SpC-C-Raf-BxB/SpC-c-Myc 
compound animals when compared to the wildtype and SpC-C-Raf-BxB single transgenic 
mice (Figure 3-8 B), respectively, confirming the possibility to detect changes in the gene 
expression in the tumour cells using total lung RNA in qPCR analysis. These data suggest a 
neuroendocrine character of the columnar tumours. 
3.4 Generation and Analysis of a human NSCLC cell line expressing chicken c-Myc 
The goal of this part of the thesis was to generate a c-Myc-expressing NSCLC cell line to test 
whether the expression of c-Myc is sufficient to induce tumour progression to metastasis and 
to obtain a human cell culture system that is comparable to our NSCLC mouse model. 
3.4.1 Introduction of chicken c-Myc into the human NSCLC cell line A549 
 To obtain a c-Myc-expressing cell line, chicken c-Myc was introduced into the non-
metastatic human NSCLC cell line A549 using the J5-virus (Kurie et al., 1990). Since this 
virus has no marker for eukaryotic selection, the infected cells were seeded in soft agar and 
the resulting clones were picked after two weeks of incubation at 37°C. These clones were 
afterwards tested by immunocytochemistry using an antibody specific for chicken c-Myc. As 
shown in Figure 3-9 the clone with the strongest expression of chicken c-Myc was the clone 
A549 J5-1. Furthermore, immunocytochemistry was performed for the GATA family 
transcription factors 4 and 6 (GATA4 and 6, respectively), which were observed to be 
markers for the lineage switch from cuboidal (GATA6) to columnar shape (GATA4) tumour 
cells in our transgenic NSCLC mouse model (Rapp et al., 2009). GATA6 is expressed 
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normally in the alveolar type 
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Figure 3-9 Immunocytochemistry for chicken c-Myc in the J5-transformed A549 clones 
shows that the clones express the exogenous chicken c-Myc on different levels. The clone 
with the highest chicken c-Myc expression level was the clone 1 (referred to as A549 J5-1). 
II pneumocytes, where it drives the expression of the transcription factor TTF-1, which is 
necessary for SpC-promoter activity (Liu et al., 2002), and was recently shown to be involved 
in epithelial stem cell development and airway regeneration (Zhang et al., 2008). GATA4 on 
the other hand is necessary for the maintenance of the intestine in adult mice. As shown in 
Figure 3-10 in A549 J5-1 ectopic de novo expression of GATA4 has been observed in 
addition to GATA6 when compared to the parental cell line A549. This clone was used to 
perform the further experiments. As shown in Figure 3-11 A the clone A549 J5-1 has a 
different morphology compared to the parental cell line A549, when grown in adherent 
culture. The ability to grow anchorage-independently A549 J5-1 cells was compared in a soft 
agar assay. Although the A549 J5-1 cells are growing slower in adherent culture than the 
parental cell line (data not shown), when grown in soft agar, the size and number of colonies 
was highly significantly higher when compared to the A549 cells (Figure 3-11 B-D). These 
results show that the expression of c-Myc in the human NSCLC cell line A549 highly 
significantly increases the ability for anchorage-independent growth. 
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Figure 3-10 Immunocytochemistry for the in the mouse model identified markers for tumor 
progression GATA4 and GATA6 on several different A549 J5 clones showed that GATA6 
was relatively high in the parental cell line as well as in the low chicken c-Myc expressing 
clones, while GATA4 levels were clearly elevated in the clones J5-1 and J5-41. 
 
Figure 3-11 Characterization of the clone A549 J5-1. A After introduction of chicken c-Myc, 
the cells change their morphology and tend to detach. B Growing in soft-agar resulted in 
bigger colonies in the case of the clone A549 J5-1 (10000 cells where seeded and grown for 
21 days). C The number of colonies in 5mm
2
 was highly significantly higher for the A549 J5-
1 when compared to the parental A549 (12 squares were counted). D Counting the colonies of 
different size showed a highly significant increase of the number for the colonies that were of 
big and intermediate size, respectively, while the difference looking at the colonies that were 
of small size revealed in a slight, but significant increase in the number.  
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3.4.2 Expression levels of GATA4 and GATA6 in A549 J5-1 
To have a more quantitative indicator for GATA4 and GATA6 expression in A549 J5-1 
compared to A549, qPCR-analysis was performed using primers specific for human GATA4 
and GATA6 as well as for the GATA4-target gene mucin2 (van der Sluis et al., 2004) and for 
chicken c-Myc. As shown in Figure 3-12 A a 4-fold increase of GATA4 mRNA levels could 
be shown with high significance. As observed by immunocytochemistry, the mRNA levels of 
GATA6 were also highly significantly increased about 2-fold (Figure 3-12 B). Furthermore, 
when qPCR was performed with primers specific for the GATA4-target gene mucin2, an 
about 10-fold, highly significant increase was observed in the mRNA level (Figure 3-12 C) 
showing, that the detected GATA4 protein is nuclear. The exogenous chicken c-Myc in A549 
J5-1 served as a positive control for this experiment. As shown in Figure 3-12 D, significantly 
higher levels of chicken c-Myc mRNA levels could be detected in the clone A549 J5-1 when 
compared to the parental cell line A549. These results confirm the expected elevated 
expression levels of chicken c-Myc, GATA4, GATA6 and mucin2. 
3.4.3 Expression of neuroendocrine markers in the A549 J5-1 cells 
Since in the analysis of total lung RNA of wildtype, SpC-C-Raf-BxB single transgenic and 
SpC-C-Raf-BxB/SpC-c-Myc compound animals the only highly significantly upregulated 
gene was the SNCA and  the expression of the immature neuroendocrine marker PGP9.5 was 
observed in the vasculature of columnar tumours of the SpC-c-Myc single transgenic and of 
the SpC-C-Raf-BxB/SpC-c-Myc compound mice (Rapp et al., 2009), qPCR-analysis was 
performed to check the expression levels of more neuroendocrine markers. Tumours with 
neuroendocrine character arise from neural crest-derived neuroendocrine pulmonary cells, but 
usually not from the alveolar type II pneumocytes (Borczuk and Powell, 2007). As already 
described for the total lung RNA of compound animals (Figure 3-8 C) highly significantly 
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increased mRNA levels were observed for SNCA and PGP9.5 specific primers in the 
 
Figure 3-12 qPCR analysis of the clone A549 J5-1 compared to the parental A549 cell line. 
A+B qPCR with primers specific for GATA4 and GATA6 shows that there is a highly 
significant about 4-fold and 2-fold, respectively, increase in the relative GATA4 and GATA6 
mRNA levels in the J5-1 clone. C Using primers specific for the GATA4 target gene mucin2 
shows an about 10-fold increase of the relative mRNA levels mucin2. D Performing qPCR 
using primers specific for chicken c-Myc shows a highly significant difference in the 
expression of the oncogene. 
chicken c-Myc expressing cells A549 J5-1 when compared to the parental cell line A549 
(Figure 3-13 A+B). Furthermore, significantly increased mRNA levels were observed for the 
neuroendocrine marker and Wnt-signalling target (Kuwabara et al., 2009) NeuroD1 and the 
neuroendocrine marker Synaptobrevin in the A549 J5-1 cells when compared to the parental 
A549 cell line (Figure 3-13 C+D). In contrast to the other three assayed neuroendocrine 
markers, qPCR-analysis with primers specific for the neuroendocrine-specific Enolase, 
Enolase , showed a highly significant downregulation of this neuroendocrine enzyme upon 
expression of chicken c-Myc when compared to the parental A549 cell line (Figure 3-13 E). 
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These data confirm the induction of SNCA and PGP9.5 by the expression of c-Myc, but show 
that c-Myc does not induce a full neuroendocrine character of the tumours. 
 
Figure 3-13 qPCR analysis of the expression of neuroendocrine markers in the A549 J5-1 
cells compared to the parental A549 cell line. A qPCR with primers specific for the 
neuroendocrine marker SNCA shows a highly significant 5-fold increase in mRNA levels of 
this gene in the presence of chicken c-Myc. B qPCR with primers specific for the immature 
neuroendocrine marker PGP9.5 shows a highly significant 2-fold increase in mRNA levels of 
this gene in the presence of chicken c-Myc. C qPCR with primers specific for the 
neuroendocrine marker NeuroD1 shows a highly significant 3-fold increase in mRNA levels 
of this gene in the presence of chicken c-Myc. D The relative mRNA levels of the 
neuroendocrine marker Synaptobrevin were significantly higher in the A549 J5-1 cells when 
compared to the parental A549 cells. E qPCR with primers specific for the immature 
neuroendocrine marker Enolase  shows a highly significant 4-fold decrease in mRNA levels 
of this gene in the presence of chicken c-Myc. 
   Results 
 
 82 
3.4.4 Transplantation of A549 J5-1 in Rag1-/--mice 
If the expression of c-Myc is sufficient to induce metastasis, the transplantation of a chicken 
c-Myc expressing clone of the human non-metastatic NSCLC cell line A549 in 
immunodeficient animals should give rise to metastasis. To test this possibility, Hildegard 
Troll and Fatih Ceteci injected 10
6
 A549 and A549 J5-1 cells, respectively, subcutaneously in 
Rag1
-/-
 animals. As shown in Figure 3-14 A, the tumour incidence in the animals injected with 
the chicken c-Myc expressing A549 J5-1 cells was higher than in the mice transplanted with  
 
Figure 3-14 Transplantation of A549 and A549 J5-1 cells, respectively, in Rag
-/-
-mice. A The 
tumour incidence in A549 J5-1 injected animals was higher than in the mice injected with the 
parental A549 cell line. B The tumour growth in the animals injected with the chicken c-Myc 
expressing cells was accelerated when compared with the mice injected with the parental cell 
line. C Staining for the human Cytokeratin7 showed positive cells in the primary tumour and 
in lung and liver of animals injected with the A549 J5-1 cells. D Metastasis after screening of 
the organs for Cytokeratin7-positive cells were detected in 2 lungs and 1 liver of mice 
injected with A549 J5-1, but in no organ of animals injected with the parental cell line A549. 
the parental cell line A549. Furthermore, accelerated tumour growth was observed in the 
A549 J5-1 transplanted animals when compared to the animals injected with the control cells 
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(Figure 3-14 B). The tumours consisting of the A549 J5-1 cells were growing so fast, that the 
animals had to be sacrificed as soon as six weeks after transplantation to not exceed the 
allowed 2cm of tumour size. After sacrification the lungs, livers and lymphnodes of the 
transplanted animals were screened for expression of the human specific cytokeratin7 to be 
able detect the human A549 cells in any organ. The transplanted primary tumours were all 
positive for cytokeratin7 and in two lungs and one liver of the animals injected with A549 J5-
1 cells human cells could be observed (Figure 3-14 C). All in all in two lungs and one liver of 
the mice transplanted with A549 J5-1 cells, human cells could be detected by the cytokeratin7 
staining, while in the organs isolated from mice transplanted with the control parental cell line 
A549 no cytokeratin7-positive cells could be detected (Figure 3-14 C). These results show 
that c-Myc is sufficient to induce metastases in the human NSCLC cell line A549. 
3.4.5 shRNA-mediated GATA4 knockdown inhibits the ability of anchorage-
independent growth in A549 J5-1 
To test the role of the consistently upregulated marker GATA4 upon c-Myc-expression in the 
SpC-c-Myc single transgenic and in the SpC-C-Raf-BxB/SpC-c-Myc compound tumours and 
in the human NSCLC cell line A549 in the induction of metastasis, we performed an shRNA-
mediated knockdown of GATA4 in the A549 J5-1 cells. For this the cells were infected with 
5 different shRNA-producing viruses (sh24-sh28) and qPCR-analysis for the expression of 
the GATA4-target gene mucin2 was performed. As shown in Figure 3-15 A, the mRNA levels 
of mucin2 was significantly higher in A549 J5-1 cells when compared to the parental cell line 
A549. Only the A549 J5-1 cells infected with the shRNA25 producing virus did not have 
elevated levels of the GATA4-target gene mucin2 indicating an efficient knock down of the 
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transcription factor GATA4. When a soft agar assay was performed to test the ability of
 
Figure 3-15 shRNA-mediated knockdown of GATA4 in A549 J5-1. A qPCR-analysis for the 
GATA4-target gene mucin2 showed a significant upregulation of its expression in A549 J5-1. 
The only shRNA that efficiently knocked down the expression of the GATA4 target gene 
mucin2 was the sh25. B The soft agar assay with the A549 J5-1 cells showed a highly 
significantly reduction in the number of colonies in the A549 J5-1 cells infected with the 
shRNA25-expressing virus. 
anchorage-independent growth of the cells, the A549 J5-1 cells infected with the virus 
producing the shRNA25 did hardly form any colonies (Figure 3-15 B). These data suggest 
that the expression of GATA4 is necessary for the induction of anchorage-independent 
growth by c-Myc.  
3.4.6 Induction of DNA-demethylation upon c-Myc-expression 
The regulatory significance of epigenetic regulation of upstream and downstream genes of a 
single transcription factor has been shown to occur in the GATA gene family of transcription 
proteins in lung cancer cell lines, where the promoter-hypermethylation correlated with gene-
silencing (Guo et al., 2004). To test the possibility of the induction of genes that are involved 
in DNA-demethylation by c-Myc, qPCR-analysis was performed using primers specific for 
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GADD45 ,  and . GADD45 genes are stress inducible and function in many 
 
Figure 3-16 qPCR-analysis for expression levels of GADD45 genes. A The mRNA levels of 
GADD45  were highly significantly increased in the A549 J5-1 cells when compared to the 
parental A549 cell line. B GADD45  expression levels were highly significant higher in the 
chicken c-Myc expressing cells when compared to the parental cell line. C GADD45  
expression was highly significantly elevated upon the expression of chicken c-Myc. 
biological processes like the cell cycle, senescence, apoptosis and nucleotide excision repair. 
GADD45  was shown to have a key role in active DNA demethylation and to promote global 
DNA demethylation (Barreto et al., 2007). As shown in Figure 3-16 the expression levels of 
all GADD45 genes were increased in the chicken c-Myc expressing A549 J5-1 cells when 
compared to the mRNA levels in the parental A549 cell line, suggesting an induction of 
overall promoter-DNA-demethylation in the c-Myc-expressing cells. 
Furthermore, qPCR-analysis was performed testing the expression levels of the p53 gene 
family, the products of which act upstream of the GADD45 genes in the nucleotide excision 
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repair (Smith and Seo, 2002). The p53 gene family has three members, the p53, p63 and p73, 
 
Figure 3-17 q-PCR-analysis for the expression levels of the p53 family genes. A The mRNA 
levels of p53 were highly significantly elevated in the A549 J5-1 cells when compared to the 
parental A549 cells. B p63 expression was highly significantly induced by the expression of 
chicken c-Myc when compared to the parental A549 cell line. C No significant change in the 
relative mRNA levels of p73 was observed in the A549 J5-1 cells when compared to the 
parental A549 cell line. 
which are all transcription factors involved in development, differentiation and cell response 
to stress (Bourdon, 2007). As shown in Figure 3-17, the relative mRNA levels of p53 and p63 
were highly significantly increased in the A549 J5-1 when compared to the parental cell line 
A549, while there was no significant difference observed in the expression levels of p73. 
These data suggest that in the NSCLC cell line A549 the expression of chicken c-Myc leads 
to an upregulation of the expression of p53 and p63 and by this to an upregulation of the 
GADD45 family genes. 
3.4.7 Upregulation of angiogenesis markers in the chicken c-Myc expressing A549 
Since c-Myc has been reported to induce angiogenesis (Knies-Bamforth et al., 2004) and in 
tumours of the SpC-c-Myc single transgenic and SpC-C-Raf-BxB/SpC-c-Myc compound 
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animals a significant increase in blood and lymph vessels was observed (Rapp et al., 2009), 
immunocytochemistry for VEGF was performed. As shown in Figure 3-18 an induction of 
VEGF-expression was observed in the chicken c-Myc expressing A549 J5-1 cells when 
compared to the parental A549 cell line. These data together with the observation of VEGF-
expression in the vessels of the tumours of the SpC-c-Myc single transgenic and the SpC-C-
Raf-BxB/SpC-c-Myc compound animals suggest that c-Myc induces angiogenesis via 
upregulation of VEGF. 
 
Figure 3-18 Immunocytochemistry for the angiogenesis marker VEGF shows that there is an 
upregulation of this protein in the chicken c-Myc expressing cells compared to the parental 
cell line. 
3.4.8 Expression of the pluripotency genes Klf4 and Sox2 and the lung development 
gene Sox9 in A549 J5-1 cells 
To test the expression of markers involved in pluripotency, reprogramming and early lung 
development, qPCR-analysis was performed using primers for specific genes involved in 
these processes. Sox2 is a transcription factor that regulates embryonic stem cell pluripotency 
and is involved in lung development. Furthermore, it has been published, that Sox2 is 
expressed in NSCLC and neuroendocrine lung tumours (Sholl et al., 2009). Upon expression 
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of chicken c-Myc in the A549 cells, significantly elevated Sox2 mRNA levels have been 
observed when compared to the parental A549 cells (Figure 3-19 A). The Krüppel-like factor 
4 (Klf4) is a zinc-finger type transcription factor, that is important in 
 
Figure 3-19 qPCR-analysis of the pluripotency genes Klf4 and Sox2 and the early lung 
development gene Sox2. A The relative mRNA levels of Sox2 were significantly higher in the 
A549 J5-1 when compared to the parental A549 cells. B qPCR-analysis of the expression 
levels of Klf4 showed a highly significant increase upon expression of chicken c-Myc. C The 
expression levels of Sox9 were highly significantly higher in the A549 J5-1 cells when 
compared to the parental A549 cell line. 
reprogramming differentiated fibroblasts into inducible pluripotent stem cells and is involved 
as an oncogene in many tumours (Evans and Liu, 2008). As shown in Figure 3-19 B the 
relative mRNA levels of Klf4 were highly significantly higher in the chicken c-Myc 
expressing cells when compared to the parental A549 cell line. Sox9 is a transcription factor 
that is expressed at high levels during lung development (Perl et al., 2005). The relative 
mRNA levels of Sox9 were highly significantly increased in the A549 J5-1 cells when 
compared to the parental A549 cells (Figure 3-19 C). These data suggest that the expression 
of c-Myc in the human NSCLC cell line induces the acquisition of progenitor cell features, 
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which was also observed in the SpC-c-Myc single transgenic and SpC-C-Raf-BxB/SpC-c-
Myc compound animals (Rapp et al., 2009). 
3.4.9 Upregulation of tert in A549 J5-1 
Telomerase activation is observed in about 90% of human cancers, while most healthy tissues 
contain inactivated telomerase (Kim et al., 1994). Telomerase activation occurs after genomic 
instability in the early stages of carcinogenesis lead to telomere shortening and by this 
reduced cell survival. Telomerase activation induces genomic stability and assures cell 
 
Figure 3-20 qPCR-analysis using primers specific for telomerase. The relative mRNA levels 
of tert are significantly higher in the A549 J5-1 when compared to the parental A549 cell line. 
survival (Kim et al., 1994). Furthermore, it was published, that telomerase can be activated by 
c-Myc (Wang et al., 1998) and for this reason in the following qPCR-analysis was performed 
to test the expression levels of telomerase in the A549 J5-1 cells in comparison to the parental 
A549 cell line. As shown in Figure 3-20 the mRNA levels of telomerase were significantly 
higher in the chicken c-Myc expressing A549 J5-1 cells when compared to the parental A549 
cell line. 
3.4.10 Microarray analysis of chicken c-Myc expressing A549 
To get an overall overview about the Myc-induced changes in the gene expression profile in 
the A549 cells, microarray analyses were performed including the RNA isolated from A549 
and from A549 J5-1 cells. The microarray and the analysis of the data were done by Ellen 
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Leich, Institute for Pathology, University of Würzburg. In Figure 3-21 are shown the data 
oritinate from the analysis of differentially expressed tissue-specific genes. The lung-specific 
genes are only a small fraction of organ-specific genes being down- and upregulated after the 
expression of chicken c-Myc in the A549 cells, respectively (Figure 3-21 A). Figure 3-21 B it 
is shown that the number of genes accounting for organ identity that is downregulated by the 
expression of chicken c-Myc in the A549 cells is about fivefold higher than the number of 
genes accounting for organ identity that is upregulated by the expression of chicken c-Myc in 
the A549 cells. This observation indicates that the expression of c-Myc in NSCLC cells at 
least partially leads to the loss of organ identity. 
 
Figure 3-21 Expression of tissue-specificity genes in A549 and A549 J5-1. A The fraction of 
lung-specific genes of all genes down- and upregulated upon the expression of c-Myc in the 
A549 cells. B The number of down- and upregulated genes upon c-Myc-expression 
accounting for organ identity. 
Furthermore, the differentially expressed genes in A549 versus A549 J5-1 were assigned to 
biological processes. In Figure 3-22 are shown the biological processes that are significantly 
different in A549 and A549 J5-1. Not surprisingly, the observed differences included 
biological processes that are known to be influenced by Myc, like signal transduction, cell 
differentiation, cell proliferation and cell growth, but also processes involved in metastasis, 
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like cell motility, cell morphology, localization of the cell, inflammatory response, 
chemotaxis and taxis. Interestingly, cellular processes that are involved in imprinting were 
also changed significantly upon c-Myc-expression in the A549 cells.   
 
Figure 3-22 Gene ontology analysis for biological processes (Ashburner et al., 2000) for the 
genes differentially expressed in A549 and A549 J5-1. Shown are only the significantly 
different biological processes, p<0.05 by hypergeometric test. 
In regard to signal transduction the differentially expressed genes were assigned to specific 
pathways. In Table 3-4 are shown the ten most significantly enriched curated gene sets from 
pathway analysis of the genes upregulated in A549 J5-1. In Table 3-5 the ten most 
significantly enriched curated gene sets highlighted by pathway analysis of the genes 
downregulated in A549 J5-1 are listed. Not surprisingly, the most significant hit in the 
analysis of the genesets upregulated in the A549 J5-1 cells was the Myc oncogenic signature 
and on the third position of this analysis one can find the Myc-targets that were identified by 
ChIP analysis in diverse cell lines (Fernandez et al., 2003), supporting the authenticity of the 
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analysis tool used and the quality of the array data. The knockdown of KRas in A549 was 
shown to upregulated a specific set of genes (Sweet-Cordero et al., 2006), which was among 
the most significantly downregulated gene sets in the A549 J5-1, indicating a stimulation of  
A   
Curated 
Pathways_GSEA 
Genes that account for enrichment P-Value 
MYC_ONCOGENIC_SI
GNATURE 
RABEPK; SLC19A1; HK2; DUSP2; MYBBP1A; SLC6A15 
C16ORF14 
4.39E-
04 
BRCA1_OVEREXP_DN RABEPK; SLC19A1; GAL; BOP1; SLC7A5; CCDC85B 
7.86E-
04 
FERNANDEZ_MYC_TA
RGETS 
GAL; ID2; WT1; TERT; MAGEA3; SLC19A1 
1.06E-
03 
ADDYA_K562_HEMIN_
TREATMENT 
ID2; APOC1; TXNIP; HBA1 
1.27E-
03 
BAF57_BT549_DN HK2; GAL; PPIF; TLE4; SLCO4A1; LOC129293; C12ORF24; ADAMTS1 
1.35E-
03 
IRINOTECAN_PATHW
AY_PHARMGKB 
BCHE; CYP3A4 
2.25E-
03 
ZHAN_MULTIPLE_MY
ELOMA_VS_NORMAL
_DN 
APOC1; WNT10B; GLDC 
2.51E-
03 
SARCOMAS_GISTROM
AL_UP 
BCHE; GUCY1A3 
2.68E-
03 
WELCSH_BRCA_DN SLC19A1; BOP1 
3.15E-
03 
PENG_RAPAMYCIN_D
N 
SLC7A5; ID2; PPIF; WNT10B; CYCS; P2RX5 
3.35E-
03 
 
B 
  
Curated 
Pathways_GSEA Pathway description 
MYC_ONCOGENIC_SI
GNATURE 
Genes selected in supervised analyses to discriminate cells expressing c-Myc oncogene from 
control cells expressing GFP. 
BRCA1_OVEREXP_DN Downregulated by induction of exogenous BRCA1 in EcR-293 cells 
FERNANDEZ_MYC_TA
RGETS 
MYC target genes by ChIP in U-937,HL60 (leukemia),P493 (B-cell),T98G 
(glioblastoma),WS1 (fibroblast) 
ADDYA_K562_HEMIN_
TREATMENT 
Selected differentially expressed genes in K562 cells after hemin treatment 
BAF57_BT549_DN 
Down-regulated following stable re-expression of BAF57 in Bt549 breast cancer cells that 
lack functional BAF57 
IRINOTECAN_PATHW
AY_PHARMGKB 
 
ZHAN_MULTIPLE_MY
ELOMA_VS_NORMAL
_DN 
The 50 most significantly down-regulated genes in MM in comparison with normal bone 
marrow PCs 
SARCOMAS_GISTROM
AL_UP 
Top 20 positive significant genes associated with GI stromal tumors, versus other soft-tissue 
tumors. 
WELCSH_BRCA_DN Genes downregulated by BRCA1 
PENG_RAPAMYCIN_D
N 
Genes downregulated in response to rapamycin starvation 
Table 3-4 A GSEA annotation for curated gene sets upregulated in A549 J5-1 (Xie et al., 
2005), (Subramanian et al., 2005). Annotations were performed using genes that were at least 
1.5 times differentially expressed between the two phenotypes A549 and A549 J5-1. B 
description of the in A listed pathways. 
the mitogenic cascade upon Myc-expression. Furthermore, the pathway analysis of the A549 
J5-1 suggests a downregulation of the breast cancer associated tumour supressor gene BRCA1 
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since two of the ten most significantly upregulated gene sets upregulated in A549 J5-1 include 
genes that are downregulated by this tumour supressor. Interestingly, among the gene sets that 
were downregulated upon c-Myc-expression in the A549 cells, were genes that are 
specifically upregulated during the ageing process of the kidney and liver, indicating a more 
differentiated status of the A549 cells when compared to the A549 J5-1 cells. 
In Table 3-6 are shown the ten most significant hits for transcription factor binding motif gene 
sets that were upregulated in the A549 J5-1 cells, in Table 3-6 the ten most significant hits for 
transcription factor binding motif gene sets that were downregulated in the A549 upon c-
Myc-expression. An interesting gene set that was upregulated in the A549 J5-1 contains a 
binding site for the Myc-associated zinc-finger protein MAZ, which binds in the promoter 
region of Myc regulating transcription initiation as well as termination (Bossone et al., 1992). 
These data are consistent with negative autoregulation of endogenous Myc that regulates its 
own transcription (Cleveland et al., 1988; Goodliffe et al., 2005). On the other hand, among 
the gene sets identified to be downregulated in the A549 J5-1 cells were the genes containing 
a binding site for Myc itself, suggesting a negative feedback regulation of Myc-target genes 
upon their induction by Myc. Furthermore, gene sets have been identified in the analysis of 
transcription factor binding motifs to be upregulated in A549 J5-1 cells that are regulated by 
the mitogenic cascade, indicated by the gene set containing a binding site for the transcription 
factor Ets2, which is regulated transcriptionally and posttranscriptionally by the mitogenic 
cascade and inhibits apoptosis via induction of the transcription of the anti-apoptotic Bcl-XL 
(Yordy and Muise-Helmericks, 2000). The downregulation of gene sets that contain a binding 
motif for the E4F1 transcription factor, which induces cell cycle arrest via interaction with the 
tumour suppressors p14
ARF
 and p53 (Le Cam et al., 2006), upon c-Myc-expression in the 
A549 cells on the other hand supports the induction of cell cycle progression genes by Myc-
expression. Additionally, genes containing a binding site for Sp1 and for NFATc, which 
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A 
  
Curated 
Pathways_GSEA 
Genes that account for enrichment P-Value 
BAF57_BT549_UP 
FN1; COL15A1; C1S; COL5A1; COL1A1; RARRES1; PGM2L1; COL6A3; MAP3K8; 
GNG2; SRPX; MATN2; CFI; C8ORF4; KIAA1462; NRIP1; GALNT12; SDC2; MMP2; 
IRS1; STEAP1; TGFB2; LBH; MARCKS; CA12 ITGB8; IGFBP4; POSTN; ABCA1; 
INHBB; BTBD11; KLRC2; CGNL1; LMCD1; ZBTB1; BOC; FLJ14213; HMCN1 
8.32E-
23 
AGEING_KIDNEY_SPE
CIFIC_UP 
FN1; COL15A1; C1S; COL5A1; COL1A1; RARRES1 
PGM2L1; COL6A3; SERPINE2; FBN1; TPM1; FGG; C1R; STS; NRP1; HGF; PROM1; 
PXDN; NFKBIZ; RBMS3; MMP7; SYTL2; NOV; C11ORF9; RAB34; MGLL; ABCC3; 
PKIB; BICC1; DCDC2 
2.92E-
18 
AGEING_KIDNEY_UP 
FN1; COL15A1; C1S; COL5A1; COL1A1; RARRES1 
PGM2L1; MAP3K8; GNG2; SERPINE2; FBN1; TPM1; FGG; C1R; STS; NRP1; HGF; 
PROM1; PXDN; NFKBIZ 
RBMS3; MMP7; SYTL2; NOV; C11ORF9; RAB34; CUGBP2 
CXCL1; CD14; PTPRE; SPON2; SAMD9; CD38; ST8SIA4; SHANK2; C4ORF18; 
APBB1IP; ARL4C; QPCT; DOCK11 
3.01E-
16 
BOQUEST_CD31PLUS_
VS_CD31MINUS_UP 
FN1 ; COL15A1 ; MAP3K8 
SRPX ; MATN2 ; CFI ; C8ORF4 ; KIAA1462 ; NRIP1 
SERPINE2 ; CUGBP2 ; CXCL1 ; CD14 ; PTPRE ; RNASE4 ; CES1 ; CFH ; WNT5A ; 
SOX4 ; AGTR1 ; SEPP1 ; THBS1 ; IL15 ; SLC2A3 ; RGS2 ; NEDD9 ; PTGER2; IL8; 
CXCR7; MAST4; CTSS; PFKFB3; TLR3; LMO7 ; SLC1A1 
PDLIM5; TNFSF10; PGCP ; PTPRM; TSPAN7; ANGPTL4 
MTUS1; DKK1; CTSH; MICAL2; FRMD4B; GPR64 ; CYP26B1 ; SCG5 ; GREM1 ; 
DOK5 
3.05E-
16 
BOQUEST_CD31PLUS_
VS_CD31MINUS_DN 
FN1 ; C1S ; COL5A1 ; COL1A1; COL6A3; SRPX 
GALNT12 ; SDC2 ; MMP2; IRS1; STEAP1; SERPINE2 
FBN1; CUGBP2; SPON2; RNASE4 ; CES1 ; CFH 
WNT5A ; IGFBP3 ; ALDH1A1; HNMT; SPOCK1; TMEM45A 
COL5A2; PCDH9; PLA2G4A; ITGBL1; SETBP1; CRISPLD2 
2.23E-
13 
CORDERO_KRAS_KD_
VS_CONTROL_UP 
C1S; COL5A1; COL1A1; MAP3K8; MATN2; TGFB2; LBH; SERPINE2; TPM1; SOX4; 
IGFBP3; HGD; IGFBP7; MYL9; SLC16A4; NCF2; DKK3 
1.13E-
12 
HSIAO_LIVER_SPECIFI
C_GENES 
FN1; C1S; CFI; FGG; C1R; RNASE4; CES1; AGTR1; SEPP1; ALDH1A1; HNMT; HGD; 
DAB2; IGFBP1; CP 
APOH; F5; FGB; FGA; FGL1; ITIH2; CFHR1 
1.14E-
08 
TAKEDA_NUP8_HOXA
9_10D_UP 
FN1; CFI; GALNT12; SERPINE2; STS; SAMD9 
CD38; SOX4; THBS1; IL15; ALDH1A1; SPOCK1; TMEM45A; PTGS2; RBPMS; HPGD; 
GBP1; OAS1 
7.54E-
08 
RUTELLA_HEMATOGF
SNDCS_DIFF 
C1S; RARRES1; SDC2; MMP2; MARCKS; STS; NRP1 
MGLL; ABCC3; CUGBP2; CXCL1; CD14; RNASE4; CES1; SLC2A3 ; RGS2; NEDD9 ; 
PTGER2 ; SPOCK1; IGFBP7; DAB2 ; CCNG2; OPTN; CTSD; SLC7A7; LXN; F2RL1; 
CXCL5; NAT1; FKBP1B; NRG1; KMO; FLJ10357; CSF2RA; MYO15B; RAB20 
9.05E-
08 
HYPOXIA_REVIEW 
COL5A1; CA12; HGF; SLC2A3; IL8; IGFBP3; IGFBP1; CP; PTGS2; CCNG2; IGF2; 
EDN1 
9.25E-
08 
 
B 
  
Curated 
Pathways_GSEA 
Pathway description 
BAF57_BT549_UP 
Up-regulated following stable re-expression of BAF57 in Bt549 breast cancer cells 
that lack functional BAF57 
AGEING_KIDNEY_SPE
CIFIC_UP 
Up-regulation is associated with increasing age in normal human kidney tissue from 
74 patients, and expression is higher in kidney than in whole blood 
AGEING_KIDNEY_UP 
Up-regulation is associated with increasing age in normal human kidney tissue from 
74 patients 
BOQUEST_CD31PLUS_
VS_CD31MINUS_UP 
Genes overexpressed 3-fold or more in freshly isolated CD31+ versus freshly 
isolated CD31- cells 
BOQUEST_CD31PLUS_
VS_CD31MINUS_DN 
Genes overexpressed 3-fold or more in freshly isolated CD31- versus freshly isolated 
CD31+ cells 
CORDERO_KRAS_KD_
VS_CONTROL_UP 
Genes upregulated in kras knockdown vs control in A549 cells 
HSIAO_LIVER_SPECIFI
C_GENES 
Liver selective genes 
 
TAKEDA_NUP8_HOXA
9_10D_UP 
Effect of NUP98-HOXA9 on gene transcription at 10 d after transduction UP 
RUTELLA_HEMATOGF
SNDCS_DIFF 
The 672 significantly changing genes 
HYPOXIA_REVIEW Genes known to be induced by hypoxia 
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Table 3-5 A GSEA annotation for curated gene sets upregulated in A549 (Xie et al., 2005), 
(Subramanian et al., 2005). Annotations were performed using genes that were at least 1.5 
times differentially expressed between the two phenotypes A549 and A549 J5-1. B 
description of the in A listed pathways. 
induce and are induced by VEGF, respectively, and by this have both been reported to 
promote tumour angiogenesis (Kulkarni et al., 2009; Song et al., 2009), were among the most 
significantly upregulated gene sets in the A549 J5-1, reflecting the induction of angiogenesis 
by Myc. Surprisingly, the Sp1-target genes were also upon the most significant gene sets  
A   
Motif Geneset_GSEA Genes that account for enrichment P-Value 
GGGCGGR_V$SP1_Q6 
WT1; TLE4; MAZ; POLR3G; ID4; COL4A6; PRDM13; 
TRIM14; CBX5; SLC6A15; OIP5; GNG4; PTGES2; GLDC 
7.85E-
04 
CAGGTG_V$E12_Q6 
WT1; TLE4; MAZ;  POLR3; CXORF;15 HES6; NRCAM; ANKRD2; WNT10B; P2RX5; 
GUCY1A3 
1.16E-
03 
TGGAAA_V$NFAT_Q4
_01 
ID4; COL4A6; DLX1; FLI1; PDE3B; ID2; CCL5 
1.39E-
03 
CTTTGT_V$LEF1_Q2 
PRDM13; CXORF15; HES6; NRCAM; DLX1; PTPRG; 
OSBPL6; BCHE 
2.18E-
03 
GGGAGGRR_V$MAZ_
Q6 
WT1; ID4; COL4A6; PRDM13;  ANKRD; DLX1; FLI1; 
PTPRG; DAPP1; HRK; ADAMTS1 
4.37E-
03 
RYTTCCTG_V$ETS2_B PTPRG; DAPP1; PPIF 
5.51E-
03 
V$CEBPGAMMA_Q6 ID4; PRDM13; DLX1; FLI1; PTPRG;  G0S2; CYCS 
7.03E-
03 
TGACCTY_V$ERR1_Q
2 
DLX1; G0S2; PRRX2 
7.61E-
03 
TTGTTT_V$FOXO4_01 ID4; COL4A6; PRDM13; TRIM14; CXORF15; DLX1; FLI1; PDE3B; ID2; TXNIP; UGT8 
1.08E-
02 
CAGCTG_V$AP4_Q5 
TLE4; PRDM13; HES6; WNT10B; P2RX5; DLX1; 
HIST1H2BF 
1.41E-
02 
 
B 
  
Motif Geneset_GSEA 
Genes with promoter regions [-2kb,2kb] around transcription start site containing the 
motif 
GGGCGGR_V$SP1_Q6 CTTTGT which matches annotation for LEF1: lymphoid enhancer-binding factor 1 
CAGGTG_V$E12_Q6 CAGGTG which matches annotation for TCF3: transcription factor 3 
TGGAAA_V$NFAT_Q4
_01 
NNNGNCAGTTN which matches annotation for MYB: v-myb 
CTTTGT_V$LEF1_Q2 GGGCGGR which matches annotation for SP1: Sp1 transcription factor 
GGGAGGRR_V$MAZ_
Q6 
TWTTTAATTGGTT which matches annotation for NKX6-1: NK6 
RYTTCCTG_V$ETS2_B 
ANCAATCAW which matches annotation for PBX1: pre-B-cell leukemia transcription factor 
1 
V$CEBPGAMMA_Q6 
CTBATTTCARAAW which matches annotation for CEBPG: CCAAT/enhancer binding 
protein (C/EBP), gamma 
TGACCTY_V$ERR1_Q2 
CACGTGS which matches annotation for MYC: v-myc myelocytomatosis viral oncogene 
homolog (avian) 
TTGTTT_V$FOXO4_01 CAGCTG which matches annotation for REPIN1: replication initiator 1 
CAGCTG_V$AP4_Q5 NTGCGTGGGCGK which matches annotation for EGR3: early growth response 3 
Table 3-6 A GSEA annotation for motif gene sets higher expressed in A549 J5-1 
(Subramanian et al., 2005). Annotations were performed using genes that were at least 1.5 
times differentially expressed between the two phenotypes A549 and A549 J5-1. B 
description of the in A listed motifs.  
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identified to be downregulated in the A549 J5-1 cells, suggesting that the presence and 
absence of Myc can both activate the same transcription factors, but resulting in different sets 
of target genes. As many as four transcription factors identified in the transcription factor 
A   
Motif Geneset_GSEA Genes that account for enrichment P-Value 
SCGGAAGY_V$ELK
1_02 
TRIM46; PDE5A; CLMN; SHANK2; INSIG2 
3.64E-
11 
GGGCGGR_V$SP1_Q
6 
TRIM46; PDE5A; NDN; RAB3IP; WNT5A; ALS2CR8; BMP4; ABCA1; PFKFB3; KCNJ2; 
COL1A1; SOX4; ARHGAP26 DLG3; MARCKS; CYP26B1; CCNG2; AXIN2; 
CYP24A1;CPNE4; TCEA3; ITGB8; RASSF2; TGFB1I1; NRP2; SERPINI1; IGF2; THBS3; 
MYH10; GPR37; MLLT3; PPARA; HPGD; PLCB1; HAS2; BAMBI; ITGBL1; POLD4; 
MAML2; SLC16A2; ENO2; NEDD9; CNTN1; RAB34; IGFBP7; MUC1; DSC2; MAOB; 
OPTN; ABCC3; MLPH 
1.45E-
06 
RCGCANGCGY_V$N
RF1_Q6 
NDN; RAB3IP; WNT5A; ALS2CR8; NBEA; VAV3; SGCB 
1.86E-
06 
CACGTG_V$MYC_Q
2 
TRIM46; BMP4; ABCA1; PFKFB3; TGFB2; FXYD2; 
PLA2G4A; MTUS1; MICAL2; ARMCX2 
6.74E-
06 
MGGAAGTG_V$GA
BP_B 
CLMN; NDN; BMP4; PCDH7; PKIB; CTSS; AGPAT4 
9.14E-
05 
GTGACGY_V$E4F1_
Q6 
TGFB2; PCDH7; PKIB; LTBP1; CRH; WSB1; CHGB 
6.51E-
04 
GATTGGY_V$NFY_
Q6_01 
BMP4; KCNJ2; COL1A1; SOX4; ARHGAP26; DLG3; 
MARCKS; CYP26B1; CCNG2 L;TBP1; ANK3; FGD4; 
GCA; CDH6; PCDH9; IRS1; MMD; SORT1 
8.24E-
04 
V$HNF1_Q6 
RAB3IP; AXIN2; FXYD2; FGA; FGB; SEMA3A; NRP1; 
UGT1A6; RNASE4; C11ORF9; SLC4A4; IGFBP1; 
ANXA13; CLDN10; F2RL1; SPINK1 
1.67E-
03 
V$CEBPB_02 
RAB3IP; WNT5A; KCNJ2; CYP24A1; CPNE4; PLA2G4A; PCDH7; FGA; FGB; MAP2K6; 
COL4A3; COL4A4; RBPMS; CP; KCNE3 
5.39E-
03 
V$HNF1_01 
RAB3IP; TCEA3; FXYD2; PLA2G4A; FGA; SEMA3A; 
NRP1; UGT1A6; RNASE4; C11ORF9; SLC4A4; IGFBP1; 
ANXA13; DAB2 
6.26E-
03 
 
B 
 
Motif Geneset_GSEA 
Genes with promoter regions [-2kb,2kb] around transcription start site containing the 
motif 
SCGGAAGY_V$ELK
1_02 
SCGGAAGY which matches annotation for ELK1: ELK1, member of ETS oncogene family 
GGGCGGR_V$SP1_Q
6 
which matches annotation for SP1: Sp1 transcription factor 
RCGCANGCGY_V$N
RF1_Q6 
RCGCANGCGY which matches annotation for NRF1: nuclear respiratory factor1 
CACGTG_V$MYC_Q
2 
CACGTG which matches annotation for MYC: v-myc myelocytomatosis viral oncogene 
homolog (avian) 
MGGAAGTG_V$GA
BP_B 
MGGAAGTG which matches annotation for GABPA: GA binding protein transcription factor, 
alpha subunit 60kDa<br> GABPB2: GA binding protein transcription factor, beta subunit 2 
GTGACGY_V$E4F1_
Q6 
GTGACGY which matches annotation for E4F1: E4F transcription factor 1 
GATTGGY_V$NFY_
Q6_01 
GATTGGY. Motif does not match any known transcription factor 
V$HNF1_Q6 
WRGTTAATNATTAACNNN which matches annotation for TCF1: transcription factor 1, 
hepatic; LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor 
V$CEBPB_02 
NKNTTGCNYAAYNN which matches annotation for CEBPB: CCAAT/enhancer binding 
protein (C/EBP), beta 
V$HNF1_01 
GGTTAATNWTTAMCN which matches annotation for TCF1: transcription factor 1, hepatic; 
LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor 
Table 3-7 GSEA annotation for motif gene sets higher in A549  (Subramanian et al., 2005). 
Annotations were performed using genes that were at least 1.5 times differentially expressed 
between the two cell lines A549 and A549 J5-1. B description of the in A listed motifs.  
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binding motif analysis of gene sets upregulated in the A549 J5-1 cells are involved in 
dedifferentiation or early embryonal developmental processes, clearly showing that these are 
affected by the expression of c-Myc. I.e. Sp1 plays a crucial role in mediating early events of 
physiological mucous epithelial cell differentiation of bronchial epithelial cells (Hong et al., 
2008), Tcf3 is expressed during embryonal lung development in the primordial and alveolar 
epithelium (Tebar et al., 2001), Lef1 is involved in the development of multiple organs 
(Eastman and Grosschedl, 1999) and MAZ protein levels show an increase upon 
differentiation of ES cells (Tarasov et al., 2008). Additionally, among the most significantly 
downregulated gene sets upon c-Myc-expression in the A549 cells were two transcription 
factors identified that are involved in differentiation and the expression of organ-specific 
genes, GABPB2, which is involved in B-cell lineage differentiation and HNF1, which is a 
liver-specific transcription factor (Servitja et al., 2009). Interestingly, the above mentioned 
transcription factor Lef1 has also been recently identified to be one of the mediators of 
chemotactic invasion and colony outgrowth in lymph node derived lung adenocarcinoma cells 
(Nguyen et al., 2009), consistent with the metastatic potential of the A549 J5-1 cells. 
Additionally, a gene set containing a binding site for the transcription factor FoxO4 was 
among the most significantly upregulated gene sets identified for A549 J5-1 cells. FoxO4 is 
known to activate amongst others the transcription of the DNA-damage responsive Gadd45a 
(Kobayashi et al., 2005), which was shown to be upregulated in the A549 J5-1 cells in the 
qPCR experiments shown before. 
Not only genetic and epigenetic alterations of protein encoding genes are responsible for 
tumour development. Over the past few years also many microRNAs have been implicated in 
various human cancers (Croce, 2009). MicroRNAs are small, 19-22 nucleotide long, non-
coding RNAs that inhibit gene expression at the posttranscriptional level. Given the frequency 
with which microRNA target sequences are conserved within 3‟UTRs, it is estimated that 20 
to 30% of all human genes are targets for microRNAs (Peter, 2009). Therefore a GSEA 
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annotation was also performed for microRNA targets upregulated and downregulated in c-
Myc-expressing A549 cells in comparison to the parental cell line A549. An upregulation of 
microRNA target genes can be interpreted as a downregulation of the corresponding 
microRNA. In Table 3-8 the ten most significantly upregulated microRNA target gene sets in 
the A549 J5-1 cells are shown, in Table 3-9 the ten most significantly downregulated 
microRNA target gene sets in the A549 J5-1 cells. First of all, the upregulation of the micro-  
microRNA targets_GSEA Genes that account for enrichment P-Value 
TGTTTAC,MIR-30A-5P,MIR-30C,MIR-
30D,MIR-30B,MIR-30E-5P 
BNC1; GLDC 3,87E-03 
TGGTGCT,MIR-29A,MIR-29B,MIR-29C DUSP2; TUBB2B 8,49E-03 
TTTGCAC,MIR-19A,MIR-19B ID4; PTPRG 8,82E-03 
TGCTGCT,MIR-15A,MIR-16,MIR-15B,MIR-
195,MIR-424,MIR-497 
TLE4; SLC7A2; G0S2 9,74E-03 
ACCAAAG,MIR-9 ID4; FLI1 1,09E-02 
ACTGTGA,MIR-27A,MIR-27B ID2; ECE2 1,48E-02 
CAGTATT,MIR-200B,MIR-200C,MIR-429 FLI1; ID2  1,59E-02 
GCACTTT,MIR-17-5P,MIR-20A,MIR-
106A,MIR-106B,MIR-20B,MIR-519D 
BNC1; DUSP2; TXNIP; SOLH 2,63E-02 
AATGTGA,MIR-23A,MIR-23B PPIF; DLX1 2,78E-02 
GTGCCTT,MIR-506 TLE4; PPIF ;NRCAM; PRDM13; TRIB3; NUDCD2 3,17E-02 
Table 3-8 GSEA annotation for microRNA target gene sets upregulated in A549 J5-1 
(Subramanian et al., 2005). Annotations were performed using genes that were at least 1.5 
times differentially expressed between the two cell lines A549 and A549 J5-1. 
microRNA targets_GSEA Genes that account for enrichment P-Value 
TGAATGT,MIR-181A,MIR-181B,MIR-
181C,MIR-181D 
ST8SIA4; MYH10; WSB1; PDLIM5; ITGB8; NPTXR; 
GREM1; SLC2A3; ARNT2 
1,79E-04 
GTGCCTT,MIR-506 
ST8SIA4; MYH10; WSB1; NRP2; NAV1; PCDH9; NRP1; 
SESTD1; FOXQ1; RAB34; FAM62B; PLCB1; SHANK2; 
ABCA1; FLRT3; DAPK1; FLJ10357; PDE5A; COL5A1 
5,11E-04 
CTGAGCC,MIR-24 RASSF2; NEDD9 6,02E-04 
TGCTGCT,MIR-15A,MIR-16,MIR-15B,MIR-
195,MIR-424,MIR-497 
NRP2; NAV1; PCDH9; PDLIM5; SLC4A4; LPHN2; 
MMD; KCNJ2; COBLL1; HAS2; RSPO3; AXIN2; 
ARMCX2; RNF43; CLDN2 
9,18E-04 
GTGCAAT,MIR-25,MIR-32,MIR-92,MIR-
363,MIR-367 
SOX4; CXCL5; FBN1; SDC2; DSC2 1,35E-03 
CTACCTC,LET-7A,LET-7B,LET-7C,LET-
7D,LET-7E,LET-7F,MIR-98,LET-7G,LET-7I 
SLC4A4; COL1A1; PGM2L1; COL5A2; SYT11; MGLL; 
CGNL1; DKK3 
1,70E-03 
ATTCTTT,MIR-186 LPHN2; CACNB3; WNT5A; HNMT 1,72E-03 
CTCAGGG,MIR-125B,MIR-125A ST8SIA4; SLC4A4; SORT1; MTUS1; LBH; ABHD6 1,95E-03 
TGTTTAC,MIR-30A-5P,MIR-30C,MIR-
30D,MIR-30B,MIR-30E-5P 
ST8SIA4; MYH10; NRP2; NRP1; MMD;  
SOX4; CUGBP2; YPEL2; NRIP1; RGS2; IRS1; FHOD3; 
INSIG2; SEMA3A; CYP24A1; SGCB 
3,07E-03 
TGCCTTA,MIR-124A 
MYH10; NRP2; NAV1; SESTD1; FOXQ1; RAB34; 
FAM62B; KCNJ2; CACNB3; PPARA; PTPRE; BTBD11; 
MLLT3; RBMS3; CNTN1 
3,13E-03 
Table 3-9 GSEA annotation for microRNA target gene sets upregulated in A549 
(Subramanian et al., 2005). Annotations were performed using genes that were at least 1.5 
times differentially expressed between the two cell lines A549 and A549 J5-1. 
RNAs miR-24 and Let-7, which both target Myc-RNA (Lal et al., 2009; Sampson et al., 
2007), in the c-Myc-expressing A549 cells is consistent with a negative feedback regulation 
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of Myc upon its expression (Cleveland et al., 1988). Furthermore, the ability of Myc to 
promote cell growth and proliferation was reflected in this analysis by the upregulation of 
gene sets that are targets of microRNAs responsible for suppression of cell growth, i.e. miR-
30 (Wu et al., 2009); blocking G(1)/S-transition, like miR-195 (Xu et al., 2009); and that 
inhibit proliferation, like miR-9 does via targeting of NF B (Guo et al., 2009); and the 
downregulation of gene sets that are targets of microRNAs that increase proliferation, like 
themiR-92, which targets p63 (Manni et al., 2009), in A549 J5-1 cells. Additionally, target 
genes of the microRNA miR-200 were found to be among the most significantly upregulated 
gene sets in this analysis upon c-Myc-expression. The miR-200 inhibits the ability to 
metastasize in tumour cell lines derived from mice that develop metastatic lung 
adenocarcinoma owing to expression of mutant KRas and p53 via targeting genes involved in 
EMT (Gibbons et al., 2009). Although in the SpC-C-Raf-BxB/SpC-c-Myc metastasis model 
for NSCLC no EMT was observed (Rapp et al., 2009), these data indicate that genes involved 
in this process are regulated by Myc. The oncogenic potential of Myc is clearly shown by the 
upregulation of microRNA target gene sets for microRNAs identified to be involved in 
tumour development, i.e. the tumour suppressor microRNAs miR-15 and -16, in the A549 J5-
1 cells. Furthermore, in this analysis a gene set was observed to be downregulated upon c-
Myc-expression in the A549 cells, which comprises targets of the microRNA miR-181 that 
has been shown inhibit hepatic cell differentiation through targeting GATA6 among other 
genes (Ji et al., 2009). This result indicates a downregulation of GATA6 upon c-Myc 
expression, which is in line with our observation of a GATA6/GATA4 switch in the c-Myc-
expressing tumours in the NSCLC mouse model (Rapp et al., 2009). 
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4 Discussion 
4.1 Melanoma 
Two strategies were followed to examine the role of B-Raf in melanoma development. The 
first approach was to generate transgenic animals that express the oncogenic B-Raf
V600E
 
melanocyte-specific and inducible. Furthermore B-Raf-deficient embryos were used to 
determine the role of B-Raf in early embryonal development to gain information about its 
non-pathological function. Surprisingly, it was observed that the early embryonal melanocyte 
development is not dependent on B-Raf. 
4.1.1 Generation of a transgenic mouse model for melanocyte-specific and inducible 
expression of B-Raf
V600E
 
The goal of this work was to establish a mouse model to study the role of B-Raf
V600E
 in 
melanoma development and have a mouse model to test new therapeutic approaches for B-
Raf
V600E
-positive melanoma. To have a flexible system, that can also be used to study the 
effect of the expression of B-Raf
V600E
 in other organs than the skin, i.e. the lung, and to avoid 
the risk of embryonal lethality as far as possible, a construct was generated that enables the 
tetracycline-inducible expression of B-Raf
V600E
 in combination with the tissue-specific 
expression of rtTA. In principle, it is necessary to express a strong oncogene like B-Raf
V600E
 
inducible, because the constitutive expression of an oncogene in many tissues already during 
early embryonal development is likely to result in embryonal lethality, since the constitutive 
active mitogenic cascade would interfere with many developmental signaling pathways. 
Furthermore, to be able to distinguish the transgenic B-Raf
V600E
 from the endogenous 
wildtype B-Raf, the B-Raf
V600E
 was additionally tagged with EGFP. For being able to test the 
expression of the construct easily and to later have the possibility of in vivo low light imaging, 
the construct also contains the luciferase, which is expressed under the control of the 
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bidirectional tetracycline-inducible promoter in the other direction than B-Raf
V600E
-EGFP. 
The construct that was generated for this purpose in this work is shown in Figure 3-1. 
Furthermore, as shown in the results-part, the B-Raf
V600E
 resulting from the expression of this 
construct in NIH3T3 cells is functional in respect to Erk-phosphorylation, detectable in 
respect of the EGFP-tag and the Luciferase-activity and inducible by doxycycline. To target 
the expression of B-Raf
V600E
 to a specific cell type, in our case the melanocytes, the resulting 
mouse line would have to be combined with a transgenic mouse line expressing the rtTA-
protein tissue-specific manner. For the melanocyte-specific transgene expression for this 
purpose one would chose promoters that drive the expression of members of the Tyrosinase 
gene family, like the Tyrosinase-related protein 1 (TRP1), DCT or the Tyrosinase. In mice, in 
situ-hybridization and lacZ reporter assays have shown that DCT is expressed in cells of the 
pigment cell lineage, the melanoblast, melanocytes and cells of the retinal pigment epithelium 
(Pollock et al.). In migrating melanoblasts the expression of DCT starts at the embryonic day 
E11 and with this starts somewhat earlier than the expression of the two related genes TRP1 
and Tyrosinase (Guyonneau et al., 2004). Nevertheless, even if the expression profile of a 
certain promoter is known, it is difficult to predict the phenotype of the resulting animal. For 
this reason it is important to make the effort of developing an inducible system, because 
different promoter/oncogene combinations can more easily be tested. 
Surprisingly, as described in 3.1.3, after microinjection of the linearized construct, only two 
of the founder-lines that were positively tested for the transgene via PCR from tail-DNA were 
transmitting the transgene to their offspring. Although it has been shown that a very tight 
regulation of gene expression is possible in the context of the Tet system by the successful 
expression of the lethal diphtheria toxin gene in transgenic mice (Deuschle et al., 1995), it is 
sometimes difficult to establish cell lines or transgenic animals where genes encoding 
potentially toxic products are under Tet control (Lai et al., 2004). These problems mainly 
result from episomal and multiple copy status of the transferred DNA, a situation when 
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chromatin suppression is lacking and cumulated expression from multiple copies of the target 
gene might compromise the survival of candidate cells. Additionally, the conditional 
expression of a B-Raf
V600E
-knock-in allel in a Cre/LoxP-approach resulted in combination 
with the expression of the Cre-recombinase under the control of a CMV-promoter in 
embryonal lethality at embryonic day E7 (Mercer et al., 2005). This suggests, that a leakiness 
of the tetracycline-inducible promoter resulting from an integration site in a chromosomal 
region where chromatin suppression is lacking would lead to a limited survival of the target 
cells and by this to embryonal lethality or to a mosaic animal not containing transgene bearing 
cells in any organ that might be affected due to its expression. The probability of an 
undesirable integration site would be increased if more DNA would be injected into the 
blastocysts. Furthermore, if the injected DNA integrates in a transcriptionally inactive part of 
the genome, this will result in viable transgene-positive animals that transmit the transgene in 
a mendelian ratio to their offspring, which is probably the case for the two transgene-
transmitting founder-lines. 
To circumvent the problems that we encountered, it might be helpful to combine the 
generated plasmid with a tetracycline-controlled transcriptional silencer (tTS), which is the 
fusion of the bacterial Tet repressor and the silencer domain derived from a transcriptional 
silencer (Forster et al., 1999), i.e. in place of the reporter gene luciferase, to mitigate the leaky 
expression associated with tetracycline-regulated promoter. By this the gene activity is shut 
down completely by tTS binding to the promoter in the absence of the inducer doxycycline 
and thus actively shields the promoter from the endogenous transcriptional machinery. This 
might provide the possibility to develop a tightly controllable doxycycline inducible gene 
expression system (Lai et al., 2004). 
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4.1.2 B-Raf is not involved in early embryonal melanocyte development 
In interesting recent publications it was shown that the tumourigenic phenotype of cancer cell 
lines can be suppressed by the mouse embryonal microenvironment and the developmental 
plasticity of the tumour cells was manifested as the tumour cells contributed to the formation 
of normal tissue. When GFP-labeled human metastatic melanoma cells were transplanted into 
the embryonic chick neural tube, they invaded the chick periphery in a programmed manner 
along stereotypical neural crest cell migratory pathways and populated peripheral destinations 
and  a subpopulation of these cells even expressed melanogenic markers that could not be 
detected at the time point of transplantation. Importantly, the transplanted melanoma cells did 
not form tumours (Kulesa et al., 2006). The other way around, the influence of a tumourigenic 
microenvironment on melanocytes has been shown to induce the acquisition of tumour cell-
like characteristics (Seftor et al., 2005). Furthermore, in expression profiling studies 
comparing melanoma cell lines with normal melanocytes, pathways were identified that might 
be involved in the transformation of melanocytes to melanoma, including those involved in 
embryonal development (Hoek et al., 2004). These data and other reports suggest that the 
development of metastatic characteristics might be a faulty reversal of ontogeny (Rapp, 
2007). As described in the introduction, B-Raf plays an important role in melanoma. For these 
reasons, in this work, the role of B-Raf in the early embryonal melanocyte development was 
examined, to gain more information about pathways and events that might also be involved in 
reprogramming of melanocytes to malignant melanoma cells.  
The expression of the neural crest marker Sox10 in neural tubes of E11.5 embryos of B-Raf-
deficient animals and the detection of the same amount of p75/Sox10 double-positive cells in 
neural tube explant cultures of wildtype and B-Raf-deficient embryos suggested a normal 
early neural crest development in the absence of B-Raf. This was confirmed by in-situ 
hybridization using Sox10-specific probes showing the localization of the Sox10-positive 
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cells localized in the migratory stream form the neural crest stem cell population to the dorsal 
root ganglia. 
Furthermore, the results of this work showed that neither the expression of Mitf is impaired in 
neural tubes of E11.5 embryos, nor the localization of Mitf-positive cells in respect to the 
neural crest development in E9.5 embryos in the absence of B-Raf. As shown in Figure 3-7, 
the Mitf-expressing cells in the wildtype as well as in the B-Raf-deficient embryos are located 
dorsal of the neural tube and along the dorso-lateral migratory pathway. These results were 
surprising, because B-Raf
V600E
 plays a central role in the regulation of Mitf expression and 
protein stability in melanoma cell lines. On the one hand, oncogenic B-Raf induces the 
expression of Mitf via the activation of the mitogenic cascade, which is controlled by the 
transcription factor BRN2 that targets Mitf is targeted for degradation via phosphorylation by 
ERK. Long-term inhibition of the constitutively active mitogenic cascade in B-Raf
V600E
-
positive melanoma cells using a MEK-inhibitor leads to an almost complete loss of Mitf 
expression. Furthermore, it was shown that B-Raf as well as Mitf are essential for melanocyte 
proliferation, but  wildtype B-Raf seems not to regulate Mitf expression in normal 
melanocytes and also the transcription factor BRN2 is not expressed in mature melanocytes 
(Wellbrock et al., 2008). BRN2 is a neuronal-specific transcription factor that is expressed in 
the melanoblasts but becomes downregulated as these cells differentiate into melanocytes 
(Cook et al., 2003) and that was previously shown to link oncogenic B-Raf to melanoma 
proliferation (Goodall et al., 2004). Wellbrock et al. showed that BRN2 expression is induced 
by oncogenic but not by wildtype B-Raf, suggesting that the ability of B-Raf to induce the 
transcription of BRN2 and by this regulate the expression of Mitf is a newly acquired function 
of the oncogenic protein (Wellbrock et al., 2008). In line with this, in this work no difference 
between wildtype and B-Raf-deficient embryos could be shown in respect to Mitf expression 
and to the localization of Mitf-expressing cells in the melanogenic developmental pathway. 
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Mitf is considered to be the master regulator of melanocyte biology, mainly because it 
regulates the expression of the melanogenic enzymes like DCT or Tyrosinase (Levy et al., 
2006). As the B-Raf-deficient neural crest stem cells were positive for this master regulator of 
melanocyte biology it was not surprising to detect DCT expression in the neural tubes of 
E11.5 wildtype as well as B-Raf-deficient embryos. Furthermore, the dorso-lateral 
localization of the DCT-positive cells in the in-situ hybridization on sections of E11.5 
embryos indicates that unlike in the development of cortical neurons (Camarero et al., 2006), 
B-Raf is not necessary for migration along the developmental pathways in the melanocyte 
development. 
4.2 NSCLC 
Two different models were used to understand the role of c-Myc in the induction of 
metastasis and tumour cell reprogramming. First of all in the NSCLC metastasis mouse model 
gene expression profiling was performed to identify pathways that become activated prior to 
metastasis. Surprisingly, the most significant gene found was a neuroendocrine marker, which 
usually is a feature of SCLC (Travis et al., 2004). Next Myc was introduced into a non-
metastatic human NSCLC cell line. It could be shown that these cells express the same 
markers that were identified by (Rapp et al., 2009) in the NSCLC mouse model for Myc-
induced metastasis and that Myc is sufficient to convert a non-metastatic NSCLC cell line 
into metastasizing cells. Furthermore, a panel of genes was identified that might be involved 
in the metastatic conversion upon Myc-expression.   
4.2.1 Secondary mutations in long latency SpC-c-Myc single transgenic animals 
As described in 3.3.1 the tumour development in single transgenic SpC-c-Myc animals was 
delayed when compared to the SpC-C-Raf-BxB/SpC-c-Myc compound mice. This 
demonstrates that Myc alone is incapable to promote tumour formation in this NSCLC model 
and requires additional mutations to rescue transformation activity due to its deleterious 
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(apoptotic) single oncogene effects as described in 1.6.1. In this work, a mutation screen was 
performed and frequent mutations in Exon1 of KRas and in Exon6 of LKB1 were detected in 
the primary lung tumours of the single transgenic SpC-c-Myc animals. These mutations were 
exclusive with one exception of the analyzed SpC-c-Myc single transgenic mice, which had a 
different mutation in Exon6 of LKB1 (6389). Furthermore, a mutation in Exon1 of KRas 
could only be detected in two, a mutation in Exon6 of LKB1 in none of the analyzed primary 
lung tumours of the SpC-C-Raf-BxB/SpC-c-Myc compound animals. This observation is 
consistent with the mutually exclusive pattern of Ras and Raf mutations in human tumours 
(Storm and Rapp, 1993). Furthermore, these data suggest that in the type II-pneumocytes an 
oncogenic signaling of the mitogenic cascade, i.e. induced by C-Raf-BxB or constitutive 
active KRas, leads to the inactivation of the tumoursupressor LKB1. In the single transgenic 
SpC-c-Myc the expansion of the cells in the observed pleomorphic clusters is blocked by the 
deleterious effects of Myc on cell survival. The activation of the mitogenic cascade via C-Raf-
BxB (Rapp et al., 2009) or an activating KRas mutation antagonizes these effects as well as 
the inactivation of the proapoptotic tumour suppressor LKB1 (Zhong et al., 2008). 
4.2.2 Is metastasis an early event 
The occurrence of KRas-mutations in a high frequency of primary lung tumours in the SpC-c-
Myc single transgenic mice suggested the possibility to use these mutation data for lineage 
tracing from the primary lung tumour cells to the liver and lymph node metastases. Therefore 
in this work, liver and lymphnode metastases were screened for mutations in Exon1 of KRas. 
Surprisingly, as shown in Table 3-2, all analyzed metastases of the single transgenic SpC-c-
Myc mice did not carry a mutation in KRas Exon1 with one exception (16740), although they 
had mutations in this gene in their primary lung tumours. The animal 16740, which had an 
identical mutation in KRas Exon1 in the primary lung tumour and the corresponding liver 
metastasis had multiple organ metastases, including besides liver pancreas, kidney and brain. 
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These data strongly indicate that metastasis is an early event and support the suspicion of 
early seeding of metastasis initiating cells. 
4.2.3 Induction of neuroendocrine markers by c-Myc 
Although the cell population of the pulmonary neuroendocrine bodies, that is also described 
as “Clara-like cells” (De Proost et al., 2008) is different from TypeII-pneumocytes expressing 
the transgenes C-Raf-BxB and c-Myc, in this work a highly significant upregulation of the 
neuroendocrine marker SNCA has been observed in the lung tumours of the SpC-C-Raf-
BxB/SpC-c-Myc compound animals. Hyperplasia of pulmonary neuroendocrine cells is 
frequently observed in response to acute or chronic lung damage suggesting that they play a 
role in the regeneration of the pulmonary epithelium after injury (Peake et al., 2000). One 
could argue that the increased expression of SNCA is rather a consequence of the changes in 
the normal microenvironment leading to an increase of the SNCA-expressing cell population 
in the lung than a true effect of the expression of c-Myc in the alveolar type II cells, since this 
data derived from analysis of total lung RNA. But when we performed qPCR experiments on 
the c-Myc-expressing A549 J5-1 cells data also showed a highly significant upregulation of 
SNCA. Furthermore, in this cell culture model for human NSCLC the significant upregulation 
of more markers of the neuroendocrine system, like pgp9.5, Synaptobrevin and NeuroD1, was 
observed. SNCA is normally expressed in neuronal tissue and is located in close vicinity to - 
and is loosely associated with - presynaptic vesicles and thus is considered to play a role in 
synaptic release of neurotransmitters. Furthermore, it appears to be involved in the etiology of 
neurodegenerative diseases and has also been reported to play a role in ovarian tumours, but 
its function in the malignant cells and other nonneuronal tissue remains unclear (Bruening et 
al., 2000). Synaptobrevin is an integral membrane protein present in synaptic vesicles and is 
often used as a synaptic marker (Jontes et al., 2004). NeuroD1 has been reported to possibly 
play a role in the development of neuroendocrine subpopulations in the lung (Ito et al., 2000). 
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Poulsen et al. showed that the expression of pgp9.5 is not restricted to the neuroendocrine cell 
population and stated that the constitutive expression of b-Myb in typeII-pneumocytes leads 
to elevated expression levels of pgp9.5 in the lung (Poulsen et al., 2008). Interestingly, in the 
data of the microarray comparing genes differentially expressed in A549 versus A549 J5-1 
cells the Myb-binding-protein1a (MYBBP1a) was one of the genes accounting for the 
enrichment of genes of the Myc-oncogenic signature in the A549 J5-1 cells. The only 
neuroendocrine marker that was significantly downregulated in the qPCR analysis comparing 
the expression profile of the A549 with A549 J5-1 was Enolase, suggesting the direct 
regulation of the other analyzed neuroendocrine markers rather than the induction of a master 
regulator of a complete neuroendocrine phenotype. Summarizing these data, I have shown 
that the expression of the neuroendocrine genes SNCA, NeuroD1 and Synaptobrevin were 
significantly upregulated in the typeII-pneumocytes and the A549 cells, respectively, upon c-
Myc-expression, although the mechanism and the consequences of the expression of these 
genes remain to be elucidated. All in all despite the unknown mechanism and role of these 
neuroendocrine markers, the expression of genes that are characteristic for other tissues is 
consistent with epigenetic instability or reprogramming events. Furthermore, pgp9.5 was 
significantly upregulated in qPCR analysis of the A549 J5-1 cells in comparison to the 
parental A549 cell line and in histological analysis of the lungs of the SpC-C-Raf-BxB/SpC-
c-Myc compound and late SpC-c-Myc animals (Rapp et al., 2009). The literature suggests an 
involvement of b-Myb in the induction of pgp9.5 in typeII-pneumocytes, which is strongly 
supported by the microarray data of this work. These data suggest an upregulation of b-Myb 
upon c-Myc-expression, which should be determined via qPCR-analysis in future work.  
4.2.4 Myc is sufficient to induce metastasis 
If Myc is sufficient to induce metastasis in NSCLC the introduction of c-Myc into a non-
metastatic NSCLC cell line should lead to metastatic conversion of these cells. To test this 
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possibility as described in 3.4 in this work chicken c-Myc was introduced into the human non-
metastatic cell line A549 and resulting clones were tested for chicken c-Myc expression. 
Comparing the ability for anchorage-independent growth in a soft-agar assay of the parental 
cell line A549 and the high-chicken c-Myc expressing clone A549 J5-1 showed highly 
significant differences in the size and number of resulting colonies (Figure 3-11). These data 
suggest an enhanced ability of anchorage-independent growth of the cells upon Myc 
expression. The high-chicken c-Myc expressing clone A549 J5-1 was also subcutaneously 
injected into Rag
-/-
-mice and accelerated tumour growths was observed as well as metastasis 
to lung and liver in a small fraction of the A549 J5-1 injected animals. Since the tumours of 
the animals injected with A549 J5-1 were growing rapidly, the mice had to be sacrificed as 
soon as six weeks after transplantation to not exceed the allowed 2cm of tumour diameter. 
Keeping in mind this short time span of the experiment, it was not surprising that metastasis 
occurred only with low frequency and this fact suggests that a longer time frame, i.e. possibly 
by surgical removal of the primary tumour, could increase the metastasis rate in A549 J5-1 
injected animals. Additionally, among the identified microRNA targets significantly 
upregulated in the A549 J5-1 cells, were targets of the microRNA miR-200, which was 
published to inhibit metastasis (Gibbons et al., 2009). Unfortunately this microRNA was not 
assessed in the performed microarray. An upregulation of the target genes suggest a 
downregulation of the corresponding microRNA. Furthermore, among the identified 
transcription factor targets significantly upregulated in the A549 J5-1 cells, were targets of the 
transcription factor Lef1, which has recently been identified to be one of the mediators of 
chemotactic invasion and colony outgrowth in lymph node derived lung adenocarcinoma cells 
(Nguyen et al., 2009). These data clearly show that Myc is able to convert non-metastatic 
tumour cells into metastasizing cells. All in all the ability to convert the non-metastatic A549 
cells to metastasizing cells via the expression of chicken c-Myc now provides a system to 
study the events required for this switch in phenotype. 
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4.2.5 GATA4 in NSCLC 
In the lung tumours and liver metastases of the SpC-C-Raf-BxB/SpC-c-Myc compound and 
the SpC-c-Myc single transgenic animals the expression of the intestine maintenance 
transcription factor GATA4 was observed. In contrast, GATA4 was absent in the lung 
tumours of SpC-C-Raf-BxB animals, which expressed instead GATA6, a transcription factor 
that is involved in airway regeneration, (Rapp et al., 2009). In this work the GATA4- and 
GATA6-expression of A549 and A549 J5-1 cells was analyzed. In contrast to the switch from 
GATA6- to GATA4-expression observed in the SpC-C-Raf/SpC-c-Myc compound and SpC-
c-Myc single transgenic animals, in the A549 J5-1 an upregulation of both GATA4 as well as 
GATA6 was seen, as shown in Figure 3-10 and Figure 3-12. Furthermore, to establish 
functionality of GATA4-protein, qPCR was performed also for the expression of its target 
gene mucin2, which was in fact significantly upregulated in the A549 J5-1 cells. Although for 
the human NSCLC cell line A549 the mutually exclusive pattern of GATA4- and GATA6-
expression that was observed in the SpC-C-Raf-BxB/SpC-c-Myc compound and SpC-c-Myc 
single transgenic lung tumours and liver metastases could not been shown, the results clearly 
demonstrate the induction of GATA4 upon Myc-expression and its functionality by the 
upregulation of its target mucin2. Interestingly, among the microRNA targets that came up in 
the microarray comparing the gene expression profile of A549 and A549 J5-1 cells, the 
microRNA-181 target genes were downregulated in the c-Myc-expressing A549 cells, 
indicating an upregulation of the corresponding microRNA. The microRNA-181 was 
published to inhibit hepatic cell differentiation and targets amongst other GATA6 for 
degradation (Ji et al., 2009). These data suggest that there is a process activated in the A549 
J5-1 cells that might lead to the downregulation of GATA6 and consequently TTF1, but other 
factors might superimpose positive regulation. Furthermore GATA1-activity was shown to be 
regulated posttranscriptionally via heterodimerization with a cofactor, indicating that this 
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could be also true for GATA6 and even in the presence of GATA4 as well as GATA6, 
GATA4 might be dominant (Haenlin et al., 1997).   
If loss of organ identity of transformed typeII-pneumocytes is a prerequisite for metastasis as 
postulated by us (Rapp, 2007) and GATA4 is the mediator by counteracting GATA6 together 
with its target TTF1, the knockdown of GATA4 in the A549 J5-1 would block the emergence 
of the metastatic phenotype. To address this issue, A549 J5-1 cells were transfected with 
GATA4 shRNAs. To confirm the efficient knockdown of GATA4, qPCR on the resulting cell 
lines was performed and as shown in Figure 3-15, mucin2-expression was significantly 
reduced. The ability of anchorage independent-growth was tested by growing the cells in soft-
agar, which resulted in a significant reduction of the counted colonies upon GATA4 
knockdown. These data suggest, that GATA4 knockdown might be capable to at least 
partially block the metastatic conversion by Myc. To further investigate whether this 
suspicion is close to reality, a transplantation experiment of the GATA4 knockdown cells into 
immunodeficient mice might be informative. 
Recently it was shown that the overexpression of Hdac1 downregulates the expression of 
GATA4 in cardiomyocyte formation and that Wnt/Lef1 signalling downregulates the 
expression of Hdac1 (Liu et al., 2009). Interestingly, the data of the microarray performed 
with the A549 and A549 J5-1 cells showed an enrichment of genes targeted by the 
transcription factor Lef1 upregulated in the A549 J5-1 cells, indicating an upregulation of the 
transcription factor itself. Furthermore, many genes accounting for the enrichment of specific 
pathways, transcription factor or microRNA targets in the microarray analysis presented in 
this work are components of WNT-signaling or are involved in the regulation of the latter. All 
in all this data indicates that WNT/Lef1-signalling might be involved in the regulation of 
GATA4-expression. Additionally, the involvement of the histone deacetylase Hdac1 suggests 
an epigenetic mechanism of the regulation of GATA4. 
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GATA4 is known to be silenced via promoter hypermethylation in primary ovarian, lung and 
gastrointestinal cancer (Akiyama et al., 2003; Guo et al., 2004; Guo et al., 2006; Wakana et 
al., 2006). In this work, it was shown that the GADD45 genes, which play a key role in active 
DNA demethylation and promote global DNA demethylation via a DNA repair mechanism 
(Barreto et al., 2007), are significantly upregulated upon c-Myc-expression in the A549 cells. 
Furthermore, the p53 family members p53 and p63 that act upstream of the GADD45 genes in 
the nucleotide excision repair (Smith and Seo, 2002) were also shown to be upregulated in the 
A549 J5-1 cells. Additionally, analysis of the data of differentially expressed genes in A549 
and A549 J5-1 cells identified by the microarray performed in this work in respect to cellular 
processes support an induction of genes involved in the cellular processes of genetic 
imprinting upon c-Myc expression. The observation that genes that are downregulated upon 
the expression of the SWI/SNF-chromatin-remodeling-complex subunit BAF57 and targets of 
the transcription factor FoxO4, which is involved in the regulation of GADD45 genes 
(Kobayashi et al., 2005) were found to be significantly upregulated in the A549 J5-1 cells also 
is in line with these data. Furthermore, among the transcription factors, which came up in the 
analysis of upregulated transcription factor target genes in A549 J5-1, the transcription factor 
Ets2 was identified that induces DNA-repair via ERCC5 (Crawford et al., 2007). 
All in all these data suggest not only an induction of GATA4 expression in NSCLC upon c-
Myc-expression, but furthermore indicate an epigenetic mechanism for the regulation of 
GATA4-expression via histone deacetylation and promoter demethylation. As GATA4 is not 
necessary for integrity of the adult lung it may be the ideal target for novel therapeutic 
approaches.  
4.2.6 Further characterization of c-Myc-expressing A549 cells 
Myc has been reported to induce angiogenesis in vivo by a VEGF-dependent mechanism 
(Knies-Bamforth et al., 2004). The finding of this work that Myc is able to induce the 
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expression of VEGF in the human NSCLC cell line A549 is in line with the previously 
observed significantly increased VEGF expression and an invasion of blood and lymph 
vessels in the lung tumours of SpC-C-Raf-BxB/SpC-c-Myc compound and SpC-c-Myc single 
transgenic animals (Rapp et al., 2009), supporting that Myc induces angiogenesis in NSCLC 
by upregulation of VEGF expression. Additionally, in the microarray data comparing the gene 
expression profile of the A549 and A549 J5-1 cells showed an upregulation of target genes 
for the transcription factor Sp1, which is known to induce VEGF-regulated angiogenesis 
(Song et al., 2009), and for the transcription factor NFATc, which is induced by VEGF 
(Kulkarni et al., 2009), upon c-Myc-expression, strongly supporting the before discussed data. 
Furthermore, in this work the induction of Sox2, Sox9 and Klf4-expression was observed upon 
c-Myc expression in the A549 cells. Sox2 and Klf4 are together with Myc involved in the 
induction of pluripotent stem cells (Takahashi and Yamanaka, 2006) and Sox9 is highly 
expressed during lung development, but absent in the adult lung (Perl et al., 2005), indicating 
a dedifferentiation of the NSCLC cells upon the expression of Myc. Additionally, the 
observation of a fivefold reduced expression of tissue-specific genes in the A549 J5-1 cells 
compared to the A549 parental cell line in the microarray analysis strongly support a loss of 
organ identity upon Myc-expression. This was also supported by the data on downregulation 
of genes involved in the ageing process of the kidney and liver-specific genes together with 
the target genes of the liver-specific transcription factor HNF1 in the A549 J5-1 cells. The 
combined data indicate a more differentiated status of the A549 cells when compared to the 
A549 J5-1 cells. Moreover the upregulation of target genes of the transcription factors Sp1, 
Tcf3, Lef1 and MAZ in the c-Myc expressing cells, which are involved in dedifferentiation or 
early embryonal development processes is in line with this conclusion. 
Finally another tumour-associated gene, tert, was upregulated upon c-Myc-expression in the 
A549 cells going in line with the literature that tert is activated by Myc (Wang et al., 1998). 
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Furthermore tert activation assures cell survival after occurrence of genomic instability (Kim 
et al., 1994). 
4.2.7 Microarray-Analysis of the A549 J5-1 cells 
Surprisingly, an upregulation of GATA4 expression was not detected in the A549 J5-1 cells 
in the microarray experiment. On the other hand, the upregulation of a lot of processes, 
pathways, transcription factor targets and microRNA targets in the A549 J5-1 that we would 
expect to be induced by Myc-expression, were observed. I.e. among the most significant gene 
sets identified in the pathway analysis of genes upregulated in the A549 J5-1 cells were the 
Myc oncogenic signature and the Myc-target genes. Thus the microarray data show the 
expected changes in the expression profile of the A549 J5-1 cells compared to the A549 cells. 
The fact that not all Myc targets light up may have several reasons. First of all, as shown in 
Figure 3-10, the population of A549 J5-1 cells is heterogeneous in respect to GATA4-
expression. Furthermore, changes in mRNAs that are expressed at low levels are hardly 
detectable in the microarray, even if they were detected in qPCR analysis, which has a much 
lower threshold in respect to absolute RNA-concentrations. Additionally, in the microarray 
only RNAs can be detected that are intact in the 5‟-end due to technical reasons, so RNAs that 
have a fast turnover are hardly detectable by this method. 
In regard to Myc expression the microarray data suggest a feedback regulation of Myc. Target 
genes of the Myc-associated zink-finger protein MAZ for example, which binds in the 
promoter region of Myc regulating transcription initiation as well as the termination (Bossone 
et al., 1992), were upregulated in the A549 J5-1 cells. Furthermore, the downregulation of 
genes containing a binding site for Myc in the A549 J5-1 cells suggests a negative feedback 
regulation of Myc-target genes upon their induction by Myc. Additionally, the microRNAs 
miR-24 and Let-7, which both target Myc-RNA (Lal et al. 2009)(Sampson et al., 2007), were 
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upregulated in the A549 J5-1 cells, supporting a negative feedback regulation of Myc upon its 
expression. 
In several analysis of the microarray data obtained for A549 and A549 J5-1 cells revealed the 
oncogenic potential of Myc. For example the upregulation of genes of the Myc-oncogenic-
signature, the downregulation of the breast cancer associated tumour suppressor gene BRCA1 
and the downregulation of the tumour suppressor microRNAs miR-15 and -16 in the A549 J5-
1 cells clearly reflect the oncogenic potential of Myc. Upon c-Myc-expression in the A549 
cells additionally genes associated with proliferation were upregulated, while genes involved 
in block of proliferation were downregulated. Not surprisingly, among the identified 
microRNAs upregulated in the A549 J5-1 cells, there were the microRNA-24 and let-7, which 
downregulate Myc, suggesting activation of a negative feedback loop in the cells responding 
to the forced expression of the exogenous c-Myc. 
Last but not least, the data analyses of the microarray reflect the proliferative potential of 
Myc. First of all, the mitogenic cascade seems to be stimulated by c-Myc-expression, since 
we observed a significant downregulation of the set of genes that was reported to be 
upregulated after a knockdown of KRas (Sweet-Cordero et al., 2006) in the A549 cells upon 
c-Myc-expression. Additionally an upregulation of gene sets being targets of the transcription 
factor ETS, which is regulated by the mitogenic cascade, in the A549 J5-1 cells was seen. 
Furthermore, the downregulation of a gene set containing a binding site for the transcription 
factor E4F1, which induces cell cycle arrest as described in the results-section, in the A549 
J5-1 cells supports the induction of cell cycle progression genes upon c-Myc-expression. 
These include the downregulation of the microRNA miR-30, which blocks G(1)/S-transition, 
in the A549 J5-1 cells. 
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